```
RESULT   1
US-08-424-268-7
; Sequence 7, Application US/08424268
; Patent No. 5821118
;  GENERAL INFORMATION:
;    APPLICANT:  Omer, Charles A
;    APPLICANT:  Diehl, Ronald E
;    APPLICANT:  Gibbs, Jackson B
;    APPLICANT:  Kohl, Nancy E
;    TITLE OF INVENTION:  Assay for Inhibitors of Farnesyl-Protein
;    TITLE OF INVENTION:  Transferase
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Merck & Co., Inc.
;      STREET:  P.O.Box 2000
;      CITY:  Rahway
;      STATE:  New Jersey
;      COUNTRY:  United States of America
;      ZIP:  07065-0907
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  Power Mac
;      OPERATING SYSTEM:  System 7.5.3
;      SOFTWARE:  Microsoft Word 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/424,268
;      FILING DATE:  4/24/95
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Muthard, David A
;      REGISTRATION NUMBER:  35,297
;      REFERENCE/DOCKET NUMBER:  18858PC
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (908)594-3903
;      TELEFAX:  (908) 594-4720
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  1140 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-08-424-268-7

  Query Match           87.5%;  Score 14;  DB 1;  Length 1140;
  Best Local Similarity  86.7%;  Pred. No. 1.6e+02;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 agggngucggggagg 15
           |||| |:||||||||
Db      14 AGGGGGTCGGGGAGG 28
```

GenCore version 4.5

OM nucleic - nucleic search, using sw model

Run on: June 3, 2002, 20:26:59 ; Search time 84.82 Seconds
(without alignments)
46.335 Million cell updates/sec

Title: US-09-438-917-2
Perfect score: 16
Sequence: 1 agggngucggggaggu 16

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 383533 seqs, 122816752 residues

Total number of hits satisfying chosen parameters: 767066

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_NA:*
1: /cgn2_6/ptodata/1/ina/5A_COMB.seq:*
2: /cgn2_6/ptodata/1/ina/5B_COMB.seq:*
3: /cgn2_6/ptodata/1/ina/6A_COMB.seq:*
4: /cgn2_6/ptodata/1/ina/6B_COMB.seq:*
5: /cgn2_6/ptodata/1/ina/PCTUS_COMB.seq:*
6: /cgn2_6/ptodata/1/ina/backfiles1.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	14	87.5	1140	1	US-08-424-268-7	Sequence 7, Appli
	2	14	87.5	1140	5	PCT-US93-10442-7	Sequence 7, Appli
	3	14	87.5	1664	1	US-07-863-169A-6	Sequence 6, Appli
	4	14	87.5	1664	2	US-08-429-964-6	Sequence 6, Appli
	5	14	87.5	1664	3	US-07-935-087-6	Sequence 6, Appli
	6	14	87.5	1664	5	PCT-US93-08062-6	Sequence 6, Appli
c	7	14	87.5	2291	2	US-08-476-062A-53	Sequence 53, Appl
c	8	14	87.5	2310	2	US-08-476-062A-41	Sequence 41, Appl
c	9	14	87.5	2310	5	PCT-US96-01314-41	Sequence 41, Appl
c	10	14	87.5	2405	3	US-08-549-846-3	Sequence 3, Appli
c	11	14	87.5	35081	2	US-08-752-760A-1	Sequence 1, Appli
c	12	13.4	83.8	1301	2	US-08-641-314C-1	Sequence 1, Appli
c	13	13.4	83.8	1932	2	US-08-967-364-6	Sequence 6, Appli
c	14	13.4	83.8	1932	3	US-09-368-408-6	Sequence 6, Appli
c	15	13.4	83.8	2543	1	US-08-555-669-11	Sequence 11, Appl
c	16	13.4	83.8	2543	3	US-09-073-663-11	Sequence 11, Appl
c	17	13.4	83.8	15664	1	US-08-402-282-3	Sequence 3, Appli
c	18	13.4	83.8	15664	1	US-08-508-004-3	Sequence 3, Appli
c	19	13.4	83.8	15664	1	US-08-402-066-3	Sequence 3, Appli
c	20	13.4	83.8	15664	1	US-08-402-068-3	Sequence 3, Appli
c	21	13.4	83.8	18609	4	US-08-943-731-1	Sequence 1, Appli
c	22	13.4	83.8	20084	4	US-08-943-731-5	Sequence 5, Appli
	23	13.4	83.8	33529	4	US-09-144-085-3	Sequence 3, Appli
	24	13	81.2	53	1	US-08-171-389-186	Sequence 186, App
	25	13	81.2	53	1	US-08-123-936-186	Sequence 186, App
	26	13	81.2	53	2	US-08-475-228A-186	Sequence 186, App
	27	13	81.2	53	3	US-08-482-080A-186	Sequence 186, App
	28	13	81.2	53	5	PCT-US93-12388-186	Sequence 186, App
c	29	13	81.2	2115	1	US-08-395-800A-7	Sequence 7, Appli
	30	13	81.2	2126	2	US-08-789-354-1	Sequence 1, Appli
	31	13	81.2	2126	3	US-09-110-937-1	Sequence 1, Appli
	32	13	81.2	2126	3	US-09-058-725B-1	Sequence 1, Appli
	33	13	81.2	2126	3	US-09-232-857-1	Sequence 1, Appli
c	34	13	81.2	4601	3	US-08-726-214-15	Sequence 15, Appl
c	35	13	81.2	8535	3	US-08-716-351A-1	Sequence 1, Appli
c	36	13	81.2	9661	3	US-08-716-351A-3	Sequence 3, Appli
c	37	12.4	77.5	17	2	US-08-173-489C-96	Sequence 96, Appl
	38	12.4	77.5	18	2	US-09-212-771-45	Sequence 45, Appl
c	39	12.4	77.5	243	1	US-07-730-853-6	Sequence 6, Appli
c	40	12.4	77.5	243	1	US-08-280-041-6	Sequence 6, Appli
	41	12.4	77.5	340	4	US-08-836-075A-69	Sequence 69, Appl
c	42	12.4	77.5	474	1	US-07-730-853-2	Sequence 2, Appli
c	43	12.4	77.5	474	1	US-08-280-041-2	Sequence 2, Appli
	44	12.4	77.5	523	4	US-08-896-164-13	Sequence 13, Appl
c	45	12.4	77.5	716	4	US-08-998-416-942	Sequence 942, App

ALIGNMENTS

RESULT 1
US-08-424-268-7
; Sequence 7, Application US/08424268
; Patent No. 5821118
; GENERAL INFORMATION:
; APPLICANT: Omer, Charles A
; APPLICANT: Diehl, Ronald E
; APPLICANT: Gibbs, Jackson B
; APPLICANT: Kohl, Nancy E
; TITLE OF INVENTION: Assay for Inhibitors of Farnesyl-Protein
; TITLE OF INVENTION: Transferase
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merck & Co., Inc.
; STREET: P.O.Box 2000
; CITY: Rahway
; STATE: New Jersey
; COUNTRY: United States of America
; ZIP: 07065-0907
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: Power Mac
; OPERATING SYSTEM: System 7.5.3
; SOFTWARE: Microsoft Word 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/424,268
; FILING DATE: 4/24/95
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Muthard, David A
; REGISTRATION NUMBER: 35,297
; REFERENCE/DOCKET NUMBER: 18858PC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (908)594-3903
; TELEFAX: (908) 594-4720
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1140 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-08-424-268-7

Query Match 87.5%; Score 14; DB 1; Length 1140;
Best Local Similarity 86.7%; Pred. No. 1.6e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

```
Qy      1 agggngucggggagg 15
          |||| |:|||||||||
Db     14 AGGGGGTCGGGGAGG 28


RESULT   2
PCT-US93-10442-7
; Sequence 7, Application PC/TUS9310442
;  GENERAL INFORMATION:
;    APPLICANT:  Omer, Charles A
;    APPLICANT:  Diehl, Ronald E
;    APPLICANT:  Gibbs, Jackson B
;    APPLICANT:  Kohl, Nancy E
;    TITLE OF INVENTION:  Assay for Inhibitors of Farnesyl-Protein
;    TITLE OF INVENTION:  Transferase
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Merck & Co., Inc.
;      STREET:  P.O.Box 2000
;      CITY:  Rahway
;      STATE:  New Jersey
;      COUNTRY:  United States of America
;      ZIP:  07065-0907
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/10442
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/968,782
;      FILING DATE:  10/30/92
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Muthard, David A
;      REGISTRATION NUMBER:  35,297
;      REFERENCE/DOCKET NUMBER:  18858
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (908)594-3903
;      TELEFAX:  (908) 594-4720
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  1140 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    JS93-10442-7


  Query Match             87.5%;  Score 14;  DB 5;  Length 1140;
  Best Local Similarity   86.7%;  Pred. No. 1.6e+02;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy      1 agggngucggggagg 15
          |||| |:|||||||||
Db     14 AGGGGGTCGGGGAGG 28


RESULT   3
US-07-863-169A-6
; Sequence 6, Application US/07863169A
; Patent No. 5420245
;  GENERAL INFORMATION:
;    APPLICANT:  Brown, Michael S.
;    APPLICANT:  Goldstein, Joseph L.
;    APPLICANT:  Reiss, Yuval
;    TITLE OF INVENTION:  Tetrapeptide-Based Inhibitors of Farnesyl
;    TITLE OF INVENTION:  Transferase
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Arnold, White & Durkee
;      STREET:  P.O. Box 4433
;      CITY:  Houston
;      STATE:  Texas
;      COUNTRY:  United States of America
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS/ASCII
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/863,169A
;      FILING DATE:  03-APR-1992
;      CLASSIFICATION:  530
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/822,011
;      FILING DATE:  19-JAN-1992
;      CLASSIFICATION:  530
;      APPLICATION NUMBER:  US 07/937,893
;      FILING DATE:  18-APR-1991
;      CLASSIFICATION:  530
;      APPLICATION NUMBER:  US 615,715
;      FILING DATE:  20-NOV-1990
;      CLASSIFICATION:  530
;      APPLICATION NUMBER:  US 510,706
;      FILING DATE:  18-APR-1990
;      CLASSIFICATION:  530
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Parker, David L.
;      REGISTRATION NUMBER:  32,165
;      REFERENCE/DOCKET NUMBER:  UTSD:297/PAR
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (512) 418-3000
;      TELEFAX:  (713) 789-2679
;      TELEX:  79-0924
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  1664 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-07-863-169A-6


  Query Match             87.5%;  Score 14;  DB 1;  Length 1664;
  Best Local Similarity   86.7%;  Pred. No. 1.5e+02;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy      1 agggngucggggagg 15
          |||| |:|||||||||
Db     14 AGGGGGTCGGGGAGG 28


RESULT   4
US-08-429-964-6
; Sequence 6, Application US/08429964
; Patent No. 5962243
;  GENERAL INFORMATION:
;    APPLICANT:  BROWN, MICHAEL S.
;    APPLICANT:  GOLDSTEIN, JOSEPH L.
;    APPLICANT:  REISS, YUVAL
;    APPLICANT:  JAMES, GUY L.
;    TITLE OF INVENTION:  METHODS FOR THE IDENTIFICATION OF FARNESYL
;    TITLE OF INVENTION:  TRANSFERASE INHIBITORS
;    NUMBER OF SEQUENCES:  85
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  ARNOLD, WHITE & DURKEE
;      STREET:  P.O. BOX 4433
;      CITY:  HOUSTON
;      STATE:  TEXAS
```

```
;      COUNTRY:  UNITED STATES OF AMERICA
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS/ASCII
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/429,964
;      FILING DATE:  27-APR-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/021,625
;      FILING DATE:  16-FEB-1993
;      CLASSIFICATION:  435
;      APPLICATION NUMBER:  US 07/822,011
;      FILING DATE:  ABANDONED
;      CLASSIFICATION:  435
;      APPLICATION NUMBER:  PCT/US/91/02650
;      FILING DATE:  18-APR-1991
;      CLASSIFICATION:  435
;      APPLICATION NUMBER:  US 07/615,715
;      FILING DATE:  20-NOV-1990
;      CLASSIFICATION:  435
;      APPLICATION NUMBER:  US 07/510,706
;      FILING DATE:  18-APR-1990 (ABANDONED)
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  PARKER, DAVID L.
;      REGISTRATION NUMBER:  32,165
;      REFERENCE/DOCKET NUMBER:  UTSD:432/PAR
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (512) 418-3000
;      TELEFAX:  (713) 789-2679
;      TELEX:  79-0924
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  1664 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-429-964-6


  Query Match             87.5%;  Score 14;  DB 2;  Length 1664;
  Best Local Similarity   86.7%;  Pred. No. 1.5e+02;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 agggngucggggagg 15
           |||| |:||||||||
Db      14 AGGGGGTCGGGGAGG 28


RESULT   5
US-07-935-087-6
; Sequence 6, Application US/07935087
; Patent No. 6083917
;  GENERAL INFORMATION:
;    APPLICANT:  BROWN, MICHAEL S.
;    APPLICANT:  GOLDSTEIN, JOSEPH L.
;    APPLICANT:  REISS, YUVAL
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  THE IDENTIFICATION,
;    TITLE OF INVENTION:  CHARACTERIZATION,
;    TITLE OF INVENTION:  AND INHIBITION OF FARNESYL
;    TITLE OF INVENTION:  PROTEIN TRANSFERASE
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  ARNOLD, WHITE & DURKEE
;      STREET:  P.O. BOX 4433
;      CITY:  HOUSTON
;      STATE:  TEXAS
;      COUNTRY:  USA
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  FLOPPY DISK
;      COMPUTER:  IBM PC COMPATIBLE
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WORDPERFECT 5.1 (converted to ASCII-DOS)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/935,087
;      FILING DATE:  19920824
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/822,011
;      FILING DATE:  01/16/92
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  PARKER, DAVID L.
;      REGISTRATION NUMBER:  32,165
;      REFERENCE/DOCKET NUMBER:  UTSD:269/PAR
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  512-320-7200
;      TELEFAX:  512-474-7577
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  1664 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-07-935-087-6


  Query Match             87.5%;  Score 14;  DB 3;  Length 1664;
  Best Local Similarity   86.7%;  Pred. No. 1.5e+02;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 agggngucggggagg 15
           |||| |:||||||||
Db      14 AGGGGGTCGGGGAGG 28


RESULT   6
PCT-US93-08062-6
; Sequence 6, Application PC/TUS9308062
;  GENERAL INFORMATION:
;    APPLICANT:
;    SEQUENCE CHARACTERISTICS:
;    SEQUENCE CHARACTERISTICS:  BROWN, MICHAEL S.
;    SEQUENCE CHARACTERISTICS:  GOLDSTEIN, JOSEPH L.
;    SEQUENCE CHARACTERISTICS:  REISS, YUVAL
;    SEQUENCE CHARACTERISTICS:  MARSTERS, JR., JAMES C.
;      ADDRESSEE:  METHODS AND COMPOSITIONS FOR
;      ADDRESSEE:  THE IDENTIFICATION,
;      ADDRESSEE:  CHARACTERIZATION AND
;      ADDRESSEE:  INHIBITION OF
;      ADDRESSEE:  FARNESYLTRANSFERASE
;    NUMBER OF SEQUENCES:  71
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  ARNOLD, WHITE & DURKEE
;      STREET:  P.O. BOX 4433
;      CITY:  HOUSTON
;      STATE:  TEXAS
;      COUNTRY:  UNITED STATES OF AMERICA
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  FLOPPY DISK/ASKII
;      COMPUTER:  IBM PC COMPATIBLE
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WORDPERFECT 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/08062
;      FILING DATE:  AUGUST 24, 1993
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/935,087
```

```
;       FILING DATE:  24 AUGUST 1992 (24.08.92)
;       NAME:  UNKNOWN
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  PARKER, DAVID L.
;       REGISTRATION NUMBER:  32,165
;       REFERENCE/DOCKET NUMBER:  UTFD377PCT
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  512-320-7200
;       TELEFAX:  512-474-7577
;       TELEX:  NOT APPLICABLE
;   INFORMATION FOR SEQ ID NO:  6:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  1664 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
PCT-US93-08062-6


  Query Match             87.5%;  Score 14;  DB 5;  Length 1664;
  Best Local Similarity   86.7%;  Pred. No. 1.5e+02;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 agggngucggggagg 15
           |||| |:|||||||||
Db      14 AGGGGGTCGGGGAGG 28


RESULT   7
US-08-476-062A-53/c
; Sequence 53, Application US/08476062A
; Patent No. 5877275
;  GENERAL INFORMATION:
;     APPLICANT:  Arnaout, M. Amin
;     TITLE OF INVENTION:  CONTROLLING CELLULAR IMMUNE/INFLAMMATORY
;     TITLE OF INVENTION:  RESPONSES WITH BETA2 INTEGRINS
;     NUMBER OF SEQUENCES:  53
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Fish & Richardson P.C.
;       STREET:  225 Franklin Street
;       CITY:  Boston
;       STATE:  MA
;       COUNTRY:  US
;       ZIP:  02110-2804
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Diskette
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  Windows95
;       SOFTWARE:  FastSEQ for Windows Version 2.0
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/476,062A
;       FILING DATE:  07-JUN-1995
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/216,081
;       FILING DATE:  21-MAR-1994
;       APPLICATION NUMBER:  07/637,830
;       FILING DATE:  04-JAN-1991
;       APPLICATION NUMBER:  07/539,842
;       FILING DATE:  18-JUN-1990
;       APPLICATION NUMBER:  07/212,573
;       FILING DATE:  28-JUN-1988
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Freeman, John W.
;       REGISTRATION NUMBER:  29,066
;       REFERENCE/DOCKET NUMBER:  00786/068003
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  617/542-5070
;       TELEFAX:  617/542-8906
;       TELEX:  200154
;   INFORMATION FOR SEQ ID NO:  53:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  2291 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA
US-08-476-062A-53


  Query Match             87.5%;  Score 14;  DB 2;  Length 2291;
  Best Local Similarity   86.7%;  Pred. No. 1.5e+02;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 agggngucggggagg 15
           |||| |:|||||||||
Db    1109 AGGGTGTCGGGGAGG 1095


RESULT   8
US-08-476-062A-41/c
; Sequence 41, Application US/08476062A
; Patent No. 5877275
;  GENERAL INFORMATION:
;     APPLICANT:  Arnaout, M. Amin
;     TITLE OF INVENTION:  CONTROLLING CELLULAR IMMUNE/INFLAMMATORY
;     TITLE OF INVENTION:  RESPONSES WITH BETA2 INTEGRINS
;     NUMBER OF SEQUENCES:  53
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Fish & Richardson P.C.
;       STREET:  225 Franklin Street
;       CITY:  Boston
;       STATE:  MA
;       COUNTRY:  US
;       ZIP:  02110-2804
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Diskette
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  Windows95
;       SOFTWARE:  FastSEQ for Windows Version 2.0
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/476,062A
;       FILING DATE:  07-JUN-1995
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/216,081
;       FILING DATE:  21-MAR-1994
;       APPLICATION NUMBER:  07/637,830
;       FILING DATE:  04-JAN-1991
;       APPLICATION NUMBER:  07/539,842
;       FILING DATE:  18-JUN-1990
;       APPLICATION NUMBER:  07/212,573
;       FILING DATE:  28-JUN-1988
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Freeman, John W.
;       REGISTRATION NUMBER:  29,066
;       REFERENCE/DOCKET NUMBER:  00786/068003
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  617/542-5070
;       TELEFAX:  617/542-8906
;       TELEX:  200154
;   INFORMATION FOR SEQ ID NO:  41:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  2310 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  cDNA
;     FEATURE:
;       NAME/KEY:  Coding Sequence
;       LOCATION:  1...2307
US-08-476-062A-41


  Query Match             87.5%;  Score 14;  DB 2;  Length 2310;
  Best Local Similarity   86.7%;  Pred. No. 1.5e+02;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy      1 agggngucggggagg 15
          |||| |:||||||||
Db   1133 AGGGTGTCGGGGAGG 1119


RESULT   9
PCT-US96-01314-41/c
; Sequence 41, Application PC/TUS9601314
;  GENERAL INFORMATION:
;     APPLICANT:  M. Amin Arnaout
;     TITLE OF INVENTION:  METHODS FOR IDENTIFYING INTEGRIN
;     TITLE OF INVENTION:  ANTAGONISTS
;     NUMBER OF SEQUENCES:  78
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Fish & Richardson P.C.
;       STREET:  225 Franklin Street
;       CITY:  Boston
;       STATE:  Massachusetts
;       COUNTRY:  U.S.A.
;       ZIP:  02110-2804
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       COMPUTER:  IBM PS/2 Model 50Z or 55SX
;       OPERATING SYSTEM:  MS-DOS (Version 5.0)
;       SOFTWARE:  WordPerfect (Version 5.1)
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  PCT/US96/01314
;       FILING DATE:  30-JAN-96
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/380,167
;       FILING DATE:  30-JAN-95
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  John W. Freeman
;       REGISTRATION NUMBER:  29,066
;       REFERENCE/DOCKET NUMBER:  00786/267001
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (617) 542-5070
;       TELEFAX:  (617) 542-8906
;       TELEX:  200154
;   INFORMATION FOR SEQ ID NO:  41:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  2310 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (genomic)
;     US96-01314-41


  Query Match             87.5%;  Score 14;  DB 5;  Length 2310;
  Best Local Similarity   86.7%;  Pred. No. 1.5e+02;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy      1 agggngucggggagg 15
          |||| |:||||||||
Db   1133 AGGGTGTCGGGGAGG 1119


RESULT  10
US-08-549-846-3/c
; Sequence 3, Application US/08549846
; Patent No. 6083751
;  GENERAL INFORMATION:
;     APPLICANT:  FELDHAUS, ANDREW L.
;     APPLICANT:  JONES, LORI A.
;     TITLE OF INVENTION:  CHIMERIC RECEPTORS FOR THE GENERATION OF
;     TITLE OF INVENTION:  SELECTIVITY-ACTIVATABLE T(h)-INDEPENDENT CYTOTOXIC T CELLS
;     NUMBER OF SEQUENCES:  4
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  MORRISON & FOERSTER
;       STREET:  755 PAGE MILL ROAD
;       CITY:  PALO ALTO
;       STATE:  CA
;       COUNTRY:  USA
;       ZIP:  94304-1018
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/549,846
;       FILING DATE:  01-NOV-1995
;       CLASSIFICATION:  435
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  DYLAN, TYLER
;       REGISTRATION NUMBER:  37,612
;       REFERENCE/DOCKET NUMBER:  22627-20013.01
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (415) 813-5600
;       TELEFAX:  (415) 494-0792
;       TELEX:  706141 MRSNFOERS SFO
;   INFORMATION FOR SEQ ID NO:  3:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  2405 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-549-846-3


  Query Match             87.5%;  Score 14;  DB 3;  Length 2405;
  Best Local Similarity   86.7%;  Pred. No. 1.5e+02;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy      1 agggngucggggagg 15
          |||| |:||||||||
Db   1217 AGGGTGTCGGGGAGG 1203


RESULT  11
US-08-752-760A-1/c
; Sequence 1, Application US/08752760A
; Patent No. 5877011
;  GENERAL INFORMATION:
;     APPLICANT:  Armentano, Donna
;     APPLICANT:  Gregory, Richard J.
;     APPLICANT:  Smith, Alan E.
;     TITLE OF INVENTION:  CHIMERIC ADENOVIRAL VECTORS
;     NUMBER OF SEQUENCES:  3
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Baker & Botts, L.L.P.
;       STREET:  30 Rockefeller Plaza
;       CITY:  New York
;       STATE:  NY
;       COUNTRY:  U.S.A.
;       ZIP:  10112
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Diskette
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  DOS
;       SOFTWARE:  FastSEQ Version 2.0
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/752,760A
;       FILING DATE:  20-NOV-1996
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:
;       FILING DATE:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Seide, Rochelle K
;       REGISTRATION NUMBER:  32,300
;       REFERENCE/DOCKET NUMBER:  A31385
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  212-705-5000
;       TELEFAX:  212-705-5020
```

```
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  35081 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-752-760A-1


  Query Match             87.5%;  Score 14;  DB 2;  Length 35081;
  Best Local Similarity   86.7%;  Pred. No. 1.2e+02;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy      1 agggngucggggagg 15
          |||| |:|||||||||
Db  30229 AGGGGGTCGGGGAGG 30215


RESULT  12
US-08-641-314C-1/c
; Sequence 1, Application US/08641314C
; Patent No. 5977440
; GENERAL INFORMATION:
;    APPLICANT:  LUTHE, DAWN S.
;    APPLICANT:  WILLIAMS, W. P.
;    APPLICANT:  BINGHUA, JIANG
;    APPLICANT:  PECHAN, TIBOR
;    TITLE OF INVENTION:  DNA MOLECULE ENCODING A 33 KD CYSTEINE
;    TITLE OF INVENTION:  PROTEINASE AND ITS USE IN TRANSFORMING PLANTS TO PROVIDE
;    TITLE OF INVENTION:  INSECT RESISTANCE
;    NUMBER OF SEQUENCES:  11
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  OBLON. SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
;      ADDRESSEE:  P.C.
;      STREET:  1755 S. JEFFERSON DAVIS HIGHWAY
;      CITY:  ARLINGTON
;      STATE:  VA
;      COUNTRY:  USA
;      ZIP:  22202
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/641,314C
;      FILING DATE:  30-APR-1996
;      CLASSIFICATION:  800
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  KELBER, STEVEN B.
;      REGISTRATION NUMBER:  30,073
;      REFERENCE/DOCKET NUMBER:  2343-045-27
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  703-413-3000
;      TELEFAX:  703-413-2220
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  1301 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-641-314C-1


  Query Match             83.8%;  Score 13.4;  DB 2;  Length 1301;
  Best Local Similarity   75.0%;  Pred. No. 2.9e+02;
  Matches   12;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy      1 agggngucggggaggu 16
          | || |:|||||||||:
Db    362 ATGGCGTCGGGGAGGT 347


RESULT  13
US-08-967-364-6/c
; Sequence 6, Application US/08967364
; Patent No. 5989859
; GENERAL INFORMATION:
;    APPLICANT:  Bandman, Olga
;    APPLICANT:  Lal, Preeti
;    APPLICANT:  Guegler, Karl J.
;    APPLICANT:  Shah, Purvi
;    APPLICANT:  Corley, Neil C.
;    TITLE OF INVENTION:  VESICLE TRAFFICKING PROTEINS
;    NUMBER OF SEQUENCES:  9
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Incyte Pharmaceuticals, Inc.
;      STREET:  3174 Porter Dr.
;      CITY:  Palo Alto
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94304
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/967,364
;      FILING DATE:  No. 5989859ember 7, 1997
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Cerrone, Michael C.
;      REGISTRATION NUMBER:  39,132
;      REFERENCE/DOCKET NUMBER:  PF-0417 US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  650-855-0555
;      TELEFAX:  650-845-4166
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  1932 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    IMMEDIATE SOURCE:
;      LIBRARY:  3086794
;      CLONE:  HEAONOT03
US-08-967-364-6


  Query Match             83.8%;  Score 13.4;  DB 2;  Length 1932;
  Best Local Similarity   75.0%;  Pred. No. 2.8e+02;
  Matches   12;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy      1 agggngucggggaggu 16
          |||| |: |||||||:
Db    759 AGGGTGTAGGGGAGGT 744


RESULT  14
US-09-368-408-6/c
; Sequence 6, Application US/09368408
; Patent No. 6071703
; GENERAL INFORMATION:
;    APPLICANT:  Bandman, Olga
;    APPLICANT:  Lal, Preeti
;    APPLICANT:  Guegler, Karl J.
;    APPLICANT:  Shah, Purvi
;    APPLICANT:  Corley, Neil C.
;    TITLE OF INVENTION:  VESICLE TRAFFICKING PROTEINS
;    NUMBER OF SEQUENCES:  9
;    CORRESPONDENCE ADDRESS:
```

```
;       ADDRESSEE:  Incyte Pharmaceuticals, Inc.
;       STREET:  3174 Porter Dr.
;       CITY:  Palo Alto
;       STATE:  CA
;       COUNTRY:  USA
;       ZIP:  94304
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Diskette
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  DOS
;       SOFTWARE:  FastSEQ for Windows Version 2.0
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/09/368,408
;       FILING DATE:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/967,364
;       FILING DATE:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Cerrone, Michael C.
;       REGISTRATION NUMBER:  39,132
;       REFERENCE/DOCKET NUMBER:  PF-0417 US
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  650-855-0555
;       TELEFAX:  650-845-4166
;   INFORMATION FOR SEQ ID NO:  6:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  1932 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     IMMEDIATE SOURCE:
;       LIBRARY:  3086794
;       CLONE:  HEAONOT03
US-09-368-408-6


  Query Match             83.8%;  Score 13.4;  DB 3;  Length 1932;
  Best Local Similarity   75.0%;  Pred. No. 2.8e+02;
  Matches   12;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1 agggngucggggaggu 16
           |||| |:| |||||||:
Db     759 AGGGTGTAGGGGAGGT 744


RESULT  15
US-08-555-669-11/c
; Sequence 11, Application US/08555669
; Patent No. 5773248
;  GENERAL INFORMATION:
;    APPLICANT:  Brewton, Richard G.
;    APPLICANT:  Mayne, Richard
;    TITLE OF INVENTION:  TYPE IX COLLAGEN AND FRAGMENTS THEREOF
;    NUMBER OF SEQUENCES:  32
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pennie & Edmonds
;      STREET:  1155 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  USA
;      ZIP:  10036
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/555,669
;      FILING DATE:  13-NOV-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Halluin, Albert P.
;      REGISTRATION NUMBER:  25,227
;      REFERENCE/DOCKET NUMBER:  8389-030
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-854-3660
;      TELEFAX:  415-854-3694
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  11:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  2543 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  cDNA
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  47..2098
US-08-555-669-11


  Query Match             83.8%;  Score 13.4;  DB 1;  Length 2543;
  Best Local Similarity   75.0%;  Pred. No. 2.8e+02;
  Matches   12;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1 agggngucggggaggu 16
           |||| |:| |||||||:
Db     523 AGGGGGTCCGGGAGGT 508


Search completed: June  3, 2002, 22:04:38
Job time: 5859 sec
```

Db 329 ACGGCG1

RESULT 5
US-08-424-268-7
; Sequence 7, Application US/08424268
; Patent No. 5821118
; GENERAL INFORMATION:
; APPLICANT: Omer, Charles A
; APPLICANT: Diehl, Ronald E
; APPLICANT: Gibbs, Jackson B
; APPLICANT: Kohl, Nancy E
; TITLE OF INVENTION: Assay for Inhibitors of Farnesyl-Protein
; TITLE OF INVENTION: Transferase
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merck & Co., Inc.
; STREET: P.O.Box 2000
; CITY: Rahway
; STATE: New Jersey
; COUNTRY: United States of America
; ZIP: 07065-0907
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: Power Mac
; OPERATING SYSTEM: System 7.5.3
; SOFTWARE: Microsoft Word 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/424,268
; FILING DATE: 4/24/95
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Muthard, David A

; REGISTRATION NUMBER: 35,297
; REFERENCE/DOCKET NUMBER: 18858PC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (908)594-3903
; TELEFAX: (908) 594-4720
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1140 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-08-424-268-7

Query Match 89.3%; Score 13.4; DB 1; Length 1140;
Best Local Similarity 93.3%; Pred. No. 3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 agggcgtcggggagg 15
|||| ||||||||||
Db 14 AGGGGGTCGGGGAGG 28

RESULT 6
PCT-10442-7

GenCore version 4.5

OM nucleic - nucleic search, using sw model

Run on: June 3, 2002, 22:07:23 ; Search time 84.82 Seconds
(without alignments)
43.439 Million cell updates/sec

Title: US-09-438-917-18
Perfect score: 15
Sequence: 1 agggcgtcggggagg 15

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

[redacted]ched: 383533 seqs, 122816752 residues

Total number of hits satisfying chosen parameters: 767066

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_NA:*
1: /cgn2_6/ptodata/1/ina/5A_COMB.seq:*
2: /cgn2_6/ptodata/1/ina/5B_COMB.seq:*
3: /cgn2_6/ptodata/1/ina/6A_COMB.seq:*
4: /cgn2_6/ptodata/1/ina/6B_COMB.seq:*
5: /cgn2_6/ptodata/1/ina/PCTUS_COMB.seq:*
6: /cgn2_6/ptodata/1/ina/backfiles1.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.		Score	% Query Match	Length	DB	ID	Description
[redacted]	1	13.4	89.3	725	4	US-08-998-416-808	Sequence 808, App
c	2	13.4	89.3	925	3	US-08-858-003-1	Sequence 1, Appli
c	3	13.4	89.3	925	3	US-09-078-166-1	Sequence 1, Appli
c	4	13.4	89.3	925	4	US-08-997-467-1	Sequence 1, Appli
	5	13.4	89.3	1140	1	US-08-424-268-7	Sequence 7, Appli
	6	13.4	89.3	1140	5	PCT-US93-10442-7	Sequence 7, Appli
c	7	13.4	89.3	1301	2	US-08-641-314C-1	Sequence 1, Appli
c	8	13.4	89.3	1632	1	US-07-959-941-1	Sequence 1, Appli
c	9	13.4	89.3	1632	1	US-08-259-924-1	Sequence 1, Appli
	10	13.4	89.3	1664	1	US-07-863-169A-6	Sequence 6, Appli
	11	13.4	89.3	1664	2	US-08-429-964-6	Sequence 6, Appli
	12	13.4	89.3	1664	3	US-07-935-087-6	Sequence 6, Appli
	13	13.4	89.3	1664	5	PCT-US93-08062-6	Sequence 6, Appli
c	14	13.4	89.3	2291	2	US-08-476-062A-53	Sequence 53, Appl
c	15	13.4	89.3	2310	2	US-08-476-062A-41	Sequence 41, Appl
c	16	13.4	89.3	2310	5	PCT-US96-01314-41	Sequence 41, Appl
c	17	13.4	89.3	2405	3	US-08-549-846-3	Sequence 3, Appli
c	18	13.4	89.3	2424	1	US-08-821-119-16	Sequence 16, Appl
c	19	13.4	89.3	3684	2	US-08-760-075A-17	Sequence 17, Appl
c	20	13.4	89.3	3684	4	US-09-338-546-17	Sequence 17, Appl
	21	13.4	89.3	4175	1	US-08-306-691B-49	Sequence 49, Appl
	22	13.4	89.3	4175	4	US-08-202-841A-1	Sequence 1, Appli
	23	13.4	89.3	4175	5	PCT-US93-06251-84	Sequence 84, Appl
c	24	13.4	89.3	7171	3	US-08-478-507-10	Sequence 10, Appl
c	25	13.4	89.3	7171	4	US-09-128-275A-10	Sequence 10, Appl
c	26	13.4	89.3	15664	1	US-08-402-282-3	Sequence 3, Appli
c	27	13.4	89.3	15664	1	US-08-508-004-3	Sequence 3, Appli
c	28	13.4	89.3	15664	1	US-08-402-066-3	Sequence 3, Appli
c	29	13.4	89.3	15664	1	US-08-402-068-3	Sequence 3, Appli
	30	13.4	89.3	33529	4	US-09-144-085-3	Sequence 1, Appli
c	31	13.4	89.3	35081	2	US-08-752-760A-1	Sequence 7, Appli
c	32	13.4	89.3	44377	2	US-08-804-227C-7	Sequence 1, Appli
c	33	13.4	89.3	44377	2	US-08-804-198-1	Sequence 2, Appli
c	34	13.4	89.3	4403765	4	US-09-103-840A-2	Sequence 1, Appli
c	35	13.4	89.3	4411529	4	US-09-103-840A-1	Sequence 7, Appli
	36	13	86.7	806	3	US-09-154-083-7	Sequence 4, Appli
c	37	13	86.7	927	4	US-09-254-733-4	Sequence 1, Appli
c	38	13	86.7	1060	1	US-08-090-013-1	Sequence 1, Appli
c	39	13	86.7	1060	1	US-08-081-328-1	Sequence 1, Appli
c	40	13	86.7	1060	1	US-08-232-249-1	Sequence 7, Appli
c	41	13	86.7	1060	2	US-08-921-426-7	Sequence 1, Appli
c	42	13	86.7	1060	2	US-08-833-642A-1	Sequence 3, Appli
c	43	13	86.7	1060	2	US-08-140-008A-3	Sequence 1, Appli
c	44	13	86.7	1060	2	US-08-389-423-1	Sequence 7, Appli
c	45	13	86.7	1060	3	US-08-816-915-7	

ALIGNMENTS

```
RESULT 1
US-08-998-416-808
; Sequence 808, Application US/08998416
; Patent No. 6239264
; GENERAL INFORMATION:
;   APPLICANT: Philippsen, Peter
;   APPLICANT: Pohlmann, Rainer
;   APPLICANT: Steiner, Sabine
;   APPLICANT: Mohr, Christine
;   APPLICANT: Wendland, Jurgen
;   APPLICANT: Knechtle, Philipp
;   APPLICANT: Rebischung, Corinne
;   TITLE OF INVENTION: GENOMIC DNA SEQUENCES OF ASHBYA GOSSYPII
;   TITLE OF INVENTION: AND USES THEREOF
;   NUMBER OF SEQUENCES: 1152
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: No. 6239264artis Corporation
;     STREET: 3054 Cornwallis Road
;     CITY: Research Triangle Park
;     STATE: No. 6239264th Carolina
;     COUNTRY: USA
;     ZIP: 27709
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: Floppy disk
;     COMPUTER: IBM PC compatible
;     OPERATING SYSTEM: PC-DOS/MS-DOS
;     SOFTWARE: PatentIn Release #1.0, Version #1.30
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/08/998,416
;     FILING DATE: 24-DEC-1997
;     CLASSIFICATION: 435
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: CH 0016/97
;     FILING DATE: 31-DEC-1996
;   ATTORNEY/AGENT INFORMATION:
;     NAME: Meigs, J. Timothy
;     REGISTRATION NUMBER: 38,241
;     REFERENCE/DOCKET NUMBER: PF/5-30306/A/CGC1976
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: 919-541-8587
;     TELEFAX: 919-541-8689
; INFORMATION FOR SEQ ID NO: 808:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 725 base pairs
;     TYPE: nucleic acid
;     STRANDEDNESS: single
;     TOPOLOGY: linear
;   MOLECULE TYPE: DNA (genomic)
;   ORIGINAL SOURCE:
;     ORGANISM: PAG1515UP
```

US-08-998-416-808

Query Match 89.3%; Score 13.4; DB 4; Length 725;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 agggcgtcggggagg 15
||||||||||| ||||
Db 445 AGGGCGTCGGCGAGG 459

RESULT 2
US-08-858-003-1/c
; Sequence 1, Application US/08858003
; Patent No. 6060234
; GENERAL INFORMATION:
; APPLICANT: Katz, Leonard
; APPLICANT: Stassi, Diane L.
; APPLICANT: Summers Jr., Richard G.
; APPLICANT: Ruan, Xiaoan
; APPLICANT: Pereda-Lopez, Ana
; APPLICANT: Kakavas, Stephan J.
; TITLE OF INVENTION: NOVEL POLYKETIDE DERIVATIVES
; TITLE OF INVENTION: AND RECOMBINANT METHODS FOR MAKING SAME
; NUMBER OF SEQUENCES: 34
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Abbott Laboratories
; STREET: 100 Abbott Park Rd.
; CITY: Abbott Park
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/858,003
; FILING DATE: 16-MAY-1979
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Dianne Casuto
; REGISTRATION NUMBER: P-40,943
; REFERENCE/DOCKET NUMBER: 4952.US.P2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (847)-938-3137
; TELEFAX: (847)-938-2623
; TELEX:
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 925 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
US-08-858-003-1

Query Match 89.3%; Score 13.4; DB 3; Length 925;
Best Local Similarity 93.3%; Pred. No. 3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 agggcgtcggggagg 15
| |||||||||||||
Db 329 ACGGCGTCGGGGAGG 315

RESULT 3
US-09-078-166-1/c
; Sequence 1, Application US/09078166
; Patent No. 6063561
; GENERAL INFORMATION:
; APPLICANT: Katz, Leonard
; APPLICANT: Stassi, Diane L.
; APPLICANT: Summers Jr., Richard G.
; APPLICANT: Ruan, Xiaoan
; APPLICANT: Pereda-Lopez, Ana
; APPLICANT: Kakavas, Stephan J.
; TITLE OF INVENTION: NOVEL POLYKETIDE DERIVATIVES
; TITLE OF INVENTION: AND RECOMBINANT METHODS FOR MAKING SAME
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Abbott Laboratories
; STREET: 100 Abbott Park Rd.
; CITY: Abbott Park
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/078,166
; FILING DATE: 16-MAY-1979
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Dianne Casuto
; REGISTRATION NUMBER: P-40,943
; REFERENCE/DOCKET NUMBER: 4952.US.P2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (847)-938-3137
; TELEFAX: (847)-938-2623
; TELEX:
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 925 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
US-09-078-166-1

Query Match 89.3%; Score 13.4; DB 3; Length 925;
Best Local Similarity 93.3%; Pred. No. 3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 agggcgtcggggagg 15
| |||||||||||||
Db 329 ACGGCGTCGGGGAGG 315

RESULT 4
US-08-997-467-1/c
; Sequence 1, Application US/08997467
; Patent No. 6200813
; GENERAL INFORMATION:
; APPLICANT: Katz, Leonard
; APPLICANT: Stassi, Diane L.
; APPLICANT: Summers Jr., Richard G.
; APPLICANT: Ruan, Xiaoan
; APPLICANT: Pereda-Lopez, Ana
; APPLICANT: Kakavas, Stephan J.
; TITLE OF INVENTION: NOVEL POLYKETIDE DERIVATIVES
; TITLE OF INVENTION: AND RECOMBINANT METHODS FOR MAKING SAME
; NUMBER OF SEQUENCES: 34
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Abbott Laboratories

```
;      STREET:  100 Abbott Park Rd.
;      CITY:  Abbott Park
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60064-3500
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/997,467
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/858,003
;      FILING DATE:  16-MAY-1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dianne Casuto
;      REGISTRATION NUMBER:  P-40,943
;      REFERENCE/DOCKET NUMBER:  4952.US.P2
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (847)-938-3137
;      TELEFAX:  (847)-938-2623
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  925 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
US-08-997-467-1


  Query Match             89.3%;  Score 13.4;  DB 4;  Length 925;
  Best Local Similarity   93.3%;  Pred. No. 3e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 agggcgtcggggagg 15
           | ||||||||||||||
Db     329 ACGGCGTCGGGGAGG 315


RESULT   5
US-08-424-268-7
[redacted]equence 7, Application US/08424268
[redacted]tent No. 5821118
;  GENERAL INFORMATION:
;    APPLICANT:  Omer, Charles A
;    APPLICANT:  Diehl, Ronald E
;    APPLICANT:  Gibbs, Jackson B
;    APPLICANT:  Kohl, Nancy E
;    TITLE OF INVENTION:  Assay for Inhibitors of Farnesyl-Protein
;    TITLE OF INVENTION:  Transferase
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Merck & Co., Inc.
;      STREET:  P.O.Box 2000
;      CITY:  Rahway
;      STATE:  New Jersey
;      COUNTRY:  United States of America
;      ZIP:  07065-0907
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  Power Mac
;      OPERATING SYSTEM:  System 7.5.3
;      SOFTWARE:  Microsoft Word 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/424,268
;      FILING DATE:  4/24/95
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Muthard, David A
;      REGISTRATION NUMBER:  35,297
;      REFERENCE/DOCKET NUMBER:  18858PC
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (908)594-3903
;      TELEFAX:  (908) 594-4720
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  1140 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-08-424-268-7


  Query Match             89.3%;  Score 13.4;  DB 1;  Length 1140;
  Best Local Similarity   93.3%;  Pred. No. 3e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 agggcgtcggggagg 15
           |||| ||||||||||
Db      14 AGGGGGTCGGGGAGG 28


RESULT   6
PCT-US93-10442-7
; Sequence 7, Application PC/TUS9310442
;  GENERAL INFORMATION:
;    APPLICANT:  Omer, Charles A
;    APPLICANT:  Diehl, Ronald E
;    APPLICANT:  Gibbs, Jackson B
;    APPLICANT:  Kohl, Nancy E
;    TITLE OF INVENTION:  Assay for Inhibitors of Farnesyl-Protein
;    TITLE OF INVENTION:  Transferase
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Merck & Co., Inc.
;      STREET:  P.O.Box 2000
;      CITY:  Rahway
;      STATE:  New Jersey
;      COUNTRY:  United States of America
;      ZIP:  07065-0907
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/10442
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/968,782
;      FILING DATE:  10/30/92
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Muthard, David A
;      REGISTRATION NUMBER:  35,297
;      REFERENCE/DOCKET NUMBER:  18858
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (908)594-3903
;      TELEFAX:  (908) 594-4720
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  1140 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
PCT-US93-10442-7
```

```
  Query Match             89.3%;  Score 13.4;  DB 5;  Length 1140;
  Best Local Similarity   93.3%;  Pred. No. 3e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 agggcgtcggggagg 15
           |||| ||||||||||
Db      14 AGGGGGTCGGGGAGG 28


RESULT   7
US-08-641-314C-1/c
; Sequence 1, Application US/08641314C
; Patent No. 5977440
;  GENERAL INFORMATION:
;    APPLICANT:  LUTHE, DAWN S.
;    APPLICANT:  WILLIAMS, W. P.
;    APPLICANT:  BINGHUA, JIANG
;    APPLICANT:  PECHAN, TIBOR
;    TITLE OF INVENTION:  DNA MOLECULE ENCODING A 33 KD CYSTEINE
;    TITLE OF INVENTION:  PROTEINASE AND ITS USE IN TRANSFORMING PLANTS TO PROVIDE
;    TITLE OF INVENTION:  INSECT RESISTANCE
;    NUMBER OF SEQUENCES:  11
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  OBLON. SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
;      ADDRESSEE:  P.C.
;      STREET:  1755 S. JEFFERSON DAVIS HIGHWAY
;      CITY:  ARLINGTON
;      STATE:  VA
;      COUNTRY:  USA
;      ZIP:  22202
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/641,314C
;      FILING DATE:  30-APR-1996
;      CLASSIFICATION:  800
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  KELBER, STEVEN B.
;      REGISTRATION NUMBER:  30,073
;      REFERENCE/DOCKET NUMBER:  2343-045-27
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  703-413-3000
;      TELEFAX:  703-413-2220
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  1301 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-641-314C-1


  Query Match             89.3%;  Score 13.4;  DB 2;  Length 1301;
  Best Local Similarity   93.3%;  Pred. No. 2.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 agggcgtcggggagg 15
           | ||||||||||||||
Db     362 ATGGCGTCGGGGAGG 348


RESULT   8
US-07-959-941-1/c
; Sequence 1, Application US/07959941
; Patent No. 5364781
;  GENERAL INFORMATION:
;    APPLICANT:  HUTCHINSON, Charles R.
;    APPLICANT:  MADDURI, Krishna M.
;    APPLICANT:  TORTI, Francesca
;    APPLICANT:  COLOMBO, Anna L.
;    TITLE OF INVENTION:  PROCESS FOR PREPARING DAUNORUBICIN
;    NUMBER OF SEQUENCES:  6
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Nikaido, Marmelstein, Murray & Oram
;      STREET:  655 Fifteenth Street N.W. Suite 330
;      CITY:  Washington
;      STATE:  D.C.
;      COUNTRY:  U.S.A.
;      ZIP:  20005-5701
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/959,941
;      FILING DATE:  19921009
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 793,873
;      FILING DATE:  18-NOV-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Chin, Monica F.
;      REGISTRATION NUMBER:  P-36,105
;      REFERENCE/DOCKET NUMBER:  1615-1816CIP
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202)638-5000
;      TELEFAX:  (202)638-4810
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  1632 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  204..1271
US-07-959-941-1


  Query Match             89.3%;  Score 13.4;  DB 1;  Length 1632;
  Best Local Similarity   93.3%;  Pred. No. 2.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 agggcgtcggggagg 15
           | ||||||||||||||
Db     583 ATGGCGTCGGGGAGG 569


RESULT   9
US-08-259-924-1/c
; Sequence 1, Application US/08259924
; Patent No. 5563064
;  GENERAL INFORMATION:
;    APPLICANT:  HUTCHINSON, Charles R.
;    APPLICANT:  MADDURI, Krishna M.
;    APPLICANT:  TORTI, Francesca
;    APPLICANT:  COLOMBO, Anna L.
;    TITLE OF INVENTION:  PROCESS FOR PREPARING DAUNORUBICIN
;    NUMBER OF SEQUENCES:  6
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Nikaido, Marmelstein, Murray & Oram
;      STREET:  655 Fifteenth Street N.W. Suite 330
;      CITY:  Washington
;      STATE:  D.C.
;      COUNTRY:  U.S.A.
;      ZIP:  20005-5701
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
```

; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/259,924
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 793,873
; FILING DATE: 18-NOV-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/959,941
; FILING DATE: 09-OCT-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Kitts, Monica C.
; REGISTRATION NUMBER: 36,105
; REFERENCE/DOCKET NUMBER: 1615-4003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)638-5000
; TELEFAX: (202)638-4810
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1632 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 204..1271
US-08-259-924-1

Query Match 89.3%; Score 13.4; DB 1; Length 1632;
Best Local Similarity 93.3%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 agggcgtcggggagg 15
| ||||||||||||||
Db 583 ATGGCGTCGGGGAGG 569

RESULT 10
US-07-863-169A-6
; Sequence 6, Application US/07863169A
; Patent No. 5420245
; GENERAL INFORMATION:
; APPLICANT: Brown, Michael S.
; APPLICANT: Goldstein, Joseph L.
; APPLICANT: Reiss, Yuval
; TITLE OF INVENTION: Tetrapeptide-Based Inhibitors of Farnesyl
; TITLE OF INVENTION: Transferase
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: United States of America
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS/ASCII
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/863,169A
; FILING DATE: 03-APR-1992
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/822,011
; FILING DATE: 19-JAN-1992
; CLASSIFICATION: 530
; APPLICATION NUMBER: US 07/937,893
; FILING DATE: 18-APR-1991
; CLASSIFICATION: 530
; APPLICATION NUMBER: US 615,715
; FILING DATE: 20-NOV-1990
; CLASSIFICATION: 530
; APPLICATION NUMBER: US 510,706
; FILING DATE: 18-APR-1990
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Parker, David L.
; REGISTRATION NUMBER: 32,165
; REFERENCE/DOCKET NUMBER: UTSD:297/PAR
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (512) 418-3000
; TELEFAX: (713) 789-2679
; TELEX: 79-0924
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1664 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-07-863-169A-6

Query Match 89.3%; Score 13.4; DB 1; Length 1664;
Best Local Similarity 93.3%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 agggcgtcggggagg 15
| ||||||||||||||
Db 14 AGGGGGTCGGGGAGG 28

RESULT 11
US-08-429-964-6
; Sequence 6, Application US/08429964
; Patent No. 5962243
; GENERAL INFORMATION:
; APPLICANT: BROWN, MICHAEL S.
; APPLICANT: GOLDSTEIN, JOSEPH L.
; APPLICANT: REISS, YUVAL
; APPLICANT: JAMES, GUY L.
; TITLE OF INVENTION: METHODS FOR THE IDENTIFICATION OF FARNESYL
; TITLE OF INVENTION: TRANSFERASE INHIBITORS
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ARNOLD, WHITE & DURKEE
; STREET: P.O. BOX 4433
; CITY: HOUSTON
; STATE: TEXAS
; COUNTRY: UNITED STATES OF AMERICA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS/ASCII
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/429,964
; FILING DATE: 27-APR-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/021,625
; FILING DATE: 16-FEB-1993
; CLASSIFICATION: 435
; APPLICATION NUMBER: US 07/822,011
; FILING DATE: ABANDONED
; CLASSIFICATION: 435
; APPLICATION NUMBER: PCT/US/91/02650
; FILING DATE: 18-APR-1991
; CLASSIFICATION: 435
; APPLICATION NUMBER: US 07/615,715

```
;       FILING DATE:  20-NOV-1990
;       CLASSIFICATION:  435
;       APPLICATION NUMBER:  US 07/510,706
;       FILING DATE:  18-APR-1990 (ABANDONED)
;       CLASSIFICATION:  435
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  PARKER, DAVID L.
;       REGISTRATION NUMBER:  32,165
;       REFERENCE/DOCKET NUMBER:  UTSD:432/PAR
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (512) 418-3000
;       TELEFAX:  (713) 789-2679
;       TELEX:  79-0924
;   INFORMATION FOR SEQ ID NO:  6:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  1664 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-429-964-6


  [redacted]ery Match             89.3%;  Score 13.4;  DB 2;  Length 1664;
  [redacted]st Local Similarity   93.3%;  Pred. No. 2.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 agggcgtcggggagg 15
           |||| ||||||||||
Db      14 AGGGGGTCGGGGAGG 28


RESULT  12
US-07-935-087-6
; Sequence 6, Application US/07935087
; Patent No. 6083917
;  GENERAL INFORMATION:
;     APPLICANT:  BROWN, MICHAEL S.
;     APPLICANT:  GOLDSTEIN, JOSEPH L.
;     APPLICANT:  REISS, YUVAL
;     TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;     TITLE OF INVENTION:  THE IDENTIFICATION,
;     TITLE OF INVENTION:  CHARACTERIZATION,
;     TITLE OF INVENTION:  AND INHIBITION OF FARNESYL
;     TITLE OF INVENTION:  PROTEIN TRANSFERASE
;     NUMBER OF SEQUENCES:  8
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  ARNOLD, WHITE & DURKEE
;       STREET:  P.O. BOX 4433
;       CITY:  HOUSTON
;       STATE:  TEXAS
;       COUNTRY:  USA
;       ZIP:  77210
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  FLOPPY DISK
;       COMPUTER:  IBM PC COMPATIBLE
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  WORDPERFECT 5.1 (converted to ASCII-DOS)
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/07/935,087
;       FILING DATE:  19920824
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US/07/822,011
;       FILING DATE:  01/16/92
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  PARKER, DAVID L.
;       REGISTRATION NUMBER:  32,165
;       REFERENCE/DOCKET NUMBER:  UTSD:269/PAR
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  512-320-7200
;       TELEFAX:  512-474-7577
;       TELEX:
;   INFORMATION FOR SEQ ID NO:  6:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  1664 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-07-935-087-6


  Query Match             89.3%;  Score 13.4;  DB 3;  Length 1664;
  Best Local Similarity   93.3%;  Pred. No. 2.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 agggcgtcggggagg 15
           |||| ||||||||||
Db      14 AGGGGGTCGGGGAGG 28


RESULT  13
PCT-US93-08062-6
; Sequence 6, Application PC/TUS9308062
;  GENERAL INFORMATION:
;     APPLICANT:
;     SEQUENCE CHARACTERISTICS:
;     SEQUENCE CHARACTERISTICS:  BROWN, MICHAEL S.
;     SEQUENCE CHARACTERISTICS:  GOLDSTEIN, JOSEPH L.
;     SEQUENCE CHARACTERISTICS:  REISS, YUVAL
;     SEQUENCE CHARACTERISTICS:  MARSTERS, JR., JAMES C.
;       ADDRESSEE:  METHODS AND COMPOSITIONS FOR
;       ADDRESSEE:  THE IDENTIFICATION,
;       ADDRESSEE:  CHARACTERIZATION AND
;       ADDRESSEE:  INHIBITION OF
;       ADDRESSEE:  FARNESYLTRANSFERASE
;     NUMBER OF SEQUENCES:  71
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  ARNOLD, WHITE & DURKEE
;       STREET:  P.O. BOX 4433
;       CITY:  HOUSTON
;       STATE:  TEXAS
;       COUNTRY:  UNITED STATES OF AMERICA
;       ZIP:  77210
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  FLOPPY DISK/ASKII
;       COMPUTER:  IBM PC COMPATIBLE
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  WORDPERFECT 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  PCT/US93/08062
;       FILING DATE:  AUGUST 24, 1993
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  07/935,087
;       FILING DATE:  24 AUGUST 1992 (24.08.92)
;       NAME:  UNKNOWN
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  PARKER, DAVID L.
;       REGISTRATION NUMBER:  32,165
;       REFERENCE/DOCKET NUMBER:  UTFD377PCT
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  512-320-7200
;       TELEFAX:  512-474-7577
;       TELEX:  NOT APPLICABLE
;   INFORMATION FOR SEQ ID NO:  6:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  1664 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
PCT-US93-08062-6


  Query Match             89.3%;  Score 13.4;  DB 5;  Length 1664;
  Best Local Similarity   93.3%;  Pred. No. 2.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy      1 agggcgtcggggagg 15
          |||| ||||||||||
Db     14 AGGGGGTCGGGGAGG 28


RESULT 14
US-08-476-062A-53/c
; Sequence 53, Application US/08476062A
; Patent No. 5877275
;  GENERAL INFORMATION:
;    APPLICANT:  Arnaout, M. Amin
;    TITLE OF INVENTION:  CONTROLLING CELLULAR IMMUNE/INFLAMMATORY
;    TITLE OF INVENTION:  RESPONSES WITH BETA2 INTEGRINS
;    NUMBER OF SEQUENCES:  53
;    CORRESPONDENCE ADDRESS:
       ADDRESSEE:  Fish & Richardson P.C.
       STREET:  225 Franklin Street
       CITY:  Boston
;      STATE:  MA
;      COUNTRY:  US
;      ZIP:  02110-2804
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  Windows95
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/476,062A
;      FILING DATE:  07-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/216,081
;      FILING DATE:  21-MAR-1994
;      APPLICATION NUMBER:  07/637,830
;      FILING DATE:  04-JAN-1991
;      APPLICATION NUMBER:  07/539,842
;      FILING DATE:  18-JUN-1990
;      APPLICATION NUMBER:  07/212,573
;      FILING DATE:  28-JUN-1988
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Freeman, John W.
;      REGISTRATION NUMBER:  29,066
;      REFERENCE/DOCKET NUMBER:  00786/068003
;    TELECOMMUNICATION INFORMATION:
       TELEPHONE:  617/542-5070
       TELEFAX:  617/542-8906
       TELEX:  200154
;  INFORMATION FOR SEQ ID NO:  53:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  2291 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-476-062A-53


  Query Match           89.3%;  Score 13.4;  DB 2;  Length 2291;
  Best Local Similarity  93.3%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy      1 agggcgtcggggagg 15
          |||| ||||||||||
Db   1109 AGGGTGTCGGGGAGG 1095


RESULT 15
US-08-476-062A-41/c
; Sequence 41, Application US/08476062A
; Patent No. 5877275
;  GENERAL INFORMATION:
;    APPLICANT:  Arnaout, M. Amin
;    TITLE OF INVENTION:  CONTROLLING CELLULAR IMMUNE/INFLAMMATORY
;    TITLE OF INVENTION:  RESPONSES WITH BETA2 INTEGRINS
;    NUMBER OF SEQUENCES:  53
;    CORRESPONDENCE ADDRESS:
       ADDRESSEE:  Fish & Richardson P.C.
       STREET:  225 Franklin Street
       CITY:  Boston
;      STATE:  MA
;      COUNTRY:  US
;      ZIP:  02110-2804
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  Windows95
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/476,062A
;      FILING DATE:  07-JUN-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/216,081
;      FILING DATE:  21-MAR-1994
;      APPLICATION NUMBER:  07/637,830
;      FILING DATE:  04-JAN-1991
;      APPLICATION NUMBER:  07/539,842
;      FILING DATE:  18-JUN-1990
;      APPLICATION NUMBER:  07/212,573
;      FILING DATE:  28-JUN-1988
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Freeman, John W.
;      REGISTRATION NUMBER:  29,066
;      REFERENCE/DOCKET NUMBER:  00786/068003
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  617/542-5070
;      TELEFAX:  617/542-8906
;      TELEX:  200154
;  INFORMATION FOR SEQ ID NO:  41:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  2310 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    FEATURE:
;      NAME/KEY:  Coding Sequence
;      LOCATION:  1...2307
US-08-476-062A-41


  Query Match           89.3%;  Score 13.4;  DB 2;  Length 2310;
  Best Local Similarity  93.3%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy      1 agggcgtcggggagg 15
          |||| ||||||||||
Db   1133 AGGGTGTCGGGGAGG 1119


Search completed: June  3, 2002, 22:07:31
Job time: 6032 sec
```

```
RESULT   7
AAX07369
ID   AAX07369 standard; cDNA; 2427 BP.
XX
AC   AAX07369;
XX
DT   07-JUN-1999  (first entry)
XX
DE   Human P2Y11 receptor cDNA.
XX
KW   P2Y11; G protein coupled receptor; human; infection; neutropaenia;
KW   agranulocytosis; cancer; leukaemia; diagnosis; therapy; ss.
XX
OS     mo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             40..2427
FT                   /*tag=  a
XX
PN   WO9902675-A1.
XX
PD   21-JAN-1999.
XX
PF   09-JUL-1998;   98WO-BE00108.
XX
PR   09-JUL-1997;   97EP-0870101.
XX
PA   (EURO-) EUROSCREEN SA.
XX
PI   Boeynaems J,  Communi D;
XX
DR   WP[illegible]; 1999-120876/10.
DR   [illegible]DB; AAW97842.
XX
[illegible]rotein-coupled receptor - useful for diagnosis, treatment and
[illegible]on of neutropaenia, agranulocytosis, infection and cancer
XX
[illegible]ig 1; 46pp; English.
XX
[illegible]ne encodes a novel human G protein coupled receptor,
```

```
CC   termed P2Y11 (see AAW97842), that has selective affinity for ATP.  A
CC   human cDNA placenta cDNA library was screened with a human P2Y4
CC   probe.  Of 9 clones obtained, 3 corresponding to a partial sequence
CC   encoding a new G protein coupled receptor displaying about 30%
CC   identity with other P2Y receptors.  This partial sequence was used
CC   as a probe to screen a human genomic DNA library.  4 Overlapping
CC   genomes clones were isolated.  Mapping and sequencing showed the
CC   new gene contained an intron at the 5' end of the coding region.
CC   The 4 clones contained the entire open reading frame for the new
CC   receptor, designated P2Y11.  The invention also provides vectors,
CC   transformed cells, anti-P2Y11 antibodies, nucleic acid probes,
CC   pharmaceutical compositions comprising such products and transgenic
CC   animals.  Antisense nucleotides (claimed) that hybridise to mRNA
CC   are used to decrease activity of P2Y11, while specific antibodies
CC   are used to block binding of P2Y11 to its ligand.  Probes are used
CC   in hybridisation assays to detect expression of P2Y11 at the RNA
CC   level, while antibodies are used similarly at the protein level in
CC   standard immunoassays, particularly for diagnosis of leukaemia.
CC   The transgenic animals are used to determine the effects of varying
CC   levels of P2Y11 expression.  These animals, and host cells, are
CC   used in drug screening methods to identify (ant)agonists that are
CC   potentially useful for treatment or prevention of disorders
CC   associated with excessive or inadequate receptor activity,
CC   specifically neutropaenia, agranulocytosis, infections and cancer.
CC   Host cells are also used to produce recombinant P2Y11.
XX
SQ   Sequence 2427 BP; 464 A; 790 C; 774 G; 399 T; 0 other;
```

```
  Query Match           77.4%;  Score 1288;  DB 20;  Length 2427;
  Best Local Similarity  96.0%;  Pred. No. 3.7e-248;
  Matches 1321;  Conservative    0;  Mismatches   55;  Indels    0;  Gaps    0;

Qy      69 cggacgcaggaggcctcgtggaggacacagcagcatgggacagtcagggaggtcccggca 128
           |||   ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       6 cggcacgaggaggcctcgtggaggacacagcagcatgggacagtcagggaggtcccggca 65

Qy     129 ccagaagcgcgccccgccccaggcgcagctccgcaacctcgaggcctatgccgcgaaccc 188
           ||||||||||||||   ||||||||||||||||||||||||||||||||||||||||||
Db      66 ccagaagcgcgcccgcgcccaggcgcagctccgcaacctcgaggcctatgccgcgaaccc 125

Qy     189 gcactcgttcgtgttcacgcgaggctgcacgggtcgcaacatccggcagctcagcctgga 248
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     126 gcactcgttcgtgttcacgcgaggctgcacgggtcgcaacatccggcagctcagcctgga 185

Qy     249 cgtgcggcgggtcatggagcccgtcactgccagccgtctgcaggttcgtaagaagaactc 308
           ||||||||||||||||||  ||||||||||||||||||||||||||||||||||||||||
Db     186 cgtgcggcgggtcatggagccgctcactgccagccgtctgcaggttcgtaagaagaactc 245

Qy     309 gctgaaggactgcgtggcagtggctgggcccctcggggtcacacactttctgatcctagc 368
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     246 gctgaaggactgcgtggcagtggctgggcccctcggggtcacacactttctgatcctgag 305

Qy     369 aaaacaagagaccaatgtctactttaagctgatgcgcctcccaggaggccccaccttgac 428
           ||||  ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     306 caaaacagagaccaatgtctactttaagctgatgcgcctcccaggaggccccaccttgac 365

Qy     429 cttccaggtcaagaagtactcgctggtgcgtgatgtggtctcctcactgcgccggcaccg 488
           |||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     366 cttccaggtgaagaagtactcgctggtgcgtgatgtggtctcctcactgcgccggcaccg 425

Qy     489 catgcacgagcagcagtttgcccacccacccctcctggtactcaacagctttggccccca 548
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     426 catgcacgagcagcagtttgcccacccacccctcctggtactcaacagctttggccccca 485

Qy     549 tggtatgcatgtgaagctcatggccaccatgttccagaacctgttcccctccatcaacgt 608
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     486 tggtatgcatgtgaagctcatggccaccatgttccagaacctgttcccctccatcaacgt 545

Qy     609 gcacaaggtgaacctgaacaccatcaagcgctgcctcctcatcgactacaaccccgactc 668
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     546 gcacaaggtgaacctgaacaccatcaagcgctgcctcctcatcgactacaaccccgactc 605
```

```
Qy    669 ccaggagctggacttccgccactatagcatcaaagttgttcctgtgggcgcgagtcgcgg 728
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    606 ccaggagctggacttccgccactatagcatcaaagttgttcctgtgggcgcgagtcgcgg 665

Qy    729 gatgaagaagctgctccaggagaagttccccaacatgagccgcctgcaggacatcagcga 788
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    666 gatgaagaagctgctccaggagaagttccccaacatgagccgcctgcaggacatcagcga 725

Qy    789 gctgctggccacgggcgcggggctgtcggagagcgaggcagagcctgacggcgaccacaa 848
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    726 gctgctggccacgggcgcggggctgtcggagagcgaggcagagcctgacggcgaccacaa 785

Qy    849 catcacagagctgcctcaggctgtcgctggccgtggcaacatgcgggcccagcagagtgc 908
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    786 catcacagagctgcctcaggctgtcgctggccgtggcaacatgcgggcccagcagagtgc 845

Qy    909 agtgcggctcaccgagatcggcccgcggatgacactgcagctcatcaaggtccaggaggg 968
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    846 agtgcggctcaccgagatcggcccgcggatgacactgcagctcatcaaggtccaggaggg 905

Qy    969 cgtcggggagggcaaagtgatgttccacagttttgtgagcaagacggaggaggagctgca 1028
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    906 cgtcggggagggcaaagtgatgttccacagttttgtgagcaagacggaggaggagctgca 965

Qy   1029 ggccatcctggaagccaaggagaagaagctgcggctgaaggctcagaggcaggcccagca 1088
          |||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||
Db    966 ggccatcctggaagccaaggagaagaagctgcggctgaaggcgcagaggcaggcccagca 1025

Qy   1089 ggcccagaatgtgcagcgcaagcaggagcagcgggaggcccacagaaagaagagcctgga 1148
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1026 ggcccagaatgtgcagcgcaagcaggagcagcgggaggcccacagaaagaagagcctgga 1085

Qy   1149 gggcatgaagaaggcacgggtcgggggtagtgatgaagaggcctctgggatcccttcaag 1208
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1086 gggcatgaagaaggcacgggtcgggggtagtgatgaagaggcctctgggatcccttcaag 1145

Qy   1209 gacggcgagcctggagttgggtgaggacgatgatgaacaggaagatgatgacatcgagta 1268
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1146 gacggcgagcctggagttgggtgaggacgatgatgaacaggaagatgatgacatcgagta 1205

Qy   1269 tttctgccaggcggtgggcgaggcgcccagtgaggacctgttccccgaggccaagcagaa 1328
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1206 tttctgccaggcggtgggcgaggcgcccagtgaggacctgttccccgaggccaagcagaa 1265

Qy   1329 acggcttgccaagtctccagggcggaagcggaagcggtgggaaatggatcgaggcagggg 1388
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1266 acggcttgccaagtctccagggcggaagcggaagcggtgggaaatggatcgaggtgccaa 1325

Qy   1389 tcgcctttgtgaccagaagtttcccaagaccaaggacaagtcccagggagcccagg 1444
            |    || | |   ||  |    || | |||||  |  ||  |||||
Db   1326 gtcctgccctgccaacttcttggcagctgccgacgacaaactcagtgggttccagg 1381
```

GenCore version 4.5

OM nucleic - nucleic search, using sw model

Run on: June 3, 2002, 22:11:06 ; Search time 366.71 Seconds
(without alignments)
7790.749 Million cell updates/sec

Title: US-09-438-917-5
Perfect score: 1664
Sequence: 1 gcctgatgtcgtcccacgcc.....tgaattggcaaaaaaaaaaa 1664

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1736436 seqs, 858457221 residues

Total number of hits satisfying chosen parameters: 3472872

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_032802:*
1: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2001A.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2001B.DAT:*
24: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	1659.2	99.7	1664	22	AAD05991	Human tumour suppr
2	1596.2	95.9	1828	21	AAA12415	cDNA encoding a hu
3	1561.6	93.8	1591	22	AAI59771	Human polynucleoti
4	1561.6	93.8	1591	22	AAI59772	Human polynucleoti
5	1551	93.2	2300	22	AAI57985	Human polynucleoti
6	17.8	85.2	2240	22	AAI57986	Human polynucleoti
7	288	77.4	2427	20	AAX07369	Human P2Y11 recept
8	6	42.0	2732	23	AAS86858	DNA encoding novel
9		29.6	13559	22	ABA15144	Human nervous syst
10	437.6	26.3	580	23	AAS86857	DNA encoding novel
11	376	22.6	559	22	AAH98050	Murine 7-transmemb
12	333.2	20.0	397	22	AAF64929	Novel human polynu
13	285.8	17.2	1495	23	ABL09953	Drosophila melanog
14	203.8	12.2	224	22	AAF64998	Novel human polynu
15	160.4	9.6	1041	21	AAC48751	Arabidopsis thalia
16	153.6	9.2	3664	23	ABL09952	Drosophila melanog
17	135.2	8.1	6713	23	ABL09932	Drosophila melanog
18	74.6	4.5	799	19	AAV55831	Nucleotide sequenc
19	74.6	4.5	1926	21	AAA50254	Epstein Barr virus
20	74.6	4.5	1926	22	AAF82902	EBV tethering prot
21	74.6	4.5	2580	21	AAA75454	Nucleotide sequenc
c 22	74.6	4.5	5452	20	AAX90923	Anti-sense strand
c 23	74.6	4.5	8705	20	AAZ23778	Vector pShuttle DN
24	74.6	4.5	9600	19	AAV21683	Vector plasmid pCM
25	74.6	4.5	10380	20	AAZ22248	Nucleotide sequenc
26	74.6	4.5	10596	14	AAQ51731	Plasmid pCisEBON f
27	74.6	4.5	10596	17	AAT40348	Plasmid pCisEBON f
28	74.6	4.5	10596	20	AAX15650	Nucleotide sequenc
c 29	74.6	4.5	16080	21	AAA59553	DNA clone pCEK C1.
30	72.8	4.4	1925	20	AAX90924	Epstein Barr Virus
31	63.8	3.8	795	19	AAV55830	FLGA insert stabil
c 32	60	3.6	51259	18	AAX83007	Partial mouse WRN
33	59.8	3.6	3489	21	AAA30290	Kaposi's sarcoma-a
34	59.8	3.6	3489	22	AAF82901	Nucleotide sequenc
c 35	59.8	3.6	32207	20	AAV73805	KSHV LUR DNA (nucl
c 36	59.8	3.6	137507	19	AAV19941	KSHV long unique c
37	59.4	3.6	1527	23	AAS68546	DNA encoding novel
c 38	59.4	3.6	1620	23	AAS68547	DNA encoding novel
c 39	59.4	3.6	2178	23	AAS86106	DNA encoding novel
40	59	3.5	747	22	AAL36022	Human musculoskele
c 41	59	3.5	747	22	AAK69723	Human immune/haema
c 42	59	3.5	748	22	AAK69722	Human immune/haema
43	58	3.5	2564	22	AAI92870	Human polynucleoti
44	58	3.5	3038	22	AAS14697	Human cDNA encodin
45	57.4	3.4	4021	21	AAC77217	Human ORFX ORF2772

ALIGNMENTS

RESULT 1
AAD05991
ID AAD05991 standard; cDNA; 1664 BP.
XX
AC AAD05991;
XX
DT 31-JUL-2001 (first entry)
XX
DE Human tumour suppressor 1 (HTS1) cDNA.
XX
KW Human tumour suppressor 1; HTS1; HPPAN; neoplastic cell; cancer; tumour;
KW leukaemia; breast; bladder; colorectal; gynaecological; lung; cytostatic;
KW antiproliferative; gene therapy; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 103..1524
FT /*tag= a
FT /product= "Human tumour suppressor 1 (HTS1) protein"
FT /transl_except= (pos:1519..1521, aa:A-Z)
FT /note= "This translation exception occurs only
FT decoding the sequence (AAE01341) shown in figure 7"
XX
PN WO200134634-A2.
XX
PD 17-MAY-2001.
XX
PF 09-NOV-2000; 2000WO-US30951.
XX
PR 12-NOV-1999; 99US-0438917.
XX

PA (IMMU-) IMMUSOL INC.
XX
PI Welch PJ, Barber JR;
XX
DR WPI; 2001-329068/34.
DR P-PSDB; AAE01341, AAE01350.
XX
PT New tumor suppressor nucleic acid molecules for detecting a neoplastic
PT cell in a sample and for regulating cell proliferation, such as, for
PT treating cancer -
XX
PS Claim 3; Fig 6; 84pp; English.
XX
CC The invention relates to human tumour suppressor 1 (HTS1) genes, also
CC referred as HPPAN and polypeptides encoded by them. The invention
CC also provides hairpin ribozymes and antibodies selective for the HTS1
CC molecules, and diagnostic methods for detecting a neoplastic cell in a
CC sample using detectable agents specific for HTS1 molecules. HTS1 and
CC its genes are useful for detecting a neoplastic cell in a sample and
CC are therefore used to diagnose and prognose cancer. HTS1 sequences are
CC introduced into neoplastic cells to regulate cell proliferation, and
CC are thus useful as therapeutics for treating cancer. They are also used
CC for identifying compounds that mimic or regulate the tumour suppressor
CC activity. Such compounds are used as therapeutics to treat cancer. HTS1
CC sequences are used to treat both solid tumours and leukaemias. They are
CC also used in gene therapy. The diagnostic methods are useful for
CC identification of neoplastic cells in solid tumours of breast, bladder,
CC colorectal, gynaecological, lung, renal cancers etc.
CC The present sequence is human tumour suppressor 1 (HTS1) cDNA.
XX
SQ Sequence 1664 BP; 371 A; 492 C; 548 G; 253 T; 0 other;

Query Match 99.7%; Score 1659.2; DB 22; Length 1664;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 1661; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1 gcctgatgtcgtcccacgccgtgccggctctcaggcgccggaagtgagctgcgcacggcc 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 gcctgatgtcgtcccacgccgtgccggctctcaggcgccggaagtgagctgcgcacggcc 60

Qy      61 ggaagcggcggacgcaggaggcctcgtggaggacacagcagcatgggacagtcagggagg 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 ggaagcggcggacgcaggaggcctcgtggaggacacagcagcatgggacagtcagggagg 120

Qy     121 tcccggcaccagaagcgcgccccgccccaggcgcagctccgcaacctcgaggcctatgcc 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 tcccggcaccagaagcgcgccccgccccaggcgcagctccgcaacctcgaggcctatgcc 180

Qy     181 gcgaacccgcactcgttcgtgttcacgcgaggctgcacgggtcgcaacatccggcagctc 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     181 gcgaacccgcactcgttcgtgttcacgcgaggctgcacgggtcgcaacatccggcagctc 240

Qy     241 agcctggacgtgcggcgggtcatggagcccgtcactgccagccgtctgcaggttcgtaag 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     241 agcctggacgtgcggcgggtcatggagcccgtcactgccagccgtctgcaggttcgtaag 300

Qy     301 aagaactcgctgaaggactgcgtggcagtggctgggcccctcggggtcacacactttctg 360
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     301 aagaactcgctgaaggactgcgtggcagtcgctgggcccctcggggtcacacactttctg 360

Qy     361 atcctagcaaaacaagagaccaatgtctactttaagctgatgcgcctcccaggaggcccc 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     361 atcctagcaaaacaagagaccaatgtctactttaagctgatgcgcctcccaggaggcccc 420

Qy     421 accttgaccttccaggtcaagaagtactcgctggtgcgtgatgtggtctcctcactgcgc 480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     421 accttgaccttccaggtcaagaagtactcgctggtgcgtgatgtggtctcctcactgcgc 480

Qy     481 cggcaccgcatgcacgagcagcagtttgcccacccacccctcctggtactcaacagcttt 540
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     481 cggcaccgcatgcacgagcagcagtttgcccacccacccctcctggtactcaacagcttt 540

Qy     541 ggccccccatggtatgcatgtgaagctcatggccaccatgttccagaacctgttcccctcc 600
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     541 ggccccccatggtatgcatgtgaagctcatggccaccatgttccagaacctgttcccctcc 600

Qy     601 atcaacgtgcacaaggtgaacctgaacaccatcaagcgctgcctcctcatcgactacaac 660
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     601 atcaacgtgcacaaggtgaacctgaacaccatcaagcgctgcctcctcatcgactacaac 660

Qy     661 cccgactcccaggagctggacttccgccactatagcatcaaagttgttcctgtgggcgcg 720
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     661 cccgactcccaggagctggacttccgccactatagcatcaaagttgttcctgtgggcgcg 720

Qy     721 agtcgcgggatgaagaagctgctccaggagaagttccccaacatgagccgcctgcaggac 780
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     721 agtcgcgggatgaagaagctgctccaggagaagttccccaacatgagccgcctgcaggac 780

Qy     781 atcagcgagctgctggccacgggcgcggggctgtcggagagcgaggcagagcctgacggc 840
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     781 atcagcgagctgctggccacgggcgcggggctgtcggagagcgaggcagagcctgacggc 840

Qy     841 gaccacaacatcacagagctgcctcaggctgtcgctggccgtggcaacatgcgggcccag 900
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     841 gaccacaacatcacagagctgcctcaggctgtcgctggccgtggcaacatgcgggcccag 900

Qy     901 cagagtgcagtgcggctcaccgagatcggcccgcggatgacactgcagctcatcaaggtc 960
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     901 cagagtgcagtgcggctcaccgagatcggcccgcggatgacactgcagctcatcaaggtc 960

Qy     961 caggagggcgtcggggagggcaaagtgatgttccacagttttgtgagcaagacggaggag 1020
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     961 caggagggcgtcggggagggcaaagtgatgttccacagttttgtgagcaagacggaggag 1020

Qy    1021 gagctgcaggccatcctggaagccaaggagaagaagctgcggctgaaggctcagaggcag 1080
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1021 gagctgcaggccatcctggaagccaaggagaagaagctgcggctgaaggctcagaggcag 1080

Qy    1081 gcccagcaggcccagaatgtgcagcgcaagcaggagcagcgggaggcccacagaaagaag 1140
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1081 gcccagcaggcccagaatgtgcagcgcaagcaggagcagcgggaggcccacagaaagaag 1140

Qy    1141 agcctggagggcatgaagaaggcacgggtcgggggtagtgatgaagaggcctctgggatc 1200
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1141 agcctggagggcatgaagaaggcacgggtcgggggtagtgatgaagaggcctctgggatc 1200

Qy    1201 ccttcaaggacggcgagcctggagttgggtgaggacgatgatgaacaggaagatgatgac 1260
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1201 ccttcaaggacggcgagcctggagttgggtgaggacgatcatgaacaggaagatgatgac 1260

Qy    1261 atcgagtatttctgccaggcggtgggcgaggcgcccagtgaggacctgttccccgaggcc 1320
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1261 atcgagtatttctgccaggcggtgggcgaggcgcccagtgaggacctgttccccgaggcc 1320

Qy    1321 aagcagaaacggcttgccaagtctccagggcggaagcggaagcggtgggaaatggatcga 1380
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1321 aagcagaaacggcttgccaagtctccagggcggaagcggaagcggtgggaaatggatcga 1380

Qy    1381 ggcaggggtcgccctttgtgaccagaagtttcccaagaccaaggacaagtcccagggagcc 1440
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1381 ggcaggggtcgccctttgtgaccagaagtttcccaagacaaaggacaagtcccagggagcc 1440

Qy    1441 caggccaggcgggggcccagaggggcttcccgggatggtgggcgaggccgggggccgaggc 1500
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1441 caggccaggcgggggcccagaggggcttcccgggatggtgggcgaggccgggggccgaggc 1500

Qy    1501 cgcccagggaagagagtggcctgagcccaagccgcaccggagcagcggctggattgaacg 1560
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1501 cgcccagggaagagagtggcctgagcccaagccgcaccggagcagcggctggattgaacg 1560

Qy    1561 ccccagattggggcccgagatgtggccctcggtttcctttcataaaggagttgtgtcccc 1620
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1561 ccccagattggggcccgagatgtggccctcggtttcctttcataaaggagttgtgtcccc 1620

Qy    1621 agcccttccactccagtaaagaactgaattggcaaaaaaaaaaa 1664
```

```
              ||||||||||||||||||||||||||||||||||||||||||||
Db   1621 agcccttccactccagtaaagaactgaattggcaaaaaaaaaaa 1664
```

RESULT 2
AAA12415

```
ID   AAA12415 standard; cDNA; 1828 BP.
XX
AC   AAA12415;
XX
DT   25-JUL-2000  (first entry)
XX
DE   cDNA encoding a human RNA-associated protein.
XX
KW   Human; RNA-associated protein; cell proliferation; cancer; inflammation;
KW   immune response; reproductive disorder; actinic keratosis;
     atherosclerosis; arteriosclerosis; bursitis; cirrhosis; hepatitis;
     mixed connective tissue disease; myelofibrosis; primary thrombocythemia;
     paroxysomal nocturnal hemoglobinuria; polycythermia vera; psoriasis;
KW   trauma; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             89..1507
FT                   /*tag=  a
FT                   /product= "RNA-associated protein"
XX
PN   WO200015799-A2.
XX
PD   23-MAR-2000.
XX
PF   17-SEP-1999;   99WO-US21688.
XX
PR   17-SEP-1998;   98US-0156039.
PR   22-SEP-1998;   98US-0158720.
PR   04-NOV-1998;   98US-0186815.
PR   08-APR-1999;   99US-0128660.
XX
PA   (INCY-) INCYTE PHARM INC.
XX
PI   Tang YT,  Corley NC,  Guegler KJ,  Gorgone GA,  Patterson C;
PI   Hillman JL,  Baughn MR,  Lal P,  Azimzai Y,  Yue H,  Yang J;
XX
DR   WPI; 2000-271437/23.
     P-PSDB; AAY84443.
PT   New polypeptides and polynucleotides, useful for preventing and
PT   treating a disorder associated with increased or decreased expression
PT   of RNA associated proteins -
XX
PS   Claim 9; Page 123-124; 131pp; English.
XX
CC   The present sequence encodes a human RNA-associated protein. The
CC   expression of RNA-associated proteins is closely associated with
CC   reproductive tissues, nervous tissues, cell proliferation including
CC   cancer, inflammation and immune responses, and so they may be used
CC   for diagnosis, treatment or prevention of cell proliferative,
CC   immune/inflammatory disorders, and reproductive disorders. Diseases
CC.  and disorders which may be treated include actinic keratosis,
CC   atherosclerosis, arteriosclerosis, bursitis, cirrhosis, hepatitis,
CC   mixed connective tissue disease, myelofibrosis, paroxysomal nocturnal
CC   hemoglobinuria, polycythermia vera, psoriasis, primary thrombocythemia
CC   and cancers, and trauma.
XX
SQ   Sequence 1828 BP; 387 A; 547 C; 607 G; 287 T; 0 other;

     Match              95.9%;  Score 1596.2;  DB 21;  Length 1828;
     al Similarity      98.7%;  Pred. No. 9.9e-310;
     620;  Conservative    0;  Mismatches   18;  Indels    3;  Gaps    1;

          gccgtgccggctctcaggcgccggaagtgagctgcgcacggccggaagcggcggacg 74
          |||||||||||||||||||||||||||||||||||||||||  ||||||||||||||||
Db      1 cacgccgtgccggctctcaggcgccggaagtgagctgcgcagcgccggaagcggcggacg 60

Qy     75 caggaggcctcgtggaggacacagcagcatgggacagtcagggaggtcccggcaccagaa 134
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 caggaggcctcgtggaggacacagcagcatgggacagtcagggaggtcccggcaccagaa 120

Qy    135 gcgcgccccgccccaggcgcagctccgcaacctcgaggcctatgccgcgaacccgcactc 194
          ||||||||     |||||||||||||||||||||||||||||||||||||||||||||||
Db    121 gcgcgcccgcgcccaggcgcagctccgcaacctcgaggcctatgccgcgaacccgcactc 180

Qy    195 gttcgtgttcacgcgaggctgcacgggtcgcaacatccggcagctcagcctggacgtgcg 254
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    181 gttcgtgttcacgcgaggctgcacgggtcgcaacatccggcagctcagcctggacgtgcg 240

Qy    255 gcgggtcatggagcccgtcactgccagccgtctgcaggttcgtaagaagaactcgctgaa 314
          |||||||||||||| |||||||||||||||||||||||||||||||||||||||||||||
Db    241 gcgggtcatggagccgctcactgccagccgtctgcaggttcgtaagaagaactcgctgaa 300

Qy    315 ggactgcgtggcagtggctgggcccctcggggtcacacactttctgatcctagcaaaaca 374
          ||||||||||||||||||||||||||||||||||||||||||||||||||||  |||
Db    301 ggactgcgtggcagtggctgggcccctcggggtcacacactttctgatcctgagcaaaac 360

Qy    375 agagaccaatgtctactttaagctgatgcgcctcccaggaggccccaccttgaccttcca 434
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    361 agagaccaatgtctactttaagctgatgcgcctcccaggaggccccaccttgaccttcca 420

Qy    435 ggtcaagaagtactcgctggtgcgtgatgtggtctcctcactgcgccggcaccgcatgca 494
          | || |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    421 ggtgaagaagtactcgctggtgcgtgatgtggtctcctcactgcgccggcaccgcatgca 480

Qy    495 cgagcagcagtttgcccacccacccctcctggtactcaacagctttggcccccatggtat 554
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    481 cgagcagcagtttgcccacccacccctcctggtactcaacagctttggcccccatggtat 540

Qy    555 gcatgtgaagctcatggccaccatgttccagaacctgttcccctccatcaacgtgcacaa 614
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    541 gcatgtgaagctcatggccaccatgttccagaacctgttcccctccatcaacgtgcacaa 600

Qy    615 ggtgaacctgaacaccatcaagcgctgcctcctcatcgactacaaccccgactcccagga 674
          ||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||||
Db    601 ggtgaacctgaacaccatcaagcgctgcctcctcatcgactacaatcccgactcccagga 660

Qy    675 gctggacttccgccactatagcatcaaagttgttcctgtgggcgcgagtcgcgggatgaa 734
          |||||||||||||||||   ||||||||||||||||||||||||||||||||||||||||
Db    661 gctggacttccgccacta---catcaaagttgttcctgtgggcgcgagtcgcgggatgaa 717

Qy    735 gaagctgctccaggagaagttccccaacatgagccgcctgcaggacatcagcgagctgct 794
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    718 gaagctgctccaggagaagttccccaacatgagccgcctgcaggacatcagcgagctgct 777

Qy    795 ggccacgggcgcggggctgtcggagagcgaggcagagcctgacggcgaccacaacatcac 854
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    778 ggccacgggcgcggggctgtcggagagcgaggcagagcctgacggcgaccacaacatcac 837

Qy    855 agagctgcctcaggctgtcgctggccgtggcaacatgcgggcccagcagagtgcagtgcg 914
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    838 agagctgcctcaggctgtcgctggccgtggcaacatgcgggcccagcagagtgcagtgcg 897

Qy    915 gctcaccgagatcggcccgcggatgacactgcagctcatcaaggtccaggagggcgtcgg 974
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    898 gctcaccgagatcggcccgcggatgacactgcagctcatcaaggtccaggagggcgtcgg 957

Qy    975 ggagggcaaagtgatgttccacagttttgtgagcaagacggaggaggagctgcaggccat 1034
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    958 ggagggcaaagtgatgttccacagttttgtgagcaagacggaggaggagctgcaggccat 1017

Qy   1035 cctggaagccaaggagaagaagctgcggctgaaggctcagaggcaggcccagcaggccca 1094
          |||||||||||||||||||||||||||||||||||| |||||||||||||||||||||||
Db   1018 cctggaagccaaggagaagaagctgcggctgaaggcgcagaggcaggcccagcaggccca 1077

Qy   1095 gaatgtgcagcgcaagcaggagcagcgggaggcccacagaaagaagagcctggagggcat 1154
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db   1078 gaatgtgcagcgcaagcaggagcagcgggaggcccacagaaagaagagcctggagggcat 1137

Qy   1155 gaagaaggcacgggtcgggggtagtgatgaagaggcctctgggatcccttcaaggacggc 1214
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1138 gaagaaggcacgggtcgggggtagtgatgaagaggcctctgggatcccttcaaggacggc 1197

Qy   1215 gagcctggagttgggtgaggacgatgatgaacaggaagatgatgacatcgagtatttctg 1274
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1198 gagcctggagttgggtgaggacgatgatgaacaggaagatgatgacatcgagtatttctg 1257

Qy   1275 ccaggcggtgggcgaggcgcccagtgaggacctgttccccgaggccaagcagaaacggct 1334
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1258 ccaggcggtgggcgaggcgcccagtgaggacctgttccccgaggccaagcagaaacggct 1317

Qy   1335 tgccaagtctccagggcggaagcggaagcggtgggaaatggatcgaggcaggggtcgcct 1394
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1318 tgccaagtctccagggcggaagcggaagcggtgggaaatggatcgaggcaggggtcgcct 1377

Qy   1395 ttgtgaccagaagtttcccaagaccaaggacaagtcccagggagcccaggccaggcgggg 1454
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1378 ttgtgaccagaagtttcccaagaccaaggacaagtcccagggagcccaggccaggcgggg 1437

Qy   1455 gcccagaggggcttcccgggatggtgggcgaggccggggccgaggccgcccagggaagag 1514
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1438 gcccagaggggcttcccgggatggtgggcgaggccggggccggggccgcccagggaagag 1497

Qy   1515 agtggcctgagcccaagccgcaccggagcagcggctggattgaacgccccagattggggc 1574
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1498 agtggcctgagcccaagccgcaccggagcagcggctggattgaacgccccagattggggc 1557

Qy   1575 ccgagatgtggccctcggtttcctttcataaaggagttgtgtccccagcccttccactcc 1634
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1558 ccgagatgtggccctcggtttcctttcataaaggagttgtgtccccagcccttccactcc 1617

Qy   1635 agtaaagaactgaattggcaa 1655
          |||||||||||||||||| |
Db   1618 agtaaagaactgaattggcca 1638
```

RESULT 3
AAI59771/c
ID AAI59771 standard; cDNA; 1591 BP.
XX
AC AAI59771;
XX
DT 22-OCT-2001 (first entry)
XX
DE Human polynucleotide SEQ ID NO 3760.
XX
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia; ss.
XX
OS Homo sapiens.
XX
PN WO200153312-A1.
XX
PD 26-JUL-2001.
XX
PF 26-DEC-2000; 2000WO-US34263.
XX
PR 21-JAN-2000; 2000US-0488725.
PR 25-APR-2000; 2000US-0552317.
PR 09-JUL-2000; 2000US-0598042.
PR 19-JUL-2000; 2000US-0620312.
PR 03-AUG-2000; 2000US-0653450.
PR 14-SEP-2000; 2000US-0662191.
PR 19-OCT-2000; 2000US-0693036.
PR 29-NOV-2000; 2000US-0727344.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
XX
DR WPI; 2001-442253/47.
DR P-PSDB; AAM40615.
XX
PT Novel nucleic acids and polypeptides, useful for treating disorders
PT such as central nervous system injuries -
XX
PS Claim 1; SEQ ID NO 3760; 10078pp; English.
XX
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders.
CC Note: The sequence data for this patent did not form part of the printed
CC specification.
XX
SQ Sequence 1591 BP; 247 A; 524 C; 463 G; 357 T; 0 other;

Query Match 93.8%; Score 1561.6; DB 22; Length 1591;
Best Local Similarity 99.1%; Pred. No. 7.8e-303;
Matches 1570; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

```
Qy     81 gcctcgtggaggacacagcagcatgggacagtcagggaggtcccggcaccagaagcgcgc 140
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1585 GCCTCGTGGAGGACACAGCAGCATGGGACAGTCAGGGAGGTCCCGGCACCAGAAGCGCGC 1526

Qy    141 cccgccccaggcgcagctccgcaacctcgaggcctatgccgcgaacccgcactcgttcgt 200
          ||  ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1525 CCGCGCCCAGGCGCAGCTCCGCAACCTCGAGGCCTATGCCGCGAACCCGCACTCGTTCGT 1466

Qy    201 gttcacgcgaggctgcacgggtcgcaacatccggcagctcagcctggacgtgcggcgggt 260
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1465 GTTCACGCGAGGCTGCACGGGTCGCAACATCCGGCAGCTCAGCCTGGACGTGCGGCGGGT 1406

Qy    261 catggagcccgtcactgccagccgtctgcaggttcgtaagaagaactcgctgaaggactg 320
          |||||||||  ||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1405 CATGGAGCCGCTCACTGCCAGCCGTCTGCAGGTTCGTAAGAAGAACTCGCTGAAGGACTG 1346

Qy    321 cgtggcagtggctgggcccctcggggtcacacactttctgatcctagcaaaacaagagac 380
          ||||||||||||||||||||||||||||||||||||||||||||||||||   |||  ||||||
Db   1345 CGTGGCAGTGGCTGGGCCCCTCGGGGTCACACACTTTCTGATCCTGAGCAAAACAGAGAC 1286

Qy    381 caatgtctactttaagctgatgcgcctcccaggaggccccaccttgaccttccaggtcaa 440
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||
Db   1285 CAATGTCTACTTTAAGCTGATGCGCCTCCCAGGAGGCCCCACCTTGACCTTCCAGGTGAA 1226

Qy    441 gaagtactcgctggtgcgtgatgtggtctcctcactgcgccggcaccgcatgcacgagca 500
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1225 GAAGTACTCGCTGGTGCGTGATGTGGTCTCCTCACTGCGCCGGCACCGCATGCACGAGCA 1166

Qy    501 gcagtttgcccacccacccctcctggtactcaacagctttggccccccatggtatgcatgt 560
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1165 GCAGTTTGCCCACCCACCCCTCCTGGTACTCAACAGCTTTGGCCCCCATGGTATGCATGT 1106

Qy    561 gaagctcatggccaccatgttccagaacctgttcccctccatcaacgtgcacaaggtgaa 620
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1105 GAAGCTCATGGCCACCATGTTCCAGAACCTGTTCCCCTCCATCAACGTGCACAAGGTGAA 1046
```

```
Qy    621 cctgaacaccatcaagcgctgcctcctcatcgactacaaccccgactcccaggagctgga 680
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1045 CCTGAACACCATCAAGCGCTGCCTCCTCATCGACTACAACCCCGACTCCCAGGAGCTGGA 986

Qy    681 cttccgccactatagcatcaaagttgttcctgtgggcgcgagtcgcgggatgaagaagct 740
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    985 CTTCCGCCACTATAGCATCAAAGTTGTTCCTGTGGGCGCGAGTCGCGGGATGAAGAAGCT 926

Qy    741 gctccaggagaagttccccaacatgagccgcctgcaggacatcagcgagctgctggccac 800
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    925 GCTCCAGGAGAAGTTCCCCAACATGAGCCGCCTGCAGGACATCAGCGAGCTGCTGGCCAC 866

Qy    801 gggcgcggggctgtcggagagcgaggcagagcctgacggcgaccacaacatcacagagct 860
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    865 GGGCGCGGGGCTGTCGGAGAGCGAGGCAGAGCCTGACGGCGACCACAACATCACAGAGCT 806

      861 gcctcaggctgtcgctggccgtggcaacatgcgggcccagcagagtgcagtgcggctcac 920
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    805 GCCTCAGGCTGTCGCTGGCCGTGGCAACATGCGGGCCCAGCAGAGTGCAGTGCGGCTCAC 746

Qy    921 cgagatcggcccgcggatgacactgcagctcatcaaggtccaggagggcgtcggggaggg 980
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    745 CGAGATCGGCCCGCGGATGACACTGCAGCTCATCAAGGTCCAGGAGGGCGTCGGGGAGGG 686

Qy    981 caaagtgatgttccacagttttgtgagcaagacggaggaggagctgcaggccatcctgga 1040
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    685 CAAAGTGATGTTCCACAGTTTTGTGAGCAAGACGGAGGAGGAGCTGCAGGCCATCCTGGA 626

Qy   1041 agccaaggagaagaagctgcggctgaaggctcagaggcaggcccagcaggcccagaatgt 1100
          |||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||
Db    625 AGCCAAGGAGAAGAAGCTGCGGCTGAAGGCGCAGAGGCAGGCCCAGCAGGCCCAGAATGT 566

Qy   1101 gcagcgcaagcaggagcagcgggaggcccacagaaagaagagcctggagggcatgaagaa 1160
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    565 GCAGCGCAAGCAGGAGCAGCGGGAGGCCCACAGAAAGAAGAGCCTGGAGGGCATGAAGAA 506

Qy   1161 ggcacgggtcgggggtagtgatgaagaggcctctgggatcccttcaaggacggcgagcct 1220
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    505 GGCACGGGTCGGGGGTAGTGATGAAGAGGCCTCTGGGATCCCTTCAAGGACGGCGAGCCT 446

Qy   1221 ggagttgggtgaggacgatgatgaacaggaagatgatgacatcgagtatttctgccaggc 1280
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    445 GGAGTTGGGTGAGGACGATGATGAACAGGAAGATGATGACATCGAGTATTTCTGCCAGGC 386

Qy   1281 ggtgggcgaggcgcccagtgaggacctgttccccgaggccaagcagaaacggcttgccaa 1340
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    385 GGTGGGCGAGGCGCCCAGTGAGGACCTGTTCCCCGAGGCCAAGCAGAAACGGCTTGCCAA 326

Qy   1341 gtctccagggcggaagcggaagcggtgggaaatggatcgaggcaggggtcgcctttgtga 1400
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    325 GTCTCCAGGGCGGAAGCGGAAGCGGTGGGAAATGGATCGAGGCAGGGGTCGCCTTTGTGA 266

Qy   1401 ccagaagtttcccaagaccaaggacaagtcccagggagcccaggccaggcgggggcccag 1460
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    265 CCAGAAGTTTCCCAAGACCAAGGACAAGTCCCAGGGAGCCCAGGCCAGGCGGGGGCCCAG 206

Qy   1461 aggggcttcccgggatggtgggcgaggccggggccgaggccgcccagggaagagagtggc 1520
          |||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||
Db    205 AGGGGCTTCCCGGGATGGTGGGCGAGGCCGGGGCCGGGGCCGCCCAGGGAAGAGAGTGGC 146

Qy   1521 ctgagcccaagccgcaccggagcagcggctggattgaacgccccagattggggcccgaga 1580
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    145 CTGAGCCCAAGCCGCACCGGAGCAGCGGCTGGATTGAACGCCCCAGATTGGGGCCCGAGA 86

Qy   1581 tgtggccctcggtttcctttcataaaggagttgtgtccccagcccttccactccagtaaa 1640
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     85 TGTGGCCCTCGGTTTCCTTTCATAAAGGAGTTGTGTCCCCAGCCCTTCCACTCCAGTAAA 26

Qy   1641 gaactgaattggcaaaaaaaaaaa 1664
          |||||||||||||||||||||||||
Db     25 GAACTGAATTGGCAAAAAAAAAAA 2
```

```
RESULT   4
AAI59772/c
ID   AAI59772 standard; cDNA; 1591 BP.
XX
AC   AAI59772;
XX
DT   22-OCT-2001  (first entry)
XX
DE   Human polynucleotide SEQ ID NO 3761.
XX
KW   Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW   peripheral nervous system; neuropathy; central nervous system; CNS;
KW   Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW   amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW   chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW   leukaemia; ss.
XX
OS   Homo sapiens.
XX
PN   WO200153312-A1.
XX
PD   26-JUL-2001.
XX
PF   26-DEC-2000; 2000WO-US34263.
XX
PR   21-JAN-2000; 2000US-0488725.
PR   25-APR-2000; 2000US-0552317.
PR   09-JUL-2000; 2000US-0598042.
PR   19-JUL-2000; 2000US-0620312.
PR   03-AUG-2000; 2000US-0653450.
PR   14-SEP-2000; 2000US-0662191.
PR   19-OCT-2000; 2000US-0693036.
PR   29-NOV-2000; 2000US-0727344.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Asundi V,  Chen R,  Ma Y,  Qian XB,  Ren F,  Wang D;
PI   Wang J,  Wang Z,  Wehrman T,  Xu C,  Xue AJ,  Yang Y,  Zhang J;
PI   Zhao QA,  Zhou P,  Goodrich R,  Drmanac RT;
XX
DR   WPI; 2001-442253/47.
DR   P-PSDB; AAM40616.
XX
PT   Novel nucleic acids and polypeptides, useful for treating disorders
PT   such as central nervous system injuries -
XX
PS   Claim 1; SEQ ID NO 3761; 10078pp; English.
XX
CC   The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC   the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC   immunosuppressant and cytostatic activity. The polynucleotides are useful
CC   in gene therapy. A composition containing a polypeptide or polynucleotide
CC   of the invention may be used to treat diseases of the peripheral nervous
CC   system, such as peripheral nervous injuries, peripheral neuropathy and
CC   localised neuropathies and central nervous system diseases, such as
CC   Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC   lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC   utilisation of the activities such as: Immune system suppression,
CC   Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC   and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC   assays for receptor activity, arthritis and inflammation, leukaemias and
CC   C.N.S disorders.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification.
XX
SQ   Sequence 1591 BP; 247 A; 524 C; 463 G; 357 T; 0 other;

  Query Match           93.8%;  Score 1561.6;  DB 22;  Length 1591;
  Best Local Similarity 99.1%;  Pred. No. 7.8e-303;
  Matches 1570;  Conservative    0;  Mismatches   14;  Indels    0;  Gaps    0;
```

```
Qy      81 gcctcgtggaggacacagcagcatgggacagtcagggaggtcccggcaccagaagcgcgc 140
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1585 GCCTCGTGGAGGACACAGCAGCATGGGACAGTCAGGGAGGTCCCGGCACCAGAAGCGCGC 1526

Qy     141 cccgccccaggcgcagctccgcaacctcgaggcctatgccgcgaacccgcactcgttcgt 200
           ||   ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1525 CCGCGCCCAGGCGCAGCTCCGCAACCTCGAGGCCTATGCCGCGAACCCGCACTCGTTCGT 1466

Qy     201 gttcacgcgaggctgcacgggtcgcaacatccggcagctcagcctggacgtgcggcgggt 260
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1465 GTTCACGCGAGGCTGCACGGGTCGCAACATCCGGCAGCTCAGCCTGGACGTGCGGCGGGT 1406

Qy     261 catggagcccgtcactgccagccgtctgcaggttcgtaagaagaactcgctgaaggactg 320
           |||||||||  ||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1405 CATGGAGCCGCTCACTGCCAGCCGTCTGCAGGTTCGTAAGAAGAACTCGCTGAAGGACTG 1346

Qy     321 cgtggcagtggctgggcccctcggggtcacacactttctgatcctagcaaaacaagagac 380
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1345 CGTGGCAGTGGCTGGGCCCCTCGGGGTCACACACTTTCTGATCCTGAGCAAAACAGAGAC 1286

Qy     381 caatgtctactttaagctgatgcgcctcccaggaggccccaccttgaccttccaggtcaa 440
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||
Db    1285 CAATGTCTACTTTAAGCTGATGCGCCTCCCAGGAGGCCCCACCTTGACCTTCCAGGTGAA 1226

Qy     441 gaagtactcgctggtgcgtgatgtggtctcctcactgcgccggcaccgcatgcacgagca 500
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1225 GAAGTACTCGCTGGTGCGTGATGTGGTCTCCTCACTGCGCCGGCACCGCATGCACGAGCA 1166

Qy     501 gcagtttgcccacccacccctcctggtactcaacagctttggcccccatggtatgcatgt 560
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1165 GCAGTTTGCCCACCCACCCCTCCTGGTACTCAACAGCTTTGGCCCCCATGGTATGCATGT 1106

Qy     561 gaagctcatggccaccatgttccagaacctgttcccctccatcaacgtgcacaaggtgaa 620
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1105 GAAGCTCATGGCCACCATGTTCCAGAACCTGTTCCCCTCCATCAACGTGCACAAGGTGAA 1046

Qy     621 cctgaacaccatcaagcgctgcctcctcatcgactacaaccccgactcccaggagctgga 680
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1045 CCTGAACACCATCAAGCGCTGCCTCCTCATCGACTACAACCCCGACTCCCAGGAGCTGGA 986

Qy     681 cttccgccactatagcatcaaagttgttcctgtgggcgcgagtcgcgggatgaagaagct 740
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     985 CTTCCGCCACTATAGCATCAAAGTTGTTCCTGTGGGCGCGAGTCGCGGGATGAAGAAGCT 926

Qy     741 gctccaggagaagttccccaacatgagccgcctgcaggacatcagcgagctgctggccac 800
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     925 GCTCCAGGAGAAGTTCCCCAACATGAGCCGCCTGCAGGACATCAGCGAGCTGCTGGCCAC 866

Qy     801 gggcgcggggctgtcggagagcgaggcagagcctgacggcgaccacaacatcacagagct 860
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     865 GGGCGCGGGGCTGTCGGAGAGCGAGGCAGAGCCTGACGGCGACCACAACATCACAGAGCT 806

Qy     861 gcctcaggctgtcgctggccgtggcaacatgcgggcccagcagagtgcagtgcggctcac 920
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     805 GCCTCAGGCTGTCGCTGGCCGTGGCAACATGCGGGCCCAGCAGAGTGCAGTGCGGCTCAC 746

Qy     921 cgagatcggcccgcggatgacactgcagctcatcaaggtccaggagggcgtcggggaggg 980
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     745 CGAGATCGGCCCGCGGATGACACTGCAGCTCATCAAGGTCCAGGAGGGCGTCGGGGAGGG 686

Qy     981 caaagtgatgttccacagttttgtgagcaagacggaggaggagctgcaggccatcctgga 1040
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     685 CAAAGTGATGTTCCACAGTTTTGTGAGCAAGACGGAGGAGGAGCTGCAGGCCATCCTGGA 626

Qy    1041 agccaaggagaagaagctgcggctgaaggctcagaggcaggcccagcaggcccagaatgt 1100
           |||||||||||||||||||||||||||| ||||||||||||||||||||||||||||||||
Db     625 AGCCAAGGAGAAGAAGCTGCGGCTGAAGGCGCAGAGGCAGGCCCAGCAGGCCCAGAATGT 566

Qy    1101 gcagcgcaagcaggagcagcgggaggcccacagaaagaagagcctggagggcatgaagaa 1160
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     565 GCAGCGCAAGCAGGAGCAGCGGGAGGCCCACAGAAAGAAGAGCCTGGAGGGCATGAAGAA 506

Qy    1161 ggcacgggtcgggggtagtgatgaagaggcctctgggatcccttcaaggacggcgagcct 1220
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     505 GGCACGGGTCGGGGGTAGTGATGAAGAGGCCTCTGGGATCCCTTCAAGGACGGCGAGCCT 446

Qy    1221 ggagttgggtgaggacgatgatgaacaggaagatgatgacatcgagtatttctgccaggc 1280
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     445 GGAGTTGGGTGAGGACGATGATGAACAGGAAGATGATGACATCGAGTATTTCTGCCAGGC 386

Qy    1281 ggtgggcgaggcgcccagtgaggacctgttccccgaggccaagcagaaaacggcttgccaa 1340
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     385 GGTGGGCGAGGCGCCCAGTGAGGACCTGTTCCCCGAGGCCAAGCAGAAACGGCTTGCCAA 326

Qy    1341 gtctccagggcggaagcggaagcggtgggaaatggatcgaggcaggggtcgcctttgtga 1400
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     325 GTCTCCAGGGCGGAAGCGGAAGCGGTGGGAAATGGATCGAGGCAGGGGTCGCCTTTGTGA 266

Qy    1401 ccagaagtttcccaagaccaaggacaagtcccagggagcccaggccaggcgggggcccag 1460
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     265 CCAGAAGTTTCCCAAGACCAAGGACAAGTCCCAGGGAGCCCAGGCCAGGCGGGGGCCCAG 206

Qy    1461 aggggcttcccgggatggtgggcgaggccggggccgaggccgcccagggaagagagtggc 1520
           ||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||
Db     205 AGGGGCTTCCCGGGATGGTGGGCGAGGCCGGGGCCGGGGCCGCCCAGGGAAGAGAGTGGC 146

Qy    1521 ctgagcccaagccgcaccggagcagcggctggattgaacgccccagattggggcccgaga 1580
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     145 CTGAGCCCAAGCCGCACCGGAGCAGCGGCTGGATTGAACGCCCCAGATTGGGGCCCGAGA 86

Qy    1581 tgtggccctcggtttccttttcataaaggagttgtgtccccagcccttccactccagtaaa 1640
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      85 TGTGGCCCTCGGTTTCCTTTCATAAAGGAGTTGTGTCCCCAGCCCTTCCACTCCAGTAAA 26

Qy    1641 gaactgaattggcaaaaaaaaaaa 1664
           |||||||||||||||||||||||||
Db      25 GAACTGAATTGGCAAAAAAAAAAA 2
```

RESULT 5
AAI57985
ID AAI57985 standard; cDNA; 2300 BP.
XX
AC AAI57985;
XX
DT 22-OCT-2001 (first entry)
XX
DE Human polynucleotide SEQ ID NO 188.
XX
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia; ss.
XX
OS Homo sapiens.
XX
PN WO200153312-A1.
XX
PD 26-JUL-2001.
XX
PF 26-DEC-2000; 2000WO-US34263.
XX
PR 21-JAN-2000; 2000US-0488725.
PR 25-APR-2000; 2000US-0552317.
PR 09-JUL-2000; 2000US-0598042.
PR 19-JUL-2000; 2000US-0620312.
PR 03-AUG-2000; 2000US-0653450.
PR 14-SEP-2000; 2000US-0662191.
PR 19-OCT-2000; 2000US-0693036.
PR 29-NOV-2000; 2000US-0727344.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;

PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
XX
DR WPI; 2001-442253/47.
DR P-PSDB; AAM38829.
XX
PT Novel nucleic acids and polypeptides, useful for treating disorders
PT such as central nervous system injuries -
XX
PS Claim 1; SEQ ID NO 188; 10078pp; English.
XX
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders.
CC Note: The sequence data for this patent did not form part of the printed
CC specification.
XX
SQ Sequence 2300 BP; 495 A; 647 C; 774 G; 376 T; 8 other;

Query Match 93.2%; Score 1551; DB 22; Length 2300;
Best Local Similarity 99.0%; Pred. No. 1.1e-300;
Matches 1560; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

```
Qy     81 gcctcgtggaggacacagcagcatgggacagtcagggaggtcccggcaccagaagcgcgc 140
Db     75 gcctcgtggaggacacagcagcatgggacagtcagggaggtcccggcaccagaagcgcgc 134

Qy    141 cccgccccaggcgcagctccgcaacctcgaggcctatgccgcgaacccgcactcgttcgt 200
Db    135 ccgcgcccaggcgcagctccgcaacctcgaggcctatgccgcgaacccgcactcgttcgt 194

Qy    201 gttcacgcgaggctgcacgggtcgcaacatccggcagctcagcctggacgtgcggcgggt 260
Db    195 gttcacgcgaggctgcacgggtcgcaacatccggcagctcagcctggacgtgcggcgggt 254

Qy    261 catggagcccgtcactgccagccgtctgcaggttcgtaagaagaactcgctgaaggactg 320
Db    255 catggagccgctcactgccagccgtctgcaggttcgtaagaagaactcgctgaaggactg 314

Qy    321 cgtggcagtggctgggcccctcggggtcacacactttctgatcctagcaaaacaagagac 380
Db    315 cgtggcagtggctgggcccctcggggtcacacactttctgatcctgagcaaaacagagac 374

Qy    381 caatgtctactttaagctgatgcgcctcccaggaggccccaccttgaccttccaggtcaa 440
Db    375 caatgtctactttaagctgatgcgcctcccaggaggccccaccttgaccttccaggtgaa 434

Qy    441 gaagtactcgctggtgcgtgatgtggtctcctcactgcgccggcaccgcatgcacgagca 500
Db    435 gaagtactcgctggtgcgtgatgtggtctcctcactgcgccggcaccgcatgcacgagca 494

Qy    501 gcagtttgcccacccacccctcctggtactcaacagctttggccccccatggtatgcatgt 560
Db    495 gcagtttgcccacccacccctcctggtactcaacagctttggccccccatggtatgcatgt 554

Qy    561 gaagctcatggccaccatgttccagaacctgttcccctccatcaacgtgcacaaggtgaa 620
Db    555 gaagctcatggccaccatgttccagaacctgttcccctccatcaacgtgcacaaggtgaa 614

Qy    621 cctgaacaccatcaagcgctgcctcctcatcgactacaaccccgactcccaggagctgga 680
Db    615 cctgaacaccatcaagcgctgcctcctcatcgactacaaccccgactcccaggagctgga 674

Qy    681 cttccgccactatagcatcaaagttgttcctgtgggcgcgagtcgcgggatgaagaagct 740
Db    675 cttccgccactatagcatcaaagttgttcctgtgggcgcgagtcgcgggatgaagaagct 734

Qy    741 gctccaggagaagttccccaacatgagccgcctgcaggacatcagcgagctgctggccac 800
Db    735 gctccaggagaagttccccaacatgagccgcctgcaggacatcagcgagctgctggccac 794

Qy    801 gggcgcggggctgtcggagagcgaggcagagcctgacggcgaccacaacatcacagagct 860
Db    795 gggcgcggggctgtcggagagcgaggcagagcctgacggcgaccacaacatcacagagct 854

Qy    861 gcctcaggctgtcgctggccgtggcaacatgcgggcccagcagagtgcagtgcggctcac 920
Db    855 gcctcaggctgtcgctggccgtggcaacatgcgggcccagcagagtgcagtgcggctcac 914

Qy    921 cgagatcggcccgcggatgacactgcagctcatcaaggtccaggagggcgtcggggaggg 980
Db    915 cgagatcggcccgcggatgacactgcagctcatcaaggtccaggagggcgtcggggaggg 974

Qy    981 caaagtgatgttccacagttttgtgagcaagacggaggaggagctgcaggccatcctgga 1040
Db    975 caaagtgatgttccacagttttgtgagcaagacggaggaggagctgcaggccatcctgga 1034

Qy   1041 agccaaggagaagaagctgcggctgaaggctcagaggcaggcccagcaggcccagaatgt 1100
Db   1035 agccaaggagaagaagctgcggctgaaggcgcagaggcaggcccagcaggcccagaatgt 1094

Qy   1101 gcagcgcaagcaggagcagcgggaggcccacagaaagaagagcctggagggcatgaagaa 1160
Db   1095 gcagcgcaagcaggagcagcgggaggcccacagaaagaagagcctggagggcatgaagaa 1154

Qy   1161 ggcacgggtcgggggtagtgatgaagaggcctctgggatcccttcaaggacggcgagcct 1220
Db   1155 ggcacgggtcgggggtagtgatgaagaggcctctgggatcccttcaaggacggcgagcct 1214

Qy   1221 ggagttgggtgaggacgatgatgaacaggaagatgatgacatcgagtatttctgccaggc 1280
Db   1215 ggagttgggtgaggacgatgatgaacaggaagatgatgacatcgagtatttctgccaggc 1274

Qy   1281 ggtgggcgaggcgcccagtgaggacctgttccccgaggccaagcagaaacggcttgccaa 1340
Db   1275 ggtgggcgaggcgcccagtgaggacctgttccccgaggccaagcagaaacggcttgccaa 1334

Qy   1341 gtctccagggcggaagcggaagcggtgggaaatggatcgaggcaggggtcgcctttgtga 1400
Db   1335 gtctccagggcggaagcggaagcggtgggaaatggatcgaggcaggggtcgcctttgtga 1394

Qy   1401 ccagaagtttcccaagaccaaggacaagtcccagggagcccaggccaggcgggggcccag 1460
Db   1395 ccagaagtttcccaagaccaaggacaagtcccagggagcccaggccaggcgggggcccag 1454

Qy   1461 aggggcttcccgggatggtgggcgaggccggggccgaggccgcccagggaagagagtggc 1520
Db   1455 aggggcttcccgggatggtgggcgaggccggggccggggccgcccagggaagagagtggc 1514

Qy   1521 ctgagcccaagccgcaccggagcagcggctggattgaacgccccagattggggcccgaga 1580
Db   1515 ctgagcccaagccgcaccggagcagcggctggattgaacgccccagattggggcccgaga 1574

Qy   1581 tgtggccctcggtttcctttcataaaggagttgtgtccccagcccttccactccagtaaa 1640
Db   1575 tgtggccctcggtttcctttcataaaggagttgtgtccccagcccttccactccagtaaa 1634

Qy   1641 gaactgaattggcaa 1655
Db   1635 gaactgaattggcca 1649
```

RESULT 6
AAI57986

```
ID   AAI57986 standard; cDNA; 2240 BP.
XX
AC   AAI57986;
XX
DT   22-OCT-2001  (first entry)
XX
DE   Human polynucleotide SEQ ID NO 189.
XX
KW   Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW   peripheral nervous system; neuropathy; central nervous system; CNS;
KW   Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW   amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW   chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW   leukaemia; ss.
XX
OS   Homo sapiens.
XX
PN   WO200153312-A1.
XX
PD   26-JUL-2001.
XX
PF   26-DEC-2000; 2000WO-US34263.
XX
PR   21-JAN-2000; 2000US-0488725.
PR   25-APR-2000; 2000US-0552317.
PR   09-JUL-2000; 2000US-0598042.
PR   19-JUL-2000; 2000US-0620312.
PR   03-AUG-2000; 2000US-0653450.
PR   14-SEP-2000; 2000US-0662191.
PR   19-OCT-2000; 2000US-0693036.
PR   29-NOV-2000; 2000US-0727344.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Asundi V,  Chen R,  Ma Y,  Qian XB,  Ren F,  Wang D;
PI   Wang J,  Wang Z,  Wehrman T,  Xu C,  Xue AJ,  Yang Y,  Zhang J;
PI   Zhao QA,  Zhou P,  Goodrich R,  Drmanac RT;
XX
DR   WPI; 2001-442253/47.
DR   P-PSDB; AAM38830.
XX
PT   Novel nucleic acids and polypeptides, useful for treating disorders
PT   such as central nervous system injuries -
XX
PS   Claim 1; SEQ ID NO 189; 10078pp; English.
XX
CC   The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC   the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC   immunosuppressant and cytostatic activity. The polynucleotides are useful
CC   in gene therapy. A composition containing a polypeptide or polynucleotide
CC   of the invention may be used to treat diseases of the peripheral nervous
CC   system, such as peripheral nervous injuries, peripheral neuropathy and
CC   localised neuropathies and central nervous system diseases, such as
CC   Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC   lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC   utilisation of the activities such as: Immune system suppression,
CC   Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC   and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC   assays for receptor activity, arthritis and inflammation, leukaemias and
CC   C.N.S disorders.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification.
XX
SQ   Sequence 2240 BP; 480 A; 636 C; 751 G; 365 T; 8 other;

  Query Match             85.2%;  Score 1417.8;  DB 22;  Length 2240;
  Best Local Similarity   95.1%;  Pred. No. 4.4e-274;
  Matches 1498;  Conservative    0;  Mismatches   17;  Indels   60;  Gaps    1;

Qy      81 gcctcgtggaggacacagcagcatgggacagtcagggaggtcccggcaccagaagcgcgc 140
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      75 gcctcgtggaggacacagcagcatgggacagtcagggaggtcccggcaccagaagcgcgc 134

Qy     141 cccgccccaggcgcagctccgcaacctcgaggcctatgccgcgaacccgcactcgttcgt 200
           ||  ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     135 ccgcgcccaggcgcagctccgcaacctcgaggcctatgccgcgaacccgcactcgttcgt 194

Qy     201 gttcacgcgaggctgcacgggtcgcaacatccggcagctcagcctggacgtgcggcgggt 260
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     195 gttcacgcgaggctgcacgggtcgcaacatccggcagctcagcctggacgtgcggcgggt 254

Qy     261 catggagcccgtcactgccagccgtctgcaggttcgtaagaagaactcgctgaaggactg 320
           |||||||||  ||||||||||||||||||||||||||||||||||||||||||||||||
Db     255 catggagccgctcactgccagccgtctgcaggttcgtaagaagaactcgctgaaggactg 314

Qy     321 cgtggcagtggctgggcccctcggggtcacacactttctgatcctagcaaaacaagagac 380
           ||||||||||||||||||||||||||||||||||||||||||||    |||  ||||||
Db     315 cgtggcagtggctgggcccctcggggtcacacactttctgatcctgagcaaaacagagac 374

Qy     381 caatgtctactttaagctgatgcgcctcccaggaggccccaccttgaccttccaggtcaa 440
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||
Db     375 caatgtctactttaagctgatgcgcctcccaggaggccccaccttgaccttccaggtgaa 434

Qy     441 gaagtactcgctggtgcgtgatgtggtctcctcactgcgccggcaccgcatgcacgagca 500
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     435 gaagtactcgctggtgcgtgatgtggtctcctcactgcgccggcaccgcatgcacgagca 494

Qy     501 gcagtttgcccacccacccctcctggtactcaacagctttggcccccatggtatgcatgt 560
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     495 gcagtttgcccacccacccctcctggtactcaacagctttggcccccatggtatgcatgt 554

Qy     561 gaagctcatggccaccatgttccagaacctgttcccctccatcaacgtgcacaaggtgaa 620
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     555 gaagctcatggccaccatgttccagaacctgttcccctccatcaacgtgcacaaggtgaa 614

Qy     621 cctgaacaccatcaagcgctgcctcctcatcgactacaaccccgactcccaggagctgga 680
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     615 cctgaacaccatcaagcgctgcctcctcatcgactacaaccccgactcccaggagctgga 674

Qy     681 cttccgccactatagcatcaaagttgttcctgtgggcgcgagtcgcgggatgaagaagct 740
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     675 cttccgccactatagcatcaaagttgttcctgtgggcgcgagtcgcgggatgaagaagct 734

Qy     741 gctccaggagaagttccccaacatgagccgcctgcaggacatcagcgagctgctggccac 800
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     735 gctccaggagaagttccccaacatgagccgcctgcaggacatcagcgagctgctggccac 794

Qy     801 gggcgcggggctgtcggagagcgaggcagagcctgacggcgaccacaacatcacagagct 860
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     795 gggcgcggggctgtcggagagcgaggcagagcctgacggcgaccacaacatcacagagct 854

Qy     861 gcctcaggctgtcgctggccgtggcaacatgcgggcccagcagagtgcagtgcggctcac 920
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     855 gcctcaggctgtcgctggccgtggcaacatgcgggcccagcagagtgcagtgcggctcac 914

Qy     921 cgagatcggcccgcggatgacactgcagctcatcaaggtccaggagggcgtcggggaggg 980
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     915 cgagatcggcccgcggatgacactgcagctcatcaaggtccaggagggcgtcggggaggg 974

Qy     981 caaagtgatgttccacagttttgtgagcaagacggaggaggagctgcaggccatcctgga 1040
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     975 caaagtgatgttccacagttttgtgagcaagacggaggaggagctgcaggccatcctgga 1034

Qy    1041 agccaaggagaagaagctgcggctgaaggctcagaggcaggcccagcaggcccagaatgt 1100
           |||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||
Db    1035 agccaaggagaagaagctgcggctgaaggcgcagaggcaggcccagcaggcccagaatgt 1094

Qy    1101 gcagcgcaagcaggagcagcgggaggcccacagaaagaagagcctggagggcatgaagaa 1160
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    1095 gcagcgcaagcaggagcagcgggaggcccacagaaagaagagcctggagggcatgaagaa 1154

Qy    1161 ggcacgggtcgggggtagtgatgaagaggcctctgggatcccttcaaggacggcgagcct 1220
           ||||||||||||||||||||||||||||||
Db    1155 ggcacgggtcgggggtagtgatgaagaggcc---------------------------- 1185
```

```
Qy   1221 ggagttgggtgaggacgatgatgaacaggaagatgatgacatcgagtatttctgccaggc 1280
                                       || ||||| ||||||||||||||||||||
Db   1186 ------------------------------gacgatgatatcgagtatttctgccaggc 1214

Qy   1281 ggtgggcgaggcgcccagtgaggacctgttccccgaggccaagcagaaacggcttgccaa 1340
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1215 ggtgggcgaggcgcccagtgaggacctgttccccgaggccaagcagaaacggcttgccaa 1274

Qy   1341 gtctccagggcggaagcggaagcggtgggaaatggatcgaggcaggggtcgcctttgtga 1400
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1275 gtctccagggcggaagcggaagcggtgggaaatggatcgaggcaggggtcgcctttgtga 1334

Qy   1401 ccagaagtttcccaagaccaaggacaagtcccagggagcccaggccaggcgggggcccag 1460
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1335 ccagaagtttcccaagaccaaggacaagtcccagggagcccaggccaggcgggggcccag 1394

Qy   1461 aggggcttcccgggatggtgggcgaggccggggccgaggccgcccagggaagagagtggc 1520
          |||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||
Db   1395 aggggcttcccgggatggtgggcgaggccggggccggggccgcccagggaagagagtggc 1454

Qy   1521 ctgagcccaagccgcaccggagcagcggctggattgaacgccccagattggggcccgaga 1580
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1455 ctgagcccaagccgcaccggagcagcggctggattgaacgccccagattggggcccgaga 1514

Qy   1581 tgtggccctcggtttcctttcataaaggagttgtgtccccagcccttccactccagtaaa 1640
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1515 tgtggccctcggtttcctttcataaaggagttgtgtccccagcccttccactccagtaaa 1574

Qy   1641 gaactgaattggcaa 1655
          ||||||||||||| |
Db   1575 gaactgaattggcca 1589
```

RESULT 7
AAX07369
ID AAX07369 standard; cDNA; 2427 BP.
XX
AC AAX07369;
XX
DT 07-JUN-1999 (first entry)
XX
DE Human P2Y11 receptor cDNA.
XX
KW P2Y11; G protein coupled receptor; human; infection; neutropaenia;
KW agranulocytosis; cancer; leukaemia; diagnosis; therapy; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 40..2427
FT /*tag= a
XX
PN WO9902675-A1.
XX
PD 21-JAN-1999.
XX
PF 09-JUL-1998; 98WO-BE00108.
XX
PR 09-JUL-1997; 97EP-0870101.
XX
PA (EURO-) EUROSCREEN SA.
XX
PI Boeynaems J, Communi D;
XX
DR WPI; 1999-120876/10.
DR P-PSDB; AAW97842.
XX
PT New G protein-coupled receptor - useful for diagnosis, treatment and
PT prevention of neutropaenia, agranulocytosis, infection and cancer
XX
PS Claim 11; Fig 1; 46pp; English.
XX
CC This cDNA clone encodes a novel human G protein coupled receptor,
CC termed P2Y11 (see AAW97842), that has selective affinity for ATP. A
CC human cDNA placenta cDNA library was screened with a human P2Y4
CC probe. Of 9 clones obtained, 3 corresponding to a partial sequence
CC encoding a new G protein coupled receptor displaying about 30%
CC identity with other P2Y receptors. This partial sequence was used
CC as a probe to screen a human genomic DNA library. 4 Overlapping
CC genomes clones were isolated. Mapping and sequencing showed the
CC new gene contained an intron at the 5' end of the coding region.
CC The 4 clones contained the entire open reading frame for the new
CC receptor, designated P2Y11. The invention also provides vectors,
CC transformed cells, anti-P2Y11 antibodies, nucleic acid probes,
CC pharmaceutical compositions comprising such products and transgenic
CC animals. Antisense nucleotides (claimed) that hybridise to mRNA
CC are used to decrease activity of P2Y11, while specific antibodies
CC are used to block binding of P2Y11 to its ligand. Probes are used
CC in hybridisation assays to detect expression of P2Y11 at the RNA
CC level, while antibodies are used similarly at the protein level in
CC standard immunoassays, particularly for diagnosis of leukaemia.
CC The transgenic animals are used to determine the effects of varying
CC levels of P2Y11 expression. These animals, and host cells, are
CC used in drug screening methods to identify (ant)agonists that are
CC potentially useful for treatment or prevention of disorders
CC associated with excessive or inadequate receptor activity,
CC specifically neutropaenia, agranulocytosis, infections and cancer.
CC Host cells are also used to produce recombinant P2Y11.
XX
SQ Sequence 2427 BP; 464 A; 790 C; 774 G; 399 T; 0 other;

Query Match 77.4%; Score 1288; DB 20; Length 2427;
Best Local Similarity 96.0%; Pred. No. 3.7e-248;
Matches 1321; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

```
Qy     69 cggacgcaggaggcctcgtggaggacacagcagcatgggacagtcagggaggtcccggca 128
          ||||     ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      6 cggcacgaggaggcctcgtggaggacacagcagcatgggacagtcagggaggtcccggca 65

Qy    129 ccagaagcgcgccccgccccaggcgcagctccgcaacctcgaggcctatgccgcgaaccc 188
          ||||||||||||||   ||||||||||||||||||||||||||||||||||||||||||
Db     66 ccagaagcgcgcccgcgcccaggcgcagctccgcaacctcgaggcctatgccgcgaaccc 125

Qy    189 gcactcgttcgtgttcacgcgaggctgcacgggtcgcaacatccggcagctcagcctgga 248
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    126 gcactcgttcgtgttcacgcgaggctgcacgggtcgcaacatccggcagctcagcctgga 185

Qy    249 cgtgcggcgggtcatggagcccgtcactgccagccgtctgcaggttcgtaagaagaactc 308
          ||||||||||||||||||  ||||||||||||||||||||||||||||||||||||||||
Db    186 cgtgcggcgggtcatggagccgctcactgccagccgtctgcaggttcgtaagaagaactc 245

Qy    309 gctgaaggactgcgtggcagtggctgggcccctcggggtcacacactttctgatcctagc 368
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    246 gctgaaggactgcgtggcagtggctgggcccctcggggtcacacactttctgatcctgag 305

Qy    369 aaaacaagagaccaatgtctactttaagctgatgcgcctcccaggaggccccaccttgac 428
          |||  ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    306 caaaacagagaccaatgtctactttaagctgatgcgcctcccaggaggccccaccttgac 365

Qy    429 cttccaggtcaagaagtactcgctggtgcgtgatgtggtctcctcactgcgccggcaccg 488
          ||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    366 cttccaggtgaagaagtactcgctggtgcgtgatgtggtctcctcactgcgccggcaccg 425

Qy    489 catgcacgagcagcagtttgcccacccacccctcctggtactcaacagctttggccccca 548
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    426 catgcacgagcagcagtttgcccacccacccctcctggtactcaacagctttggccccca 485

Qy    549 tggtatgcatgtgaagctcatggccaccatgttccagaacctgttcccctccatcaacgt 608
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    486 tggtatgcatgtgaagctcatggccaccatgttccagaacctgttcccctccatcaacgt 545

Qy    609 gcacaaggtgaacctgaacaccatcaagcgctgcctcctcatcgactacaaccccgactc 668
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    546 gcacaaggtgaacctgaacaccatcaagcgctgcctcctcatcgactacaaccccgactc 605
```

```
Qy    669 ccaggagctggacttccgccactatagcatcaaagttgttcctgtgggcgcgagtcgcgg 728
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    606 ccaggagctggacttccgccactatagcatcaaagttgttcctgtgggcgcgagtcgcgg 665

Qy    729 gatgaagaagctgctccaggagaagttccccaacatgagccgcctgcaggacatcagcga 788
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    666 gatgaagaagctgctccaggagaagttccccaacatgagccgcctgcaggacatcagcga 725

Qy    789 gctgctggccacgggcgcggggctgtcggagagcgaggcagagcctgacggcgaccacaa 848
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    726 gctgctggccacgggcgcggggctgtcggagagcgaggcagagcctgacggcgaccacaa 785

Qy    849 catcacagagctgcctcaggctgtcgctggccgtggcaacatgcgggcccagcagagtgc 908
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    786 catcacagagctgcctcaggctgtcgctggccgtggcaacatgcgggcccagcagagtgc 845

Qy    909 agtgcggctcaccgagatcggcccgcggatgacactgcagctcatcaaggtccaggaggg 968
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    846 agtgcggctcaccgagatcggcccgcggatgacactgcagctcatcaaggtccaggaggg 905

Qy    969 cgtcggggagggcaaagtgatgttccacagttttgtgagcaagacggaggaggagctgca 1028
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
D     906 cgtcggggagggcaaagtgatgttccacagttttgtgagcaagacggaggaggagctgca 965

Qy   1029 ggccatcctggaagccaaggagaagaagctgcggctgaaggctcagaggcaggcccagca 1088
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    966 ggccatcctggaagccaaggagaagaagctgcggctgaaggcgcagaggcaggcccagca 1025

Qy   1089 ggcccagaatgtgcagcgcaagcaggagcagcgggaggcccacagaaagaagagcctgga 1148
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1026 ggcccagaatgtgcagcgcaagcaggagcagcgggaggcccacagaaagaagagcctgga 1085

Qy   1149 gggcatgaagaaggcacgggtcgggggtagtgatgaagaggcctctgggatcccttcaag 1208
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1086 gggcatgaagaaggcacgggtcgggggtagtgatgaagaggcctctgggatcccttcaag 1145

Qy   1209 gacggcgagcctggagttgggtgaggacgatgatgaacaggaagatgatgacatcgagta 1268
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1146 gacggcgagcctggagttgggtgaggacgatgatgaacaggaagatgatgacatcgagta 1205

Qy   1269 tttctgccaggcggtgggcgaggcgcccagtgaggacctgttccccgaggccaagcagaa 1328
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1206 tttctgccaggcggtgggcgaggcgcccagtgaggacctgttccccgaggccaagcagaa 1265

Qy   1329 acggcttgccaagtctccagggcggaagcggaagcggtgggaaatggatcgaggcagggg 1388
          ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   1266 acggcttgccaagtctccagggcggaagcggaagcggtgggaaatggatcgaggtgccaa 1325

Qy   1389 tcgcctttgtgaccagaagtttcccaagaccaaggacaagtcccagggagcccagg 1444
            |     || | |    ||  |     || | |||||   |   ||   |||||
D    1326 gtcctgccctgccaacttcttggcagctgccgacgacaaactcagtgggttccagg 1381
```

```
RESULT   8
AAS86858/c
ID   AAS86858 standard; cDNA; 2732 BP.
XX
AC   AAS86858;
XX
DT   13-FEB-2002  (first entry)
XX
DE   DNA encoding novel human diagnostic protein #22662.
XX
KW   Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW   food supplement; medical imaging; diagnostic; genetic disorder; ss.
XX
OS   Homo sapiens.
XX
PN   WO200175067-A2.
XX
PD   11-OCT-2001.
XX
PF   30-MAR-2001; 2001WO-US08631.
XX
PR   31-MAR-2000; 2000US-0540217.
PR   23-AUG-2000; 2000US-0649167.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Drmanac RT,  Liu C,  Tang YT;
XX
DR   WPI; 2001-639362/73.
DR   P-PSDB; ABG22671.
XX
PT   New isolated polynucleotide and encoded polypeptides, useful in
PT   diagnostics, forensics, gene mapping, identification of mutations
PT   responsible for genetic disorders or other traits and to assess
PT   biodiversity  -
XX
PS   Claim 1; SEQ ID No 22662; 103pp; English.
XX
CC   The invention relates to isolated polynucleotide (I) and
CC   polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC   polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC   and gene mapping, and in recombinant production of (II). The
CC   polynucleotides are also used in diagnostics as expressed sequence tags
CC   for identifying expressed genes. (I) is useful in gene therapy techniques
CC   to restore normal activity of (II) or to treat disease states involving
CC   (II). (II) is useful for generating antibodies against it, detecting or
CC   quantitating a polypeptide in tissue, as molecular weight markers and as
CC   a food supplement. (II) and its binding partners are useful in medical
CC   imaging of sites expressing (II). (I) and (II) are useful for treating
CC   disorders involving aberrant protein expression or biological activity.
CC   The polypeptide and polynucleotide sequences have applications in
CC   diagnostics, forensics, gene mapping, identification of mutations
CC   responsible for genetic disorders or other traits to assess biodiversity
CC   and to produce other types of data and products dependent on DNA and
CC   amino acid sequences. AAS64197-AAS94564 represent novel human
CC   diagnostic coding sequences of the invention.
CC   Note: The sequence data for this patent did not appear in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 2732 BP; 511 A; 782 C; 774 G; 665 T; 0 other;
```

```
  Query Match             42.0%;  Score 699.6;  DB 23;  Length 2732;
  Best Local Similarity   98.0%;  Pred. No. 1.3e-130;
  Matches  719;  Conservative    0;  Mismatches   14;  Indels    1;  Gaps    1;

Qy    924 gatcggcccgcggatgacactgcagctcatcaaggtccaggagggcgtcggggagggcaa 983
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    734 GATCGGCCCGCGGATGACACTGCAGCTCATCAAGGTCCAGGAGGGCGTCGGGGAGGGCAA 675

Qy    984 agtgatgttccacagttttgtgagcaagacggaggaggagctgcaggccatcctggaagc 1043
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    674 AGTGATGTTCCACAGTTTTGTGAGCAAGACGGAGGAGGAGCTGCAGGCCATCCTGGAAGC 615

Qy   1044 caaggagaagaagctgcggctgaaggctcagaggcaggcccagcaggcccagaatgtgca 1103
          |||||||||||||||||||||||||| ||||||||||||||||||||||||||||||||||
Db    614 CAAGGAGAAGAAGCTGCGGCTGAAGGCGCAGAGGCAGGCCCAGCAGGCCCAGAATGTGCA 555

Qy   1104 gcgcaagcaggagcagcgggaggcccacagaaagaagagcctggagggcatgaagaaggc 1163
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    554 GCGCAAGCAGGAGCAGCGGGAGGCCCACAGAAAGAAGAGCCTGGAGGGCATGAAGAAGGC 495

Qy   1164 acgggtcgggggtagtgatgaagaggcctctgggatcccttcaaggacggcgagcctgga 1223
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    494 ACGGGTCGGGGGTAGTGATGAAGAGGCCTCTGGGATCCCTTCAAGGACGGCGAGCCTGGA 435

Qy   1224 gttgggtgaggacgatgatgaacaggaagatgatgacatcgagtatttctgccaggcggt 1283
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    434 GTTGGGTGAGGACGATGATGAACAGGAAGATGATGACATCGAGTATTTCTGCCAGGCGGT 375

Qy   1284 gggcgaggcgcccagtgaggacctgttccccgaggccaagcagaaacggcttgccaagtc 1343
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db     374 GGGCGAGGCGCCCAGTGAGGACCTGTTCCCCGAGGCCAAGCAGAAACGGCTTGCCAAGTC 315

Qy    1344 tccagggcggaagcggaagcggtgggaaatggatcgaggcaggggtcg-cctttgtgacc 1402
           |||||||||||||||||||||||||||||||||| ||||| |||| | ||||||||||
Db     314 TCCAGGGCGGAAGCGGAAGCGGTGGGAAATGGATCTAGGCAAGGGTTGCCCTTTGTGACC 255

Qy    1403 agaagtttcccaagaccaaggacaagtcccagggagcccaggccaggcgggggcccagag 1462
           | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     254 AAAAGTTTCCCAAGACCAAGGACAAGTCCCAGGGAGCCCAGGCCAGGCGGGGGCCCAGAG 195

Qy    1463 gggcttcccgggatggtgggcgaggccggggccgaggccgcccagggaagagagtggcct 1522
           |||||||||||||||||||||||||||||||| |||||||||||||| ||||||||||
Db     194 GGGCTTCCCGGGATGGTGGGCGAGGCCGGGGCCGGGGCCGCCCAGGGAAAAGAGTGGCCT 135

Qy    1523 gagcccaagccgcaccggagcagcggctggattgaacgccccagattggggcccgagatg 1582
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     134 GAGCCCAAGCCGCACCGGAGCAGCGGCTGGATTGAACGCCCCAGATTGGGGCCCGAGATG 75

      1583 tggccctcggtttcctttcataaaggagttgtgtccccagcccttccactccagtaaaga 1642
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      74 TGGCCCTCGGTTTCCTTTCATAAAGGAGTTGTGTCCCCAGCCCTTCCACTCCAGTAAAGA 15

Qy    1643 actgaattggcaaa 1656
           | | |  |  |||
Db      14 TCAGGAAGGCAAAA 1


RESULT   9
ABA15144
ID   ABA15144 standard; DNA; 13559 BP.
XX
AC   ABA15144;
XX
DT   23-JAN-2002  (first entry)
XX
DE   Human nervous system related polynucleotide SEQ ID NO 7475.
XX
KW   Human; nootropic; neuroprotective; cytostatic; dermatological; virucide;
KW   immunosuppressive; antiinflammatory; anti-HIV; antibacterial; vulnerary;
KW   antiparkinsonian; antisickling; antianaemic; antiarthritic; cancer;
KW   antirheumatic; hepatotropic; cerebroprotective; antiinflammatory;
KW   antiallergic; antidiabetic; antiulcer; anticonvulsant; antifungal;
KW   antiparasitic; cardiant; immune disorder; cardiovascular disorder;
KW   neurological disease; infection; nephrotropic; gene therapy; vaccine; ds.
XX
OS   Homo sapiens.
XX
PN   WO200159063-A2.
XX
PD   16-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01334.
XX
PR   31-JAN-2000; 2000US-0179065.
PR   04-FEB-2000; 2000US-0180628.
PR   24-FEB-2000; 2000US-0184664.
PR   02-MAR-2000; 2000US-0186350.
PR   16-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-0198123.
PR   19-MAY-2000; 2000US-0205515.
PR   07-JUN-2000; 2000US-0209467.
PR   28-JUN-2000; 2000US-0214886.
PR   30-JUN-2000; 2000US-0215135.
PR   07-JUL-2000; 2000US-0216647.
PR   07-JUL-2000; 2000US-0216880.
PR   11-JUL-2000; 2000US-0217487.
PR   11-JUL-2000; 2000US-0217496.
PR   14-JUL-2000; 2000US-0218290.
PR   26-JUL-2000; 2000US-0220963.
PR   26-JUL-2000; 2000US-0220964.
PR   14-AUG-2000; 2000US-0224518.
PR   14-AUG-2000; 2000US-0224519.
PR   14-AUG-2000; 2000US-0225213.
PR   14-AUG-2000; 2000US-0225214.
PR   14-AUG-2000; 2000US-0225266.
PR   14-AUG-2000; 2000US-0225267.
PR   14-AUG-2000; 2000US-0225268.
PR   14-AUG-2000; 2000US-0225270.
PR   14-AUG-2000; 2000US-0225447.
PR   14-AUG-2000; 2000US-0225757.
PR   14-AUG-2000; 2000US-0225758.
PR   14-AUG-2000; 2000US-0225759.
PR   18-AUG-2000; 2000US-0226279.
PR   22-AUG-2000; 2000US-0226681.
PR   22-AUG-2000; 2000US-0226868.
PR   22-AUG-2000; 2000US-0227182.
PR   23-AUG-2000; 2000US-0227009.
PR   30-AUG-2000; 2000US-0228924.
PR   01-SEP-2000; 2000US-0229287.
PR   01-SEP-2000; 2000US-0229343.
PR   01-SEP-2000; 2000US-0229344.
PR   01-SEP-2000; 2000US-0229345.
PR   05-SEP-2000; 2000US-0229509.
PR   05-SEP-2000; 2000US-0229513.
PR   06-SEP-2000; 2000US-0230437.
PR   06-SEP-2000; 2000US-0230438.
PR   08-SEP-2000; 2000US-0231242.
PR   08-SEP-2000; 2000US-0231243.
PR   08-SEP-2000; 2000US-0231244.
PR   08-SEP-2000; 2000US-0231413.
PR   08-SEP-2000; 2000US-0231414.
PR   08-SEP-2000; 2000US-0232080.
PR   08-SEP-2000; 2000US-0232081.
PR   12-SEP-2000; 2000US-0231968.
PR   14-SEP-2000; 2000US-0232397.
PR   14-SEP-2000; 2000US-0232398.
PR   14-SEP-2000; 2000US-0232399.
PR   14-SEP-2000; 2000US-0232400.
PR   14-SEP-2000; 2000US-0232401.
PR   14-SEP-2000; 2000US-0233063.
PR   14-SEP-2000; 2000US-0233064.
PR   14-SEP-2000; 2000US-0233065.
PR   21-SEP-2000; 2000US-0234223.
PR   21-SEP-2000; 2000US-0234274.
PR   25-SEP-2000; 2000US-0234997.
PR   25-SEP-2000; 2000US-0234998.
PR   26-SEP-2000; 2000US-0235484.
PR   27-SEP-2000; 2000US-0235834.
PR   27-SEP-2000; 2000US-0235836.
PR   29-SEP-2000; 2000US-0236327.
PR   29-SEP-2000; 2000US-0236367.
PR   29-SEP-2000; 2000US-0236368.
PR   29-SEP-2000; 2000US-0236369.
PR   29-SEP-2000; 2000US-0236370.
PR   02-OCT-2000; 2000US-0236802.
PR   02-OCT-2000; 2000US-0237037.
PR   02-OCT-2000; 2000US-0237038.
PR   02-OCT-2000; 2000US-0237039.
PR   02-OCT-2000; 2000US-0237040.
PR   13-OCT-2000; 2000US-0239935.
PR   13-OCT-2000; 2000US-0239937.
PR   20-OCT-2000; 2000US-0240960.
PR   20-OCT-2000; 2000US-0241785.
PR   20-OCT-2000; 2000US-0241786.
PR   20-OCT-2000; 2000US-0241787.
PR   20-OCT-2000; 2000US-0241808.
PR   20-OCT-2000; 2000US-0241809.
PR   20-OCT-2000; 2000US-0241826.
PR   20-OCT-2000; 2000US-0242221.
PR   01-NOV-2000; 2000US-0244617.
PR   08-NOV-2000; 2000US-0246474.
PR   08-NOV-2000; 2000US-0246475.
PR   08-NOV-2000; 2000US-0246476.
PR   08-NOV-2000; 2000US-0246477.
PR   08-NOV-2000; 2000US-0246478.
```

```
PR   08-NOV-2000; 2000US-0246523.
PR   08-NOV-2000; 2000US-0246524.
PR   08-NOV-2000; 2000US-0246525.
PR   08-NOV-2000; 2000US-0246526.
PR   08-NOV-2000; 2000US-0246527.
PR   08-NOV-2000; 2000US-0246528.
PR   08-NOV-2000; 2000US-0246532.
PR   08-NOV-2000; 2000US-0246609.
PR   08-NOV-2000; 2000US-0246610.
PR   08-NOV-2000; 2000US-0246611.
PR   08-NOV-2000; 2000US-0246613.
PR   17-NOV-2000; 2000US-0249207.
PR   17-NOV-2000; 2000US-0249208.
PR   17-NOV-2000; 2000US-0249209.
PR   17-NOV-2000; 2000US-0249210.
PR   17-NOV-2000; 2000US-0249211.
PR   17-NOV-2000; 2000US-0249212.
PR   17-NOV-2000; 2000US-0249213.
PR   17-NOV-2000; 2000US-0249214.
PR   17-NOV-2000; 2000US-0249215.
PR   17-NOV-2000; 2000US-0249216.
PR   17-NOV-2000; 2000US-0249217.
P[redacted]17-NOV-2000; 2000US-0249218.
P[redacted]17-NOV-2000; 2000US-0249244.
PR   17-NOV-2000; 2000US-0249245.
PR   17-NOV-2000; 2000US-0249264.
PR   17-NOV-2000; 2000US-0249265.
PR   17-NOV-2000; 2000US-0249297.
PR   17-NOV-2000; 2000US-0249299.
PR   17-NOV-2000; 2000US-0249300.
PR   01-DEC-2000; 2000US-0250391.
PR   01-DEC-2000; 2000US-0251160.
PR   05-DEC-2000; 2000US-0251030.
PR   05-DEC-2000; 2000US-0251988.
PR   05-DEC-2000; 2000US-0256719.
PR   06-DEC-2000; 2000US-0251479.
PR   08-DEC-2000; 2000US-0251856.
PR   08-DEC-2000; 2000US-0251868.
PR   08-DEC-2000; 2000US-0251869.
PR   08-DEC-2000; 2000US-0251989.
PR   08-DEC-2000; 2000US-0251990.
PR   11-DEC-2000; 2000US-0254097.
PR   05-JAN-2001; 2001US-0259678.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Barash SC,  Ruben SM;
XX
DR   WPI; 2001-541565/60.
XX
P[redacted]Nucleic acids encoding 3224 human nervous system antigen polypeptides,
P[redacted]useful for preventing, diagnosing and/or treating nervous system
PT   cancers and metastases -
XX
PS   Disclosure; SEQ ID NO 7475; 1701pp + Sequence Listing; English.
XX
CC   The invention relates to novel genes (ABA11004-ABA21534) and proteins
CC   (ABB14678-ABB18001) useful for preventing, treating or ameliorating
CC   medical conditions e.g. by protein or gene therapy. The genes are
CC   isolated from a range of human tissues disclosed in the specification.
CC   The nucleic acids, proteins, antibodies and (ant)agonists are useful
CC   in the diagnosis, treatment and prevention of: (a) cancer, e.g. breast
CC   and ovarian cancer and other cancers of the adrenal gland, bone, bone
CC   marrow, breast, gastrointestinal tract, liver, lung, or urogenital;
CC   (b) immune disorders e.g. Addison's disease, allergies, autoimmune
CC   haemolytic anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's
CC   disease, multiple sclerosis, rheumatoid arthritis and ulcerative
CC   colitis; (c) cardiovascular disorders such as myocardial ischaemias;
CC   (d) wound healing; (e) neurological diseases e.g. cerebral anoxia and
CC   epilepsy; and (f) infectious diseases such as viral, bacterial, fungal
CC   and parasitic infections.
CC   Note: The sequence data for this patent did not form part of the
CC   printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 13559 BP; 2882 A; 3867 C; 4239 G; 2571 T; 0 other;

  Query Match             29.6%;  Score 492.6;  DB 22;  Length 13559;
  Best Local Similarity   72.6%;  Pred. No. 3.6e-89;
  Matches  854;  Conservative    0;  Mismatches    4;  Indels  319;  Gaps    4;

Qy     798 cacgggcgcggggctgtcggagagcgaggcagagcctgacggcgaccacaacatcacaga 857
           || ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    3769 caggggcgcggggctgtcggagagcgaggcagagcctgacggcgaccacaacatcacaga 3828

Qy     858 gctgcctcaggctgtcgctggccgtggcaacatgcgggcccagcagagtgcagtgcggct 917
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    3829 gctgcctcaggctgtcgctggccgtggcaacatgcgggcccagcagagtgcagtgcggct 3888

Qy     918 caccg---------------------------------------------------------- 922
           |||||
Db    3889 caccgaggtgaggcccagggcagggggaccccgggctccaccagtcccaacggtgggct 3948

Qy     923 ----------------------agatcggcccgcggatgacactgcagctcatcaaggtc 960
                                 ||||||||||||||||||||||||||||||||||||||
Db    3949 gacgcttcttcctcgtcccctcagatcggcccgcggatgacactgcagctcatcaaggtc 4008

Qy     961 caggagggcgtcggggagggcaaagtgatgttccacagtttt------------------ 1002
           |||||||||||||||||||||||||||||||||||||||||
Db    4009 caggagggcgtcggggagggcaaagtgatgttccacagttttggtgaggccggggccgcc 4068

Qy    1003 ---------------------------------------------------------- 1002

Db    4069 gggggtgggggtcatgggtgtggagctgcacccggatcttggtgacccgcgtctcttgg 4128

Qy    1003 ----gtgagcaagacggaggaggagctgcaggccatcctggaagccaaggagaagaagct 1058
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    4129 ctcagtgagcaagacggaggaggagctgcaggccatcctggaagccaaggagaagaagct 4188

Qy    1059 gcggctgaaggctcagaggcaggcccagcaggcccagaatgtgcagcgcaagcaggagca 1118
           |||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||
Db    4189 gcggctgaaggcgcagaggcaggcccagcaggcccagaatgtgcagcgcaagcaggagca 4248

Qy    1119 gcgggaggccca------------------------------------------------ 1130
           ||||||||||||
Db    4249 gcgggaggcccacaggtccaggcagagctgggaagggcagggccaaggggggtccctgg 4308

Qy    1131 ----------------------------------cagaaagaagagcctggagggcatga 1156
                                               ||||||||||||||||||||||||
Db    4309 gatgggcggctatgttgacccccacgccctcctccagaaagaagagcctggagggcatga 4368

Qy    1157 agaaggcacgggtcgggggtagtgatgaagaggcctctgggatcccttcaaggacggcga 1216
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    4369 agaaggcacgggtcgggggtagtgatgaagaggcctctgggatcccttcaaggacggcga 4428

Qy    1217 gcctggagttgggtgaggacgatgatgaacaggaagatgatgacatcgagtatttctgcc 1276
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    4429 gcctggagttgggtgaggacgatgatgaacaggaagatgatgacatcgagtatttctgcc 4488

Qy    1277 aggcggtgggcgaggcgcccagtgag---------------------------------- 1302
           |||||||||||||||||||||||||
Db    4489 aggcggtgggcgaggcgcccagtgagggtatggagtggggtctgcagcagggcacccaga 4548

Qy    1303 ----------------------------------------------gacctgttccccgagg 1318
                                                          ||||||||||||||||
Db    4549 gcctgtccttgtctctgggggccctgacactgtctctccccacagacctgttccccgagg 4608

Qy    1319 ccaagcagaaacggcttgccaagtctccagggcggaagcggaagcggtgggaaatggatc 1378
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    4609 ccaagcagaaacggcttgccaagtctccagggcggaagcggaagcggtgggaaatggatc 4668

Qy    1379 gaggcaggggtcgccctttgtgaccagaagtttcccaagaccaaggacaagtcccagggag 1438
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    4669 gaggcaggggtcgccctttgtgaccagaagtttcccaagaccaaggacaagtcccagggag 4728
```

```
Qy   1439 cccaggccaggcgggggcccagaggggcttcccgggatggtgggcgaggccggggccgag 1498
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| |
Db   4729 cccaggccaggcgggggcccagaggggcttcccgggatggtgggcgaggccggggccggg 4788

Qy   1499 gccgcccagggaagagagtggcctgagcccaagccgcaccggagcagcggctggattgaa 1558
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   4789 gccgcccagggaagagagtggcctgagcccaagccgcaccggagcagcggctggattgaa 4848

Qy   1559 cgccccagattggggcccgagatgtggccctcggtttcctttcataaaggagttgtgtcc 1618
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   4849 cgccccagattggggcccgagatgtggccctcggtttcctttcataaaggagttgtgtcc 4908

Qy   1619 ccagcccttccactccagtaaagaactgaattggcaa 1655
          |||||||||||||||||||||||||||||||||| |
Db   4909 ccagcccttccactccagtaaagaactgaattggcca 4945
```

RESULT 10
AAS86857
ID AAS86857 standard; cDNA; 580 BP.
XX
AC AAS86857;
XX
DT 13-FEB-2002 (first entry)
XX
DE DNA encoding novel human diagnostic protein #22661.
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder; ss.
XX
OS Homo sapiens.
XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US08631.
XX
PR 31-MAR-2000; 2000US-0540217.
PR 23-AUG-2000; 2000US-0649167.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-639362/73.
DR P-PSDB; ABG22670.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity -
XX
PS Claim 1; SEQ ID No 22661; 103pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy techniques
CC to restore normal activity of (II) or to treat disease states involving
CC (II). (II) is useful for generating antibodies against it, detecting or
CC quantitating a polypeptide in tissue, as molecular weight markers and as
CC a food supplement. (II) and its binding partners are useful in medical
CC imaging of sites expressing (II). (I) and (II) are useful for treating
CC disorders involving aberrant protein expression or biological activity.
CC The polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. AAS64197-AAS94564 represent novel human
CC diagnostic coding sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 580 BP; 149 A; 143 C; 200 G; 88 T; 0 other;

Query Match 26.3%; Score 437.6; DB 23; Length 580;
Best Local Similarity 97.0%; Pred. No. 2.1e-78;
Matches 446; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

```
Qy    895 gcccagcagagtgcagtgcggctcaccgagatcggcccgcggatgacactgcagctcatc 954
          |||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db      1 gcccagcagagtgcagttcggctcaccgagatcggcccgcggatgacactgcagctcatc 60

Qy    955 aaggtccaggagggcgtcggggagggcaaagtgatgttccacagttttgtgagcaagacg 1014
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 aaggtccaggagggcgtcggggagggcaaagtgatgttccacagttttgtgagcaagacg 120

Qy   1015 gaggaggagctgcaggccatcctggaagccaaggagaagaagctgcggctgaaggctcag 1074
          |||||||| ||||||||||||||||||||||||||||||||||||||||||||||| |||
Db    121 gaggaggatctgcaggccatcctggaagccaaggagaagaagctgcggctgaaggcgcag 180

Qy   1075 aggcaggcccagcaggcccagaatgtgcagcgcaagcaggagcagcgggaggcccacaga 1134
          |||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||
Db    181 aggcaggcccagcaggcccagaatgtgcagcgcaagcacgagcagcgggaggcccacaga 240

Qy   1135 aagaagagcctggagggcatgaagaaggcacgggtcgggggtagtgatgaagaggcctct 1194
          ||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||
Db    241 aagaagagcctggagggcatgaagaaggcacgggtcgggggtagtgatgaaaaggcctct 300

Qy   1195 gggatcccttcaaggacggcgagcctggagttgggtgaggacgatgatgaacaggaagat 1254
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    301 gggatcccttcaaggacggcgagcctggagttgggtgaggacgatgatgaacaggaagat 360

Qy   1255 gatgacatcgagtatttctgccaggcggtgggcgaggcgcccagtgaggacctgttcccc 1314
          |||| |||||||||||| ||||||||||||||||||||||||||||||||||||||||||
Db    361 gatgccatcgagtatttttgccaggcggtgggcgaggcgcccagtgaggacctgttcccc 420

Qy   1315 gaggccaagcagaaacggcttgccaagtctccagggcgga 1354
          |||||||||||||||||||||||| | |   || | |
Db    421 gaggccaagcagaaacggcttgccaagccgcactggagca 460
```

RESULT 11
AAH98050
ID AAH98050 standard; DNA; 559 BP.
XX
AC AAH98050;
XX
DT 10-OCT-2001 (first entry)
XX
DE Murine 7-transmembrane G-protein coupled receptor coding sequence #294.
XX
KW Murine; stromal stem cell; signalling; vaccine; 7TM-GPCR;
KW 7-transmembrane G-protein coupled protein receptor; ds.
XX
OS Mus sp.
XX
PN WO200160999-A1.
XX
PD 23-AUG-2001.
XX
PF 14-FEB-2001; 2001WO-US04700.
XX
PR 14-FEB-2000; 2000US-0182377.
XX
PA (IMCL-) IMCLONE SYSTEMS INC.
PA (UYPR-) UNIV PRINCETON.
XX
PI Lemischka IR, Witte L, Pereira DS;
XX
DR WPI; 2001-522596/57.

```
XX
PT   DNA Sequences encoding 7-transmembrane G-protein coupled protein
PT   receptors characteristic of hematopoietic stem cells, useful for
PT   treating leukemia -
XX
PS   Claim 1; Page 131-132; 176pp; English.
XX
CC   The present invention relates to murine coding sequences for
CC   7-transmembrane G-protein coupled protein receptors (7TM-GPCRs). The
CC   present sequence is one such murine 7TM-GPCR coding sequence. The present
CC   sequence was derived from stromal stem cells. The present sequence
CC   and its corresponding protein are useful in the prevention, diagnosis and
CC   treatment of diseases associated with inappropriate 7TM-GPCR expression.
CC   7TM-GPCRs identify specific signalling molecules, to activate an
CC   effector-signalling cascade that triggers an intracellular response and
CC   eventually a biological effect.
XX
SQ   Sequence 559 BP; 135 A; 158 C; 137 G; 112 T; 17 other;

  Query Match             22.6%;  Score 376;  DB 22;  Length 559;
  Best Local Similarity   79.9%;  Pred. No. 4.2e-66;
  Matches  444;  Conservative    0;  Mismatches  111;  Indels    1;  Gaps    1;

Qy     296 gtaagaagaactcgctgaaggactgcgtggcagtggctgggcccctcggggtcacacact 355
           | ||||||||||| |||||||||| ||||||||||||||| ||||| ||||||||||||
Db       3 gaaagaagaactccctgaaggactgtgtggcagtggctggccccctgggggtcacacact 62

Qy     356 ttctgatcctagcaaaacaagagaccaatgtctactttaagctgatgcgcctcccaggag 415
           | || ||  |  | |||  ||| | || ||| ||||| |||||||||| ||||||||||
Db      63 tccttattttgaccaaaacagataacagtgtatacttgaagctgatgcggctcccaggag 122

Qy     416 gccccaccttgaccttccaggtcaagaagtactcgctggtgcgtgatgtggtctcctcac 475
           ||||||| ||||| |||||| |||  |||||  | ||| | || || |||||||| || |
Db     123 gccccactttgacgttccagatcagcaagtatacactgatacgggacgtggtctcttccc 182

Qy     476 tgcgccggcaccgcatgcacgagcagcagtttgcccacccacccctcctggtactcaaca 535
           ||||||| ||||| |||||||||||||||||||  |||||| |||||||||| |||||||
Db     183 tgcgccgacaccggatgcacgagcagcagtttaaccaccctcccctcctggtgctcaaca 242

Qy     536 gctttggccccccatggtatgcatgtgaagctcatggccaccatgttccagaacctgttcc 595
           |||| |||||||| || |||||  | |||||||||| |||||||||||||||||||||||
Db     243 gcttcggcccccagggcatgcacatcaagctcatggncaccatgttccagaacctgttcc 302

Qy     596 cctccatcaacgtgcacaaggtgaacctgaacaccatcaagcgctgcctcctcatcgact 655
           | |||||||||||||| |||||||||||||| ||| ||||||||||||| |||  |||
Db     303 cgtccatcaacgtgcacacggtgaacctgaacancattaagcgctgcctccccattaact 362

Qy     656 acaaccccgactcccaggagctggacttccgccactatagcatcaaagttgttcctgtgg 715
           ||||||| || | ||| |||||||| ||||| || || ||| ||||||| ||||| || |
Db     363 acaaccctgantnccaagagctgganttccgncantacagcgtcaaagtggttcccgttg 422

Qy     716 gcgcgagtcgcgggatgaagaagctgctccaggagaagttccccaacatgagccgcctgc 775
           | || ||  |||| || ||||||||  | |||| | ||||||  || |||||||| || |
Db     423 gtgcaagcngcggcattaagaagctcttacaggggnagttcctaaanatgagccgactnc 482

Qy     776 aggacatcag-cgagctgctggccacgggcgcggggctgtcggagagcgaggcagagcct 834
           ||| ||||||  | |||| ||||||||||   ||||     |        |   ||||
Db     483 aggncatcagttgggctgntggccacgggtttggggtatcagacantnaggttggagcnc 542

Qy     835 gacggcgaccacaaca 850
           || || ||  ||||||
Db     543 gatggagaaaacaaca 558


RESULT  12
AAF64929
ID   AAF64929 standard; cDNA; 397 BP.
XX
AC   AAF64929;
XX
DT   09-APR-2001  (first entry)
XX
DE   Novel human polynucleotide, SEQ ID NO: 685.
XX
KW   Human; cytostatic; gene therapy; colon cancer; prostate cancer;
KW   breast cancer; lung cancer; cancer detection; ss.
XX
OS   Homo sapiens.
XX
PN   WO200102568-A2.
XX
PD   11-JAN-2001.
XX
PF   30-JUN-2000; 2000WO-US18374.
XX
PR   02-JUL-1999;   99US-0142310.
PR   02-JUL-1999;   99US-0142311.
XX
PA   (CHIR ) CHIRON CORP.
PA   (HYSE-) HYSEQ INC.
XX
PI   Williams LT,  Escobedo J,  Innis MA,  Garcia PD,  Klinger J,  Kassam A;
PI   Reinhard C,  Randazzo F,  Kennedy GC,  Pot D,  Lamson G,  Drmanac R;
PI   Crkenjakov R,  Drmanac S,  Dickson M,  Labat I,  Leshkowitiz D;
PI   Kita D,  Garcia V,  Jones LW,  Strache-Crain B;
XX
DR   WPI; 2001-091805/10.
XX
PT   Library of polynucleotides for diagnosing a cancerous state of a
PT   mammalian cell and detecting cancer, particularly of the colon or
PT   prostate, comprises 3351 human polynucleotide sequences -
XX
PS   Claim 9; Page 643; 1046pp; English.
XX
CC   The present sequence is one of 3351 sequences in a library of human
CC   polynucleotides. The library is used to detect differentially expressed
CC   genes correlated with a cancerous state of a mammalian cell and can
CC   detect colon, prostate, breast and lung cancer. The library can be used
CC   to produce probes for detection of mRNA and to produce additional copies
CC   of the polynucleotides. The probes can be used for chromosome mapping of
CC   the polynucleotide and for detection of transcription levels. Ribozymes
CC   or antisense oligonucleotides can be generated. The polynucleotides and
CC   their gene products are used as genetic or biochemical markers (e.g. in
CC   blood or tissues) that will detect the earliest changes along the
CC   carcinogenesis pathway and/or monitor the efficacy of therapies and
CC   preventive interventions. The polynucleotides, polypeptides and
CC   antibodies against them can be used in pharmaceutical compositions to
CC   treat the cancers and proliferative disorders such as neoplasia,
CC   dysplasia and hyperplasia.
XX
SQ   Sequence 397 BP; 82 A; 126 C; 126 G; 62 T; 1 other;

  Query Match             20.0%;  Score 333.2;  DB 22;  Length 397;
  Best Local Similarity   96.2%;  Pred. No. 1.4e-57;
  Matches  352;  Conservative    0;  Mismatches   13;  Indels    1;  Gaps    1;

Qy      67 ggcggacgcaggaggcctcgtggaggacacagcagcatgggacagtcagggaggtcccgg 126
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      24 ggcggacgcaggaggcctcgtggaggacacagcagcatgggacagtcagggaggtcccgg 83

Qy     127 caccagaagcgcgccccgccccaggcgcagctccgcaacctcgaggcctatgccgcgaac 186
           ||||||||||||||||   ||||||||||||||||||||||||||||||||||||||||
Db      84 caccagaagcgcgcccgcgcccaggcgcagctccgcaacctcgaggcctatgccgcgaac 143

Qy     187 ccgcactcgttcgtgttcacgcgaggctgcacgggtcgcaacatccggcagctcagcctg 246
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     144 ccgcactcgttcgtgttcacgcgaggctgcacgggtcgcaacatccggcagctcagcctg 203

Qy     247 gacgtgcggcgggtcatggagcccgtcactgccagccgtctgcaggttcgtaagaagaac 306
           ||||||||||||||||||||  ||||||||||||||||||||||||||||||||||||
Db     204 gacgtgcggcgggtcatggagccgctcactgccagccgtctgcaggttcgtaagaagaac 263

Qy     307 tcgctgaaggactgcgtggcagtggctgggcccctcggggtcacacactttctgatccta 366
           |||||||||||||||||||||||||||||||||| ||||||||||||||||||||||
```

```
Db    264 tcgctgaaggactgcgtggcagtggctgggcccctc-gggtcacacactttctgatcctg 322

Qy    367 gcaaaacaagagaccaatgtctactttaagctgatgcgcctcccaggaggccccaccttg 426

Db    323 agcaaaacagagaccaatggctactttaagctgatgcgcctcccaggaggccgcaccttg 382

Qy    427 accttc 432

Db    383 accttc 388


RESULT 13
ABL09953
ID   ABL09953 standard; cDNA; 1495 BP.
XX
AC   ABL09953;
XX
DT   26-MAR-2002  (first entry)
XX
DE   Drosophila melanogaster expressed polynucleotide SEQ ID NO 24341.
XX
KW   Drosophila; developmental biology; cell signalling; insecticide;
KW   pharmaceutical; gene; ss.
XX
OS   Drosophila melanogaster.
XX
PN   WO200171042-A2.
XX
PD   27-SEP-2001.
XX
PF   23-MAR-2001; 2001WO-US09231.
XX
PR   23-MAR-2000; 2000US-191637P.
PR   11-JUL-2000; 2000US-0614150.
XX
PA   (PEKE ) PE CORP NY.
XX
PI   Venter JC,  Adams M,  Li PWD,  Myers EW;
XX
DR   WPI; 2001-656860/75.
DR   P-PSDB; ABB65850.
XX
PT   New isolated nucleic acid detection reagent for detecting 1000 or more
PT   genes from Drosophila and for elucidating cell signalling and cell-cell
PT   interactions -
XX
PS   Claim 1; SEQ ID NO 24341; 21pp + Sequence Listing; English.
XX
CC   The invention relates to an isolated nucleic acid detection reagent
CC   capable of detecting 1000 or more genes from Drosophila. The invention is
CC   useful in developmental biology and in elucidating cell signalling and
CC   cell-cell interactions in higher eukaryotes for the development of
CC   insecticides, therapeutics and pharmaceutical drugs. The invention
CC   discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC   sequences (ABL01840-ABL16175) and the encoded proteins
CC   (ABB57737-ABB72072).
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 1495 BP; 451 A; 387 C; 399 G; 258 T; 0 other;


  Query Match             17.2%;  Score 285.8;  DB 23;  Length 1495;
  Best Local Similarity   56.0%;  Pred. No. 5.1e-48;
  Matches  561;  Conservative    0;  Mismatches  437;  Indels    3;  Gaps    1;

Qy    126 gcaccagaagcgcgccccgccccaggcgcagctccgcaacctcgaggcctatgccgcgaa 185

Db     89 gcatccgaagacgcgcacggcggccttcaaggccagcgagccgagcgagatcgtggaggc 148

Qy    186 cccgcactcgttcgtgttcacgcgaggctgcacgggtcgcaacatccggcagctcagcct 245

Db    149 gccgcactccttcgtcatccatcgcggcctcgcctgtccgtacatcacggacctcaccct 208

Qy    246 ggacgtgcggcgggtcatggagcccgtcactgccagccgtctgcaggttcgtaagaagaa 305

Db    209 ggacttccgccgcattatggagccctttacggccagcaatctgcgcgagaagcggatgaa 268

Qy    306 ctcgctgaaggactgcgtggcagtggctgggcccctcggggtcacacactttctgatcct 365

Db    269 ccgcatcaaggactttgtcagcctgagcagcttcttccacgtctcgcacatgggcatctt 328

Qy    366 agcaaaacaagagaccaatgtctactttaagctgatgcgcctcccaggaggccccacctt 425

Db    329 caacaaggcctccacgcagctgtccttcaaagtggtccgcttgccgcgcggtccttccct 388

Qy    426 gaccttccaggtcaagaagtactcgctggtgcgtgatgtggtctcctcactgcgccggca 485

Db    389 gactttcaaggttcaccagttcaccctggccagagatgtgatctcgctaagcaaaaagca 448

Qy    486 ccgcatgcacgagcagcagtttgcccacccacccctcctggtactcaacagctttggccc 545

Db    449 gatgattgacaacgatcacttcaagcacgctccgctcgtcatcatgaacaacttcagtgg 508

Qy    546 ccatggtatgcatgtgaagctcatggccaccatgttccagaacctgttcccctccatcaa 605

Db    509 cgatggcaagcaccttaagctgatggccaccacgttccaaaacatgttcccctcaattaa 568

Qy    606 cgtgcacaaggtgaacctgaacaccatcaagcgctgcctcctcatcgactacaaccccga 665

Db    569 cttggccacggttaatatcggcaccattcgtcgctgcgtcctgttctcctacaatccgga 628

Qy    666 ctcccaggagctggacttccgccactatagcatcaaagttgttcctgtgggcgcgagtcg 725

Db    629 cacgaagctggtcgagatgcggcactactccgtgcaggtggtgccggttggcttaaagcg 688

Qy    726 cgggatgaagaagctgctccaggagaagttccccaacatgagccgcctgcaggacatcag 785

Db    689 ggcggtccagaaaatcgtcaaaggaacggtacccaatctgggcaagtgcaacgaagtcgt 748

Qy    786 cgagctgctggccacgggcgcggggctgtcggagagcgaggcagagcctgacggcgacca 845

Db    749 ggactttgtgaccaaggacggctatgcctccgaatcagaggccga---agatgatgagca 805

Qy    846 caacatcacagagctgcctcaggctgtcgctggccgtggcaacatgcgggcccagcagag 905

Db    806 atcacatgtggtgctggcacagactcttaaaagcaagggcaacttggaggacaaaaagag 865

Qy    906 tgcagtgcggctcaccgagatcggcccgcggatgacactgcagctcatcaaggtccagga 965

Db    866 ctccataaagctacacgagatcggacctcgactaaccatgcagctcatcaaaatagaaga 925

Qy    966 gggcgtcggggagggcaaagtgatgttccacagttttgtgagcaagacggaggaggagct 1025

Db    926 gggccttctgacgggcgaagtactgtatcacgaccatgtggtcaagacagaggacgaaaa 985

Qy   1026 gcaggccatcctggaagccaaggagaagaagctgcggctgaaggctcagaggcaggccca 1085

Db    986 ggaaaccctgcgcaagctggtcgaaaagaagcgaaagcagaaggagcagcgcaagaagga 1045

Qy   1086 gcaggcccagaatgtgcagcgcaagcaggagcagcgggagg 1126

Db   1046 gcaggcagagaaccgtgcccgcaacttgaagcttaagaagg 1086


RESULT 14
AAF64998
ID   AAF64998 standard; cDNA; 224 BP.
XX
AC   AAF64998;
XX
DT   09-APR-2001  (first entry)
XX
DE   Novel human polynucleotide, SEQ ID NO: 754.
XX
```

KW Human; cytostatic; gene therapy; colon cancer; prostate cancer;
KW breast cancer; lung cancer; cancer detection; ss.
XX
OS Homo sapiens.
XX
PN WO200102568-A2.
XX
PD 11-JAN-2001.
XX
PF 30-JUN-2000; 2000WO-US18374.
XX
PR 02-JUL-1999; 99US-0142310.
PR 02-JUL-1999; 99US-0142311.
XX
PA (CHIR) CHIRON CORP.
PA (HYSE-) HYSEQ INC.
XX
PI Williams LT, Escobedo J, Innis MA, Garcia PD, Klinger J, Kassam A;
PI Reinhard C, Randazzo F, Kennedy GC, Pot D, Lamson G, Drmanac R;
PI Crkenjakov R, Drmanac S, Dickson M, Labat I, Leshkowitiz D;
PI Kita D, Garcia V, Jones LW, Strache-Crain B;
XX
DR WPI; 2001-091805/10.
XX
PT Library of polynucleotides for diagnosing a cancerous state of a
PT mammalian cell and detecting cancer, particularly of the colon or
PT prostate, comprises 3351 human polynucleotide sequences -
XX
PS Claim 9; Page 652; 1046pp; English.
XX
CC The present sequence is one of 3351 sequences in a library of human
CC polynucleotides. The library is used to detect differentially expressed
CC genes correlated with a cancerous state of a mammalian cell and can
CC detect colon, prostate, breast and lung cancer. The library can be used
CC to produce probes for detection of mRNA and to produce additional copies
CC of the polynucleotides. The probes can be used for chromosome mapping of
CC the polynucleotide and for detection of transcription levels. Ribozymes
CC or antisense oligonucleotides can be generated. The polynucleotides and
CC their gene products are used as genetic or biochemical markers (e.g. in
CC blood or tissues) that will detect the earliest changes along the
CC carcinogenesis pathway and/or monitor the efficacy of therapies and
CC preventive interventions. The polynucleotides, polypeptides and
CC antibodies against them can be used in pharmaceutical compositions to
CC treat the cancers and proliferative disorders such as neoplasia,
CC dysplasia and hyperplasia.
XX
SQ Sequence 224 BP; 41 A; 78 C; 79 G; 25 T; 1 other;

Query Match 12.2%; Score 203.8; DB 22; Length 224;
Best Local Similarity 96.3%; Pred. No. 8.9e-32;
Matches 208; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

```
Qy      67 ggcggacgcaggaggcctcgtggaggacacagcagcatgggacagtcagggaggtcccgg 126
           ||||||||||||||||||  ||||||||||||||||||||||||| ||||||||||||||
Db       9 ggcggacgcaggaggcctnctggaggacacagcagcatgggacaggcagggaggtcccgg 68

Qy     127 caccagaagcgcgccccgccccaggcgcagctccgcaacctcgaggcctatgccgcgaac 186
           ||||||||||||||||   ||||||||||||||||||||||||||||||||||||||||
Db      69 caccagaagcgcgcccgcgcccaggcgcagctccgcaacctcgaggcctatgccgcgaac 128

Qy     187 ccgcactcgttcgtgttcacgcgaggctgcacgggtcgcaacatccggcagctcagcctg 246
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     129 ccgcactcgttcgtgttcacgcgaggctgcacgggtcgcaacatccggcagctcagcctg 188

Qy     247 gacgtgcggcgggtcatggagcccgtcactgccagc 282
           ||||||||||||||||||||||  ||||||||||
Db     189 gacgtgcggcgggtcatggagccgctcactgccagc 224
```

RESULT 15
AAC48751
ID AAC48751 standard; DNA; 1041 BP.
XX
AC AAC48751;
XX
DT 18-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana DNA fragment SEQ ID NO: 58633.
XX
KW Hybridisation assay; genetic mapping; gene expression control;
KW protein identification; signal transduction pathway;
KW metabolic pathway; promoter; termination sequence; ss.
XX
OS Arabidopsis thaliana.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-0301439.
XX
PR 25-FEB-1999; 99US-0121825.
PR 05-MAR-1999; 99US-0123180.
PR 09-MAR-1999; 99US-0123548.
PR 23-MAR-1999; 99US-0125788.
PR 25-MAR-1999; 99US-0126264.
PR 29-MAR-1999; 99US-0126785.
PR 01-APR-1999; 99US-0127462.
PR 06-APR-1999; 99US-0128234.
PR 08-APR-1999; 99US-0128714.
PR 16-APR-1999; 99US-0129845.
PR 19-APR-1999; 99US-0130077.
PR 21-APR-1999; 99US-0130449.
PR 23-APR-1999; 99US-0130510.
PR 23-APR-1999; 99US-0130891.
PR 28-APR-1999; 99US-0131449.
PR 30-APR-1999; 99US-0132048.
PR 30-APR-1999; 99US-0132407.
PR 04-MAY-1999; 99US-0132484.
PR 05-MAY-1999; 99US-0132485.
PR 06-MAY-1999; 99US-0132486.
PR 06-MAY-1999; 99US-0132487.
PR 07-MAY-1999; 99US-0132863.
PR 11-MAY-1999; 99US-0134256.
PR 14-MAY-1999; 99US-0134218.
PR 14-MAY-1999; 99US-0134219.
PR 14-MAY-1999; 99US-0134221.
PR 14-MAY-1999; 99US-0134370.
PR 18-MAY-1999; 99US-0134768.
PR 19-MAY-1999; 99US-0134941.
PR 20-MAY-1999; 99US-0135124.
PR 21-MAY-1999; 99US-0135353.
PR 24-MAY-1999; 99US-0135629.
PR 25-MAY-1999; 99US-0136021.
PR 27-MAY-1999; 99US-0136392.
PR 28-MAY-1999; 99US-0136782.
PR 01-JUN-1999; 99US-0137222.
PR 03-JUN-1999; 99US-0137528.
PR 04-JUN-1999; 99US-0137502.
PR 07-JUN-1999; 99US-0137724.
PR 08-JUN-1999; 99US-0138094.
PR 10-JUN-1999; 99US-0138540.
PR 10-JUN-1999; 99US-0138847.
PR 14-JUN-1999; 99US-0139119.
PR 16-JUN-1999; 99US-0139452.
PR 16-JUN-1999; 99US-0139453.
PR 17-JUN-1999; 99US-0139492.
PR 18-JUN-1999; 99US-0139454.
PR 18-JUN-1999; 99US-0139455.
PR 18-JUN-1999; 99US-0139456.
PR 18-JUN-1999; 99US-0139457.
PR 18-JUN-1999; 99US-0139458.
PR 18-JUN-1999; 99US-0139459.
PR 18-JUN-1999; 99US-0139460.
PR 18-JUN-1999; 99US-0139461.

PR 18-JUN-1999; 99US-0139462.
PR 18-JUN-1999; 99US-0139463.
PR 18-JUN-1999; 99US-0139750.
PR 18-JUN-1999; 99US-0139763.
PR 21-JUN-1999; 99US-0139817.
PR 22-JUN-1999; 99US-0139899.
PR 23-JUN-1999; 99US-0140353.
PR 23-JUN-1999; 99US-0140354.
PR 24-JUN-1999; 99US-0140695.
PR 28-JUN-1999; 99US-0140823.
PR 29-JUN-1999; 99US-0140991.
PR 30-JUN-1999; 99US-0141287.
PR 01-JUL-1999; 99US-0141842.
PR 01-JUL-1999; 99US-0142154.
PR 02-JUL-1999; 99US-0142055.
PR 06-JUL-1999; 99US-0142390.
PR 08-JUL-1999; 99US-0142803.
PR 09-JUL-1999; 99US-0142920.
PR 12-JUL-1999; 99US-0142977.
PR 13-JUL-1999; 99US-0143542.
PR 14-JUL-1999; 99US-0143624.
PR 15-JUL-1999; 99US-0144005.
PR 16-JUL-1999; 99US-0144085.
PR 16-JUL-1999; 99US-0144086.
PR 19-JUL-1999; 99US-0144325.
PR 19-JUL-1999; 99US-0144331.
PR 19-JUL-1999; 99US-0144332.
PR 19-JUL-1999; 99US-0144333.
PR 19-JUL-1999; 99US-0144334.
PR 19-JUL-1999; 99US-0144335.
PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144632.
PR 20-JUL-1999; 99US-0144884.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.
PR 22-JUL-1999; 99US-0145087.
PR 22-JUL-1999; 99US-0145089.
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.

Query Match 9.6%; Score 160.4; DB 21; Length 1041;
Best Local Similarity 51.7%; Pred. No. 5.3e-23;
Matches 421; Conservative 0; Mismatches 381; Indels 12; Gaps 2;

```
Qy    183 gaacccgcactcgttcgtgttcacgcgaggctgcacgggtcgcaacatccggcagctcag 242
          ||  ||  |    || || ||| |  ||        | | ||    |    || |||
Db     96 gattcccaagagttttgtcttctcaagaatgaaacttgctggccctgttaaacaactcca 155

Qy    243 cctggacgtgcggcgggtcatggagcccgtcactgccagccgtctgcaggttcgtaagaa 302
          ||||  || ||  | |||||   |||  ||||||   | ||||  |||     |||
Db    156 gatggatttgaggaagctcatgcttccctacactgctctcagtcttaaggagaagaagcg 215

Qy    303 gaactcgctgaaggactgcgtggcagtggctgggcccctcggggtcacacactttctgat 362
          ||||  |  | | |||||   ||   ||  | || ||  | || || ||||| || || ||
Db    216 gaacactttaagggacttttgaatgtatcaggtccaatgggtgttacacatttccttat 275

Qy    363 cctagcaaaacaagagaccaatgtctactttaagctgatgcgcctcccaggaggccccac 422
          ||  | |||  || | |     | |   |||   |     |   |||    ||||| ||
Db    276 gctttcgaaaacagcgtcttcactgtctcttagagtagcaagaacccctcagggcccgac 335
```

```
Qy    423 cttgaccttccaggtcaagaagtactcgctggtgcgtgatgtggtctcctcactgcgccg 482
          | |||||| |  |  |  |||| ||  | |     ||| | |     || | ||  ||
Db    336 tcttaccttcaaaattcatcagtattccttagcatcagatatagctcagtctcagcttcg 395

Qy    483 gcaccgcatgcacgagcagcagtttgcccacccacccctcctggtactcaacagctttgg 542
          |   |    |   | | |  ||        || ||  |  | || ||     | || ||
Db    396 acctagatgtcctcaagatcttttcaagagtcctcctttgattgtcctttctggattcgg 455

Qy    543 cccccatggtatgcatgtgaagctcatggccaccatgttccagaacctgttcccctccat 602
          | || |   ||||| |||| ||     | |  ||||| |||||  | |||||  | ||
Db    456 ttctcaagagttgcatctgaaactggcaacgattatgtttcagaatatattcccagctat 515

Qy    603 caacgtgcacaaggtgaacctgaacaccatcaagcgctgcctcctcatcgactacaaccc 662
          |  |  |||  || || ||   ||||  | || | |   | ||| |  ||||||||
Db    516 tgatattaacactgtcaagctctccacctgccagagattagtactcttgaactacaacaa 575

Qy    663 cgactcccaggagctggacttccgccactatagcatcaaagttgttcctgtgggcgcgag 722
          ||| || ||    | || ||||| || |||   || | | ||   ||||| || |
Db    576 agacaccaagctcattgatttccggcattattctataagacttcagcctgttggagtatc 635

Qy    723 tcgcgggatgaagaag---ctgctccaggagaagttccccaacatgagccgcctgcagga 779
          |||  |||| |  |||    |||   |  |  || | ||  |  | ||    ||||||||
Db    636 tcgtaggatcagaaagtttgtgcaaaatcatcaggttccagatcttaggaatctgcagga 695

Qy    780 catcagcgagctgctggccacgggcgcggggctgtcggagagcgaggcagagcctgacgg 839
          | || ||  |  |  ||| ||  |         || |||||||| | |||    || |
Db    696 tgttagtgattttgtcaccaaggctggttacggatcagagagcgaaggagatgaagaagc 755

Qy    840 cgaccacaacatcacagagctgcctcaggctgtcgctggccgtggcaacatgcgggccca 899
          |           |||| |   |      |||     ||||| |  ||||   | |||
Db    756 gg---------caacagtgacactatcatctgatctaggccgagttaacaaaggtgccac 806

Qy    900 gcagagtgcagtgcggctcaccgagatcggcccgcggatgacactgcagctcatcaaggt 959
          |||| ||||||   ||    || || || ||  | |||||  |||| ||| | || ||
Db    807 caagagcgcagtgaaactgcaagaaattggaccaagaatgactatgcaactcgttaaagt 866

Qy    960 ccaggagggcgtcggggagggcaaagtgatgttc 993
          |||| ||  |  |    ||   | | || |||
Db    867 ggaggaaggattgtgtacaggaggaatcatattc 900
```

Search completed: June 3, 2002, 22:11:58
Job time: 6124 sec

GenCore version 4.5

OM nucleic - nucleic search, using sw model

Run on: June 3, 2002, 20:29:54 ; Search time 366.71 Seconds
(without alignments)
74.911 Million cell updates/sec

Title: US-09-438-917-2
Perfect score: 16
Sequence: 1 agggngucggggaggu 16

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1736436 seqs, 858457221 residues

Total number of hits satisfying chosen parameters: 3472872

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_032802:*
1: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2001A.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2001B.DAT:*
24: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	15	93.8	16	22	AAD05988	Ribozyme binding D
	2	15	93.8	16	22	AAD06003	Ribozyme binding R
c	3	15	93.8	43	22	AAD05997	Human tumour suppr
c	4	15	93.8	2837	19	AAV10266	Rat GABA-BR1b rece
	5	15	93.8	5379	24	ABL32331	Human immune syste
	6	15	93.8	7119	24	ABL32293	Human immune syste
	7	15	93.8	7203	24	ABL34051	Human immune syste
c	8	15	93.8	8280	22	AAS30120	Human lung antigen
c	9	15	93.8	18535	22	AAS30121	Human lung antigen
	10	14	87.5	15	22	AAD06001	Human tumour suppr
	11	14	87.5	514	22	AAK78496	Human immune/haema
c	12	14	87.5	539	22	AAL01287	Human reproductive
c	13	14	87.5	567	22	AAI90687	Human polynucleoti
	14	14	87.5	580	23	AAS86857	DNA encoding novel
	15	14	87.5	1121	22	AAK80650	Human immune/haema
	16	14	87.5	1140	15	AAQ64887	cDNA encoding alph
c	17	14	87.5	1301	22	AAK80258	Human immune/haema
c	18	14	87.5	1591	22	AAI59771	Human polynucleoti
c	19	14	87.5	1591	22	AAI59772	Human polynucleoti
c	20	14	87.5	1637	21	AAC48042	Zea mays DNA fragm
	21	14	87.5	1664	15	AAQ44395	Farnesyltransferas
	22	14	87.5	1664	16	AAQ94412	Human farnesyl pro
	23	14	87.5	1664	17	AAT38710	Human farnesyl tra
	24	14	87.5	1664	22	AAD05991	Human tumour suppr
	25	14	87.5	1828	21	AAA12415	cDNA encoding a hu
c	26	14	87.5	2100	20	AAV64856	Human LFA-1 beta c
	27	14	87.5	2240	22	AAI57986	Human polynucleoti
c	28	14	87.5	2291	21	AAF21007	Human low adenosin
c	29	14	87.5	2291	21	AAF21109	Human low adenosin
c	30	14	87.5	2291	21	AAA34885	Human adenosine re
c	31	14	87.5	2291	21	AAA34987	Human adenosine re
	32	14	87.5	2300	22	AAI57985	Human polynucleoti
c	33	14	87.5	2310	20	AAV64854	Human LFA-1 beta c
c	34	14	87.5	2405	17	AAT27652	LFA-1-beta-CD28 ch
	35	14	87.5	2412	21	AAF18260	Lung cancer associ
	36	14	87.5	2427	20	AAX07369	Human P2Y11 recept
c	37	14	87.5	2704	21	AAA54361	LFA-1 CD18 domain.
c	38	14	87.5	2732	23	AAS86858	DNA encoding novel
c	39	14	87.5	2776	9	AAN80863	Sequence of cDNA c
c	40	14	87.5	2776	11	AAQ06050	Sequence encoding
c	41	14	87.5	2776	13	AAQ22780	Codes for beta-sub
c	42	14	87.5	2776	21	AAF21108	Human low adenosin
c	43	14	87.5	2776	21	AAA34986	Human adenosine re
c	44	14	87.5	2776	21	AAZ51785	LFA-1 beta subunit
c	45	14	87.5	3632	17	AAT06978	T. thermophilus ga

ALIGNMENTS

RESULT 1
AAD05988
ID AAD05988 standard; DNA; 16 BP.
XX
AC AAD05988;
XX
DT 31-JUL-2001 (first entry)
XX
DE Ribozyme binding DNA sequence of HTS1, RST 568.
XX
KW Human tumour suppressor 1; HTS1; HPPAN; neoplastic cell; cancer; tumour;
KW leukaemia; breast; bladder; colorectal; gynaecological; lung; cytostatic;
KW antiproliferative; gene therapy; ribozyme sequence tag 568; RST 568; ds.
XX
OS Unidentified.
XX
PN WO200134634-A2.
XX
PD 17-MAY-2001.
XX
PF 09-NOV-2000; 2000WO-US30951.
XX
PR 12-NOV-1999; 99US-0438917.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Welch PJ, Barber JR;
XX
DR WPI; 2001-329068/34.
XX
PT New tumor suppressor nucleic acid molecules for detecting a neoplastic
PT cell in a sample and for regulating cell proliferation, such as, for

```
Db      43 AGGGNGTCGGGGAGGT 28

RESULT   4
AAV10266/c
ID   AAV10266 standard; cDNA to mRNA; 2837 BP.
XX
AC   AAV10266;
XX
DT   03-JUN-1998  (first entry)
XX
DE   Rat GABA-BR1b receptor cDNA.
XX
KW   Gamma-animobutyric acid; GABA-BR1b receptor; rat; brain; agonist;
KW   inhibitory neurotransmitter; peripheral nervous system; antagonist;
KW   treatment; dementia; depression; anxiety; bronchial inflammation; asthma;
KW   epilepsy; cognitive function; ds.
XX
OS   Rattus norvegicus.
XX
FH   Key             Location/Qualifiers
FT   CDS             228..2762
FT                   /*tag= a
FT                   /product= GABA-BR1b
XX
PN   WO9746675-A1.
XX
PD   11-DEC-1997.
XX
PF   19-MAR-1997;    97WO-EP01370.
XX
PR   22-NOV-1996;    96US-0756091.
PR   30-MAY-1996;    96US-0655716.
XX
PA   (NOVS ) NOVARTIS AG.
XX
PI   Bettler B,  Bittiger H,  Froestl W,  Kaupmann K,  Mickel SJ;
XX
DR   WPI; 1998-042183/04.
DR   P-PSDB; AAW40118.
XX
PT   Purified GABA-B receptor or receptor protein - and antagonists of
PT   these which may be useful in treating nervous system disorders
XX
PS   Claim 3; Page 67-74; 108pp; English.
XX
CC   This cDNA sequence encodes a novel rat GABA-B receptor protein,
CC   GABA-BR1b. GABA (gamma-aminobutyric acid) is the major inhibitory
```



```
CC   neurotransmitter found in the brain and peripheral nervous system
CC   and this receptor may be used for the identification of GABA-B
CC   receptor agonists and antagonists. Such proteins may be used in
CC   treatment of dementia, depression, anxiety, epilepsy, spasticity,
CC   bronchial inflammation or asthma or to improve cognitive function.
CC   GABA-B receptor ligands and probes derived from this sequence can be
CC   used to assay for GABA-B receptors or DNA encoding them.
XX
SQ   Sequence 2837 BP; 621 A; 842 C; 764 G; 610 T; 0 other;

 Query Match              93.8%;  Score 15;  DB 19;  Length 2837;
 Best Local Similarity    81.2%;  Pred. No. 4.5e+02;
 Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 agggngucgggaggu 16
           |||| |:||||||||:
Db     148 AGGGCGTCGGGGAGGT 133
```

GenCore version 4.5

OM nucleic - nucleic search, using sw model

Run on: June 3, 2002, 20:29:54 ; Search time 366.71 Seconds
(without alignments)
74.911 Million cell updates/sec

Title: US-09-438-917-2
Perfect score: 16
Sequence: 1 agggngucggggaggu 16

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1736436 seqs, 858457221 residues

Total number of hits satisfying chosen parameters: 3472872

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_032802:*
1: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2001A.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2001B.DAT:*
24: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	15	93.8	16	22	AAD05988	Ribozyme binding D
	2	15	93.8	16	22	AAD06003	Ribozyme binding R
c	3	15	93.8	43	22	AAD05997	Human tumour suppr
c	4	15	93.8	2837	19	AAV10266	Rat GABA-BR1b rece
	5	15	93.8	5379	24	ABL32331	Human immune syste
	6	15	93.8	7119	24	ABL32293	Human immune syste
	7	15	93.8	7203	24	ABL34051	Human immune syste
c	8	15	93.8	8280	22	AAS30120	Human lung antigen
c	9	15	93.8	18535	22	AAS30121	Human lung antigen
	10	14	87.5	15	22	AAD06001	Human tumour suppr
	11	14	87.5	514	22	AAK78496	Human immune/haema
c	12	14	87.5	539	22	AAL01287	Human reproductive
c	13	14	87.5	567	22	AAI90687	Human polynucleoti
	14	14	87.5	580	23	AAS86857	DNA encoding novel
	15	14	87.5	1121	22	AAK80650	Human immune/haema
	16	14	87.5	1140	15	AAQ64887	cDNA encoding alph
c	17	14	87.5	1301	22	AAK80258	Human immune/haema
c	18	14	87.5	1591	22	AAI59771	Human polynucleoti
c	19	14	87.5	1591	22	AAI59772	Human polynucleoti
c	20	14	87.5	1637	21	AAC48042	Zea mays DNA fragm
	21	14	87.5	1664	15	AAQ44395	Farnesyltransferas
	22	14	87.5	1664	16	AAQ94412	Human farnesyl pro
	23	14	87.5	1664	17	AAT38710	Human farnesyl tra
	24	14	87.5	1664	22	AAD05991	Human tumour suppr
	25	14	87.5	1828	21	AAA12415	cDNA encoding a hu
c	26	14	87.5	2100	20	AAV64856	Human LFA-1 beta c
	27	14	87.5	2240	22	AAI57986	Human polynucleoti
c	28	14	87.5	2291	21	AAF21007	Human low adenosin
c	29	14	87.5	2291	21	AAF21109	Human low adenosin
c	30	14	87.5	2291	21	AAA34885	Human adenosine re
c	31	14	87.5	2291	21	AAA34987	Human adenosine re
	32	14	87.5	2300	22	AAI57985	Human polynucleoti
c	33	14	87.5	2310	20	AAV64854	Human LFA-1 beta c
c	34	14	87.5	2405	17	AAT27652	LFA-1-beta-CD28 ch
	35	14	87.5	2412	21	AAF18260	Lung cancer associ
	36	14	87.5	2427	20	AAX07369	Human P2Y11 recept
c	37	14	87.5	2704	21	AAA54361	LFA-1 CD18 domain.
c	38	14	87.5	2732	23	AAS86858	DNA encoding novel
c	39	14	87.5	2776	9	AAN80863	Sequence of cDNA c
c	40	14	87.5	2776	11	AAQ06050	Sequence encoding
c	41	14	87.5	2776	13	AAQ22780	Codes for beta-sub
c	42	14	87.5	2776	21	AAF21108	Human low adenosin
c	43	14	87.5	2776	21	AAA34986	Human adenosine re
c	44	14	87.5	2776	21	AAZ51785	LFA-1 beta subunit
c	45	14	87.5	3632	17	AAT06978	T. thermophilus ga

ALIGNMENTS

RESULT 1
AAD05988
ID AAD05988 standard; DNA; 16 BP.
XX
AC AAD05988;
XX
DT 31-JUL-2001 (first entry)
XX
DE Ribozyme binding DNA sequence of HTS1, RST 568.
XX
KW Human tumour suppressor 1; HTS1; HPPAN; neoplastic cell; cancer; tumour;
KW leukaemia; breast; bladder; colorectal; gynaecological; lung; cytostatic;
KW antiproliferative; gene therapy; ribozyme sequence tag 568; RST 568; ds.
XX
OS Unidentified.
XX
PN WO200134634-A2.
XX
PD 17-MAY-2001.
XX
PF 09-NOV-2000; 2000WO-US30951.
XX
PR 12-NOV-1999; 99US-0438917.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Welch PJ, Barber JR;
XX
DR WPI; 2001-329068/34.
XX
PT New tumor suppressor nucleic acid molecules for detecting a neoplastic
PT cell in a sample and for regulating cell proliferation, such as, for

PT treating cancer -
XX
PS Claim 1; Page 53; 84pp; English.
XX
CC The invention relates to human tumour suppressor 1 (HTS1) genes, also
CC referred as HPPAN and polypeptides encoded by them. The invention
CC also provides hairpin ribozymes and antibodies selective for the HTS1
CC molecules, and diagnostic methods for detecting a neoplastic cell in a
CC sample using detectable agents specific for HTS1 molecules. HTS1 and
CC its genes are useful for detecting a neoplastic cell in a sample and
CC are therefore used to diagnose and prognose cancer. HTS1 sequences are
CC introduced into neoplastic cells to regulate cell proliferation, and
CC are thus useful as therapeutics for treating cancer. They are also used
CC for identifying compounds that mimic or regulate the tumour suppressor
CC activity. Such compounds are used as therapeutics to treat cancer. HTS1
CC sequences are used to treat both solid tumours and leukaemias. They are
CC also used in gene therapy. The diagnostic methods are useful for
CC identification of neoplastic cells in solid tumours of breast, bladder,
CC colorectal, gynaecological, lung, renal cancers etc.
CC The present sequence is ribozyme binding DNA sequence of HTS1, also
CC referred as ribozyme sequence tag (RST) 568. RST 568 is present in the
CC HTS1 molecule which is targeted by the ribozyme 568.
XX
SQ Sequence 16 BP; 2 A; 1 C; 10 G; 2 T; 1 other;

Query Match 93.8%; Score 15; DB 22; Length 16;
Best Local Similarity 87.5%; Pred. No. 7.4e+02;
Matches 14; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 agggngucggggaggu 16
||||||:|||||||:
Db 1 agggngtcggggaggt 16

RESULT 2
AAD06003
ID AAD06003 standard; RNA; 16 BP.
XX
AC AAD06003;
XX
DT 31-JUL-2001 (first entry)
XX
DE Ribozyme binding RNA sequence of HTS1, RST 568.
XX
KW Human tumour suppressor 1; HTS1; HPPAN; neoplastic cell; cancer; tumour;
KW leukaemia; breast; bladder; colorectal; gynaecological; lung; cytostatic;
KW antiproliferative; gene therapy; ribozyme sequence tag 568; RST 568; ss.
XX
OS Unidentified.
XX
PN WO200134634-A2.
XX
PD 17-MAY-2001.
XX
PF 09-NOV-2000; 2000WO-US30951.
XX
PR 12-NOV-1999; 99US-0438917.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Welch PJ, Barber JR;
XX
DR WPI; 2001-329068/34.
XX
PT New tumor suppressor nucleic acid molecules for detecting a neoplastic
PT cell in a sample and for regulating cell proliferation, such as, for
PT treating cancer -
XX
PS Claim 1; Page 74; 84pp; English.
XX
CC The invention relates to human tumour suppressor 1 (HTS1) genes, also
CC referred as HPPAN and polypeptides encoded by them. The invention
CC also provides hairpin ribozymes and antibodies selective for the HTS1
CC molecules, and diagnostic methods for detecting a neoplastic cell in a
CC sample using detectable agents specific for HTS1 molecules. HTS1 and
CC its genes are useful for detecting a neoplastic cell in a sample and
CC are therefore used to diagnose and prognose cancer. HTS1 sequences are
CC introduced into neoplastic cells to regulate cell proliferation, and
CC are thus useful as therapeutics for treating cancer. They are also used
CC for identifying compounds that mimic or regulate the tumour suppressor
CC activity. Such compounds are used as therapeutics to treat cancer. HTS1
CC sequences are used to treat both solid tumours and leukaemias. They are
CC also used in gene therapy. The diagnostic methods are useful for
CC identification of neoplastic cells in solid tumours of breast, bladder,
CC colorectal, gynaecological, lung, renal cancers etc.
CC The present sequence is ribozyme binding RNA sequence of HTS1, also
CC referred as ribozyme sequence tag (RST) 568. RST 568 is present in the
CC HTS1 molecule which is targeted by the ribozyme 568.
XX
SQ Sequence 16 BP; 2 A; 1 C; 10 G; 2 U; 1 other;

Query Match 93.8%; Score 15; DB 22; Length 16;
Best Local Similarity 100.0%; Pred. No. 7.4e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 agggngucggggaggu 16
||||||||||||||||
Db 1 agggngucggggaggu 16

RESULT 3
AAD05997/c
ID AAD05997 standard; DNA; 43 BP.
XX
AC AAD05997;
XX
DT 31-JUL-2001 (first entry)
XX
DE Human tumour suppressor 1 (HTS1) cDNA primer #1.
XX
KW Human tumour suppressor 1; HTS1; HPPAN; neoplastic cell; cancer; tumour;
KW leukaemia; breast; bladder; colorectal; gynaecological; lung; cytostatic;
KW antiproliferative; gene therapy; RACE; primer; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT misc_feature 28..43
FT /*tag= a
FT /note= "This region corresponds to ribozyme (Rz)
FT 568 sequence"
XX
PN WO200134634-A2.
XX
PD 17-MAY-2001.
XX
PF 09-NOV-2000; 2000WO-US30951.
XX
PR 12-NOV-1999; 99US-0438917.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Welch PJ, Barber JR;
XX
DR WPI; 2001-329068/34.
XX
PT New tumor suppressor nucleic acid molecules for detecting a neoplastic
PT cell in a sample and for regulating cell proliferation, such as, for
PT treating cancer -
XX
PS Example 3; Page 55; 84pp; English.
XX
CC The invention relates to human tumour suppressor 1 (HTS1) genes, also
CC referred as HPPAN and polypeptides encoded by them. The invention

```
CC   also provides hairpin ribozymes and antibodies selective for the HTS1
CC   molecules, and diagnostic methods for detecting a neoplastic cell in a
CC   sample using detectable agents specific for HTS1 molecules. HTS1 and
CC   its genes are useful for detecting a neoplastic cell in a sample and
CC   are therefore used to diagnose and prognose cancer. HTS1 sequences are
CC   introduced into neoplastic cells to regulate cell proliferation, and
CC   are thus useful as therapeutics for treating cancer. They are also used
CC   for identifying compounds that mimic or regulate the tumour suppressor
CC   activity. Such compounds are used as therapeutics to treat cancer. HTS1
CC   sequences are used to treat both solid tumours and leukaemias. They are
CC   also used in gene therapy. The diagnostic methods are useful for
CC   identification of neoplastic cells in solid tumours of breast, bladder,
CC   colorectal, gynaecological, lung, renal cancers etc.
CC   The present sequence is 5' RACE (rapid amplification of cDNA ends)
CC   primer used for isolating and characterising HTS1 cDNA.
XX
SQ   Sequence 43 BP; 7 A; 19 C; 8 G; 8 T; 1 other;

  Query Match             93.8%;  Score 15;  DB 22;  Length 43;
  Best Local Similarity   87.5%;  Pred. No. 6.7e+02;
  Matches   14;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 agggngucggggaggu 16
           ||||||:||||||||:
Db      43 AGGGNGTCGGGGAGGT 28


RESULT   4
AAV10266/c
ID   AAV10266 standard; cDNA to mRNA; 2837 BP.
XX
AC   AAV10266;
XX
DT   03-JUN-1998  (first entry)
XX
DE   Rat GABA-BR1b receptor cDNA.
XX
KW   Gamma-animobutyric acid; GABA-BR1b receptor; rat; brain; agonist;
KW   inhibitory neurotransmitter; peripheral nervous system; antagonist;
KW   treatment; dementia; depression; anxiety; bronchial inflammation; asthma;
KW   epilepsy; cognitive function; ds.
XX
OS   Rattus norvegicus.
XX
FH   Key             Location/Qualifiers
FT   CDS             228..2762
FT                   /*tag=  a
FT                   /product= GABA-BR1b
XX
PN   WO9746675-A1.
XX
PD   11-DEC-1997.
XX
PF   19-MAR-1997;   97WO-EP01370.
XX
PR   22-NOV-1996;   96US-0756091.
PR   30-MAY-1996;   96US-0655716.
XX
PA   (NOVS ) NOVARTIS AG.
XX
PI   Bettler B,  Bittiger H,  Froestl W,  Kaupmann K,  Mickel SJ;
XX
DR   WPI; 1998-042183/04.
DR   P-PSDB; AAW40118.
XX
PT   Purified GABA-B receptor or receptor protein - and antagonists of
PT   these which may be useful in treating nervous system disorders
XX
PS   Claim 3; Page 67-74; 108pp; English.
XX
CC   This cDNA sequence encodes a novel rat GABA-B receptor protein,
CC   GABA-BR1b. GABA (gamma-aminobutyric acid) is the major inhibitory
CC   neurotransmitter found in the brain and peripheral nervous system
CC   and this receptor may be used for the identification of GABA-B
CC   receptor agonists and antagonists. Such proteins may be used in
CC   treatment of dementia, depression, anxiety, epilepsy, spasticity,
CC   bronchial inflammation or asthma or to improve cognitive function.
CC   GABA-B receptor ligands and probes derived from this sequence can be
CC   used to assay for GABA-B receptors or DNA encoding them.
XX
SQ   Sequence 2837 BP; 621 A; 842 C; 764 G; 610 T; 0 other;

  Query Match             93.8%;  Score 15;  DB 19;  Length 2837;
  Best Local Similarity   81.2%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 agggngucggggaggu 16
           |||| |:||||||||:
Db     148 AGGGCGTCGGGGAGGT 133


RESULT   5
ABL32331
ID   ABL32331 standard; DNA; 5379 BP.
XX
AC   ABL32331;
XX
DT   26-MAR-2002  (first entry)
XX
DE   Human immune system associated gene SEQ ID NO: 304.
XX
KW   Human; immune system disease; cytosine methylation; antiasthmatic;
KW   antiarteriosclerotic; antianaemic; cytostatic; nootropic;
KW   neuroprotective; anti-HIV; anticonvulsant; ophthalmological;
KW   antirheumatic; antiarthritic; antidiabetic; antipsoriatic;
KW   antiinflammatory; cancer; eye disease; arteriosclerosis; anaemia;
KW   acute myeloid leukaemia; Alzheimer's disease; AIDS; epilepsy;
KW   neurofibromatosis; rheumatoid arthritis; psoriasis; bowel disease;
KW   gene; ds.
XX
OS   Homo sapiens.
XX
PN   WO200200928-A2.
XX
PD   03-JAN-2002.
XX
PF   02-JUL-2001; 2001WO-EP07537.
XX
PR   30-JUN-2000; 2000DE-1032529.
PR   01-SEP-2000; 2000DE-1043826.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2002-130909/17.
XX
PT   Nucleic acid comprising fragment of chemically modified gene, useful
PT   for diagnosis and treatment of diseases associated with abnormal
PT   cytosine methylation -
XX
PS   Claim 1; SEQ ID NO 304; 32pp + Sequence Listing; German.
XX
CC   The present invention provides a number of human immune system associated
CC   genes which are modified by the methylation of cytosines. The sequences
CC   can be used in the diagnosis and treatment of immune system disorders,
CC   including eye diseases such as retinopathy, neovascular glaucoma and
CC   macular degeneration, arteriosclerosis, anaemia, cancer, acute myeloid
CC   leukaemia, Alzheimer's disease, AIDS, epilepsy, neurofibromatosis,
CC   rheumatoid arthritis, psoriasis and inflammatory/ulcerative bowel
CC   diseases. The present sequence is a gene of the invention.
XX
SQ   Sequence 5379 BP; 845 A; 491 C; 1898 G; 2145 T; 0 other;
```

```
  Query Match             93.8%;  Score 15;  DB 24;  Length 5379;
  Best Local Similarity   81.2%;  Pred. No. 4.2e+02;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy      1 agggngucggggaggu 16
          |||| |:|||||||:
Db    575 agggcgtcggggaggt 590


RESULT   6
ABL32293
ID   ABL32293 standard; DNA; 7119 BP.
XX
AC   ABL32293;
XX
DT   26-MAR-2002  (first entry)
XX
DE   Human immune system associated gene SEQ ID NO: 266.
XX
KW   Human; immune system disease; cytosine methylation; antiasthmatic;
KW   antiarteriosclerotic; antianaemic; cytostatic; nootropic;
KW   neuroprotective; anti-HIV; anticonvulsant; ophthalmological;
KW   antirheumatic; antiarthritic; antidiabetic; antipsoriatic;
KW   antiinflammatory; cancer; eye disease; arteriosclerosis; anaemia;
KW   acute myeloid leukaemia; Alzheimer's disease; AIDS; epilepsy;
KW   neurofibromatosis; rheumatoid arthritis; psoriasis; bowel disease;
KW   gene; ds.
XX
OS   Homo sapiens.
XX
PN   WO200200928-A2.
XX
PD   03-JAN-2002.
XX
PF   02-JUL-2001; 2001WO-EP07537.
XX
PR   30-JUN-2000; 2000DE-1032529.
PR   01-SEP-2000; 2000DE-1043826.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2002-130909/17.
XX
PT   Nucleic acid comprising fragment of chemically modified gene, useful
PT   for diagnosis and treatment of diseases associated with abnormal
PT   cytosine methylation  -
XX
PS   Claim 1; SEQ ID NO 266; 32pp + Sequence Listing; German.
XX
CC   The present invention provides a number of human immune system associated
CC   genes which are modified by the methylation of cytosines. The sequences
CC   can be used in the diagnosis and treatment of immune system disorders,
CC   including eye diseases such as retinopathy, neovascular glaucoma and
CC   macular degeneration, arteriosclerosis, anaemia, cancer, acute myeloid
CC   leukaemia, Alzheimer's disease, AIDS, epilepsy, neurofibromatosis,
CC   rheumatoid arthritis, psoriasis and inflammatory/ulcerative bowel
CC   diseases. The present sequence is a gene of the invention.
XX
SQ   Sequence 7119 BP; 1621 A; 211 C; 1983 G; 3304 T; 0 other;


  Query Match             93.8%;  Score 15;  DB 24;  Length 7119;
  Best Local Similarity   81.2%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy      1 agggngucggggaggu 16
          |||| |:|||||||:
Db   4585 agggcgtcggggaggt 4600


RESULT   7
ABL34051
ID   ABL34051 standard; DNA; 7203 BP.
XX
AC   ABL34051;
XX
DT   26-MAR-2002  (first entry)
XX
DE   Human immune system associated gene SEQ ID NO: 2024.
XX
KW   Human; immune system disease; cytosine methylation; antiasthmatic;
KW   antiarteriosclerotic; antianaemic; cytostatic; nootropic;
KW   neuroprotective; anti-HIV; anticonvulsant; ophthalmological;
KW   antirheumatic; antiarthritic; antidiabetic; antipsoriatic;
KW   antiinflammatory; cancer; eye disease; arteriosclerosis; anaemia;
KW   acute myeloid leukaemia; Alzheimer's disease; AIDS; epilepsy;
KW   neurofibromatosis; rheumatoid arthritis; psoriasis; bowel disease;
KW   gene; ds.
XX
OS   Homo sapiens.
XX
PN   WO200200928-A2.
XX
PD   03-JAN-2002.
XX
PF   02-JUL-2001; 2001WO-EP07537.
XX
PR   30-JUN-2000; 2000DE-1032529.
PR   01-SEP-2000; 2000DE-1043826.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2002-130909/17.
XX
PT   Nucleic acid comprising fragment of chemically modified gene, useful
PT   for diagnosis and treatment of diseases associated with abnormal
PT   cytosine methylation  -
XX
PS   Claim 1; SEQ ID NO 2024; 32pp + Sequence Listing; German.
XX
CC   The present invention provides a number of human immune system associated
CC   genes which are modified by the methylation of cytosines. The sequences
CC   can be used in the diagnosis and treatment of immune system disorders,
CC   including eye diseases such as retinopathy, neovascular glaucoma and
CC   macular degeneration, arteriosclerosis, anaemia, cancer, acute myeloid
CC   leukaemia, Alzheimer's disease, AIDS, epilepsy, neurofibromatosis,
CC   rheumatoid arthritis, psoriasis and inflammatory/ulcerative bowel
CC   diseases. The present sequence is a gene of the invention.
XX
SQ   Sequence 7203 BP; 1291 A; 250 C; 2131 G; 3521 T; 10 other;


  Query Match             93.8%;  Score 15;  DB 24;  Length 7203;
  Best Local Similarity   81.2%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy      1 agggngucggggaggu 16
          |||| |:|||||||:
Db   3477 agggggtcggggaggt 3492


RESULT   8
AAS30120/c
ID   AAS30120 standard; DNA; 8280 BP.
XX
AC   AAS30120;
XX
DT   21-NOV-2001  (first entry)
XX
DE   Human lung antigen genomic DNA #190.
XX
```

KW Lung antigen protein; human; mouse; rabbit; goat; horse; cat; dog;
KW chicken; sheep; immunosuppressive; antiarthritic; vasotropic;
KW antirheumatic; antiproliferative; cytostatic; cardiant; neuroprotective;
KW cerebroprotective; nootropic; antibacterial; virucide; fungicide; cancer;
KW ophthalmological; vulnerary; gene therapy; autoimmune disease; neoplasm;
KW hyperproliferative disorder; breast; liver; cardiovascular disorder; ds;
KW cerebrovascular disorder; nervous system disorder; bacterial infection;
KW fungal infection; viral infection; ocular disorder; endocrine disorder;
KW gastrointestinal disorder; renal disorder; respiratory disorder;
KW wound healing; skin aging; organ transplantation; food preservative;
KW tissue regeneration; anti-infertility; food additive.
XX
OS Homo sapiens.
XX
PN WO200155303-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01301.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.

PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-457723/49.
XX
PT Isolated polypeptide for treating, preventing and/or prognosing
PT respiratory disorders related to the lung including lung cancers and
PT also for testing and detection e.g. diagnosis -
XX
PS Claim 1; SEQ ID No 384; 507pp; English.
XX
CC Sequences AAS29931-AAS30164 represent genomic DNA molecules, which encode
CC the lung antigen polypeptides of the invention. Lung antigen polypeptides
CC and their associated polynucleotides are useful in the diagnosis,
CC treatment and prevention of various types of disorders in e.g. humans,
CC mice, rabbits, goats, horses, cats, dogs, chickens or sheep. A
CC pathological condition can be determined by detecting the presence or
CC absence of a mutation in a lung antigen polynucleotide. The treatable
CC disorders include autoimmune diseases such as rheumatoid arthritis,
CC hyperproliferative disorders such as neoplasms of the breast or liver,
CC cardiovascular disorders such as cardiac arrest, cerebrovascular
CC disorders such as cerebral ischaemia, nervous system disorders such as
CC Alzheimer's disease, infections caused by bacteria, viruses and fungi,
CC ocular disorders such as corneal infection, endocrine disorders such as
CC premature labour and infertility, gastrointestinal disorders such as
CC Crohn's disease, renal disorders such as glomerulonephritis and
CC respiratory disorders such as asthma and pleurisy. The polypeptides can
CC also be used to aid wound healing, to prevent skin aging due to sunburn,
CC to maintain organs before transplantation, to regenerate tissues and in
CC chemotaxis. The polypeptides can also be used as a food additive or
CC preservative to increase or decrease storage capabilities.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.

Query Match 93.8%; Score 15; DB 22; Length 8280;
Best Local Similarity 81.2%; Pred. No. 4e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Q 1 agggngucggggaggu 16
|||| |:||||||||:
Db 2187 AGGGGGTCGGGGAGGT 2172

RESULT 9
AAS30121/c
ID AAS30121 standard; DNA; 18535 BP.
XX
AC AAS30121;
XX
DT 21-NOV-2001 (first entry)
XX
DE Human lung antigen genomic DNA #191.
XX
KW Lung antigen protein; human; mouse; rabbit; goat; horse; cat; dog;
KW chicken; sheep; immunosuppressive; antiarthritic; vasotropic;
KW antirheumatic; antiproliferative; cytostatic; cardiant; neuroprotective;
KW cerebroprotective; nootropic; antibacterial; virucide; fungicide; cancer;
KW ophthalmological; vulnerary; gene therapy; autoimmune disease; neoplasm;
KW hyperproliferative disorder; breast; liver; cardiovascular disorder; ds;
KW cerebrovascular disorder; nervous system disorder; bacterial infection;
KW fungal infection; viral infection; ocular disorder; endocrine disorder;
KW gastrointestinal disorder; renal disorder; respiratory disorder;
KW wound healing; skin aging; organ transplantation; food preservative;
KW tissue regeneration; anti-infertility; food additive.
XX
OS Homo sapiens.
XX
PN WO200155303-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01301.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.

PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-457723/49.
XX
PT Isolated polypeptide for treating, preventing and/or prognosing
PT respiratory disorders related to the lung including lung cancers and
PT also for testing and detection e.g. diagnosis -
XX
PS Claim 1; SEQ ID No 385; 507pp; English.
XX
CC Sequences AAS29931-AAS30164 represent genomic DNA molecules, which encode
CC the lung antigen polypeptides of the invention. Lung antigen polypeptides
CC and their associated polynucleotides are useful in the diagnosis,
CC treatment and prevention of various types of disorders in e.g. humans,
CC mice, rabbits, goats, horses, cats, dogs, chickens or sheep. A
CC pathological condition can be determined by detecting the presence or
CC absence of a mutation in a lung antigen polynucleotide. The treatable
CC disorders include autoimmune diseases such as rheumatoid arthritis,
CC hyperproliferative disorders such as neoplasms of the breast or liver,
CC cardiovascular disorders such as cardiac arrest, cerebrovascular
CC disorders such as cerebral ischaemia, nervous system disorders such as
CC Alzheimer's disease, infections caused by bacteria, viruses and fungi,
CC ocular disorders such as corneal infection, endocrine disorders such as
CC premature labour and infertility, gastrointestinal disorders such as
CC Crohn's disease, renal disorders such as glomerulonephritis and
CC respiratory disorders such as asthma and pleurisy. The polypeptides can
CC also be used to aid wound healing, to prevent skin aging due to sunburn,
CC to maintain organs before transplantation, to regenerate tissues and in
CC chemotaxis. The polypeptides can also be used as a food additive or
CC preservative to increase or decrease storage capabilities.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.

Query Match 93.8%; Score 15; DB 22; Length 18535;
Best Local Similarity 81.2%; Pred. No. 3.7e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

```
Qy      1 agggngucggggaggu 16
          |||| |:|||||||:
Db  10108 AGGGGGTCGGGGAGGT 10093
```

RESULT 10
AAD06001
ID AAD06001 standard; cDNA; 15 BP.
XX
AC AAD06001;
XX
DT 31-JUL-2001 (first entry)
XX
DE Human tumour suppressor 1 (HTS1) cDNA fragment.
XX
KW Human tumour suppressor 1; HTS1; HPPAN; neoplastic cell; cancer; tumour;
KW leukaemia; breast; bladder; colorectal; gynaecological; lung; cytostatic;
KW antiproliferative; gene therapy; ss.
XX
OS Homo sapiens.
XX
PN WO200134634-A2.
XX
PD 17-MAY-2001.
XX
PF 09-NOV-2000; 2000WO-US30951.
XX
PR 12-NOV-1999; 99US-0438917.
XX

PA (IMMU-) IMMUSOL INC.
XX
PI Welch PJ, Barber JR;
XX
DR WPI; 2001-329068/34.
XX
PT New tumor suppressor nucleic acid molecules for detecting a neoplastic
PT cell in a sample and for regulating cell proliferation, such as, for
PT treating cancer -
XX
PS Claim 2; Page 56; 84pp; English.
XX
CC The invention relates to human tumour suppressor 1 (HTS1) genes, also
CC referred as HPPAN and polypeptides encoded by them. The invention
CC also provides hairpin ribozymes and antibodies selective for the HTS1
CC molecules, and diagnostic methods for detecting a neoplastic cell in a
CC sample using detectable agents specific for HTS1 molecules. HTS1 and
CC its genes are useful for detecting a neoplastic cell in a sample and
CC are therefore used to diagnose and prognose cancer. HTS1 sequences are
CC introduced into neoplastic cells to regulate cell proliferation, and
CC are thus useful as therapeutics for treating cancer. They are also used
CC for identifying compounds that mimic or regulate the tumour suppressor
C activity. Such compounds are used as therapeutics to treat cancer. HTS1
C sequences are used to treat both solid tumours and leukaemias. They are
CC also used in gene therapy. The diagnostic methods are useful for
CC identification of neoplastic cells in solid tumours of breast, bladder,
CC colorectal, gynaecological, lung, renal cancers etc.
CC The present sequence is human tumour suppressor 1 (HTS1) cDNA fragment.
CC Ribozyme 568 is targeted to this region to enable the identification of
CC HTS1.
XX
SQ Sequence 15 BP; 2 A; 2 C; 10 G; 1 T; 0 other;

Query Match 87.5%; Score 14; DB 22; Length 15;
Best Local Similarity 86.7%; Pred. No. 2e+03;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

```
Qy      1 agggngucggggagg 15
          |||| |:||||||||
Db      1 agggcgtcggggagg 15
```

RESULT 11
AAK78496
ID AAK78496 standard; DNA; 514 BP.
XX
AC AAK78496;
XX
DT 07-NOV-2001 (first entry)
X
D Human immune/haematopoietic antigen genomic sequence SEQ ID NO:33308.
XX
KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytostatic; gene therapy; vaccine; metastasis; ds.
XX
OS Homo sapiens.
XX
PN WO200157182-A2.
XX
PD 09-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01354.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.

PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-483426/52.
XX
PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT useful for preventing, diagnosing and/or treating cancers and
PT metastasis -
XX
PS Disclosure; SEQ ID NO 33308; 3071pp + Sequence Listing; English.
XX
CC AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC activity, and can be used in gene therapy and vaccine production. (I)
CC proteins and polynucleotides may be used in the prevention, diagnosis and
CC treatment of diseases associated with inappropriate (I) expression. For
CC example, they may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of (I) by expressing inactive proteins or to
CC supplement the patients own production of (I). Additionally, (I)
CC polynucleotides may be used to produce the secreted (I), by inserting
CC the nucleic acids into a host cell and culturing the cell to express the
CC protein. (I) proteins and polynucleotides may be used to prevent,
CC diagnose and treat immune/haematopoietic-related diseases, especially
CC cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC to AAK87694 represent human immune/haematopoietic antigen genomic
CC sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC represent sequences used in the exemplification of the present invention.
XX
SQ Sequence 514 BP; 121 A; 83 C; 137 G; 173 T; 0 other;

Query Match 87.5%; Score 14; DB 22; Length 514;
Best Local Similarity 86.7%; Pred. No. 1.4e+03;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 agggngucggggagg 15
|||| |:||||||||
Db 481 agggagtcggggagg 495

RESULT 12
AAL01287/c
ID AAL01287 standard; cDNA; 539 BP.
XX
AC AAL01287;
XX
DT 21-NOV-2001 (first entry)
XX
DE Human reproductive system related antigen cDNA SEQ ID NO: 1288.
XX
KW Human; reproductive system related antigen; reproductive system disorder;
KW cancer; gene therapy; ss.
XX
OS Homo sapiens.
XX
PN WO200155320-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01339.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.

PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
P[redacted]08-SEP-2000; 2000US-0232081.
P[redacted]12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
P[redacted]13-OCT-2000; 2000US-0239937.
P[redacted]20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-465570/50.
DR P-PSDB; AAM95317.
XX
PT Isolated nucleic acid molecule encoding a reproductive system antigen
PT is used in preventing, treating or ameliorating a medical condition -
XX
PS Claim 1; SEQ ID NO 1288; 1297pp + Sequence Listing; English.
XX
CC The present invention provides the protein and coding sequences of a
CC number of human reproductive system related antigens. These can be used
CC in the prevention and treatment of reproductive system disorders,
CC including cancer. The present sequence is a coding sequence of the
CC invention.
XX
SQ Sequence 539 BP; 134 A; 137 C; 138 G; 123 T; 7 other;

Query Match 87.5%; Score 14; DB 22; Length 539;
Best Local Similarity 86.7%; Pred. No. 1.4e+03;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 agggngucggggagg 15
|||| |:||||||||
Db 20 AGGGTGTCGGGGAGG 6

RESULT 13
AAI90687/c
ID AAI90687 standard; cDNA; 567 BP.
XX
AC AAI90687;
XX
DT 06-NOV-2001 (first entry)

XX
DE Human polynucleotide SEQ ID NO 10747.
XX
KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;
KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
KW tissue growth factor; immunomodulatory; cancer; leukaemia;
KW nervous system disorders; arthritis; inflammation; ss.
XX
OS Homo sapiens.
XX
PN WO200164835-A2.
XX
PD 07-SEP-2001.
XX
PF 26-FEB-2001; 2001WO-US04927.
XX
PR 28-FEB-2000; 2000US-0515126.
PR 18-MAY-2000; 2000US-0577409.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Drmanac RT;
XX
DR WPI; 2001-514838/56.
DR P-PSDB; AAO10756.
XX
PT Isolated nucleic acids and polypeptides, useful for preventing
PT diagnosing and treating e.g. leukaemia, inflammation and immune
PT disorders -
XX
PS Claim 1; SEQ ID NO 10747; 1399pp + Sequence Listing; English.
XX
CC The invention relates to human polynucleotides (AAI79941-AAI93841) and
CC the encoded proteins (AAO00010-AAO13910) that exhibit activity elating to
CC cytokine, cell proliferation or cell differentiation or which may induce
CC production of other cytokines in other cell populations. The
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or
CC peptide therapy. The polypeptides have various cytokine-like activities,
CC e.g. stem cell growth factor activity, haematopoiesis regulating
CC activity, tissue growth factor activity, immunomodulatory activity and
CC activin/inhibin activity and may be useful in the diagnosis and/or
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and
CC inflammation.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 567 BP; 115 A; 134 C; 135 G; 151 T; 32 other;

Query Match 87.5%; Score 14; DB 22; Length 567;
Best Local Similarity 86.7%; Pred. No. 1.4e+03;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 agggngucggggagg 15
|||| |:||||||||
Db 323 AGGGGGTCGGGGAGG 309

RESULT 14
AAS86857
ID AAS86857 standard; cDNA; 580 BP.
XX
AC AAS86857;
XX
DT 13-FEB-2002 (first entry)
XX
DE DNA encoding novel human diagnostic protein #22661.
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder; ss.
XX
OS Homo sapiens.

XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US08631.
XX
PR 31-MAR-2000; 2000US-0540217.
PR 23-AUG-2000; 2000US-0649167.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-639362/73.
DR P-PSDB; ABG22670.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity -
XX
PS Claim 1; SEQ ID No 22661; 103pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy techniques
CC to restore normal activity of (II) or to treat disease states involving
CC (II). (II) is useful for generating antibodies against it, detecting or
CC quantitating a polypeptide in tissue, as molecular weight markers and as
CC a food supplement. (II) and its binding partners are useful in medical
CC imaging of sites expressing (II). (I) and (II) are useful for treating
CC disorders involving aberrant protein expression or biological activity.
CC The polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. AAS64197-AAS94564 represent novel human
CC diagnostic coding sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 580 BP; 149 A; 143 C; 200 G; 88 T; 0 other;

Query Match 87.5%; Score 14; DB 23; Length 580;
Best Local Similarity 86.7%; Pred. No. 1.4e+03;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 agggngucggggagg 15
|||| |:||||||||
Db 71 agggcgtcggggagg 85

RESULT 15
AAK80650
ID AAK80650 standard; DNA; 1121 BP.
XX
AC AAK80650;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human immune/haematopoietic antigen genomic sequence SEQ ID NO:35462.
XX
KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytostatic; gene therapy; vaccine; metastasis; ds.
XX
OS Homo sapiens.
XX

PN WO200157182-A2.
XX
PD 09-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01354.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;

XX
DR WPI; 2001-483426/52.
XX
PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT useful for preventing, diagnosing and/or treating cancers and
PT metastasis -
XX
PS Disclosure; SEQ ID NO 35462; 3071pp + Sequence Listing; English.
XX
CC AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC activity, and can be used in gene therapy and vaccine production. (I)
CC proteins and polynucleotides may be used in the prevention, diagnosis and
CC treatment of diseases associated with inappropriate (I) expression. For
CC example, they may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of (I) by expressing inactive proteins or to
CC supplement the patients own production of (I). Additionally, (I)
CC polynucleotides may be used to produce the secreted (I), by inserting
CC the nucleic acids into a host cell and culturing the cell to express the
CC protein. (I) proteins and polynucleotides may be used to prevent,
CC diagnose and treat immune/haematopoietic-related diseases, especially
CC cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC to AAK87694 represent human immune/haematopoietic antigen genomic
CC sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC represent sequences used in the exemplification of the present invention.
XX
SQ Sequence 1121 BP; 252 A; 275 C; 305 G; 289 T; 0 other;

Query Match 87.5%; Score 14; DB 22; Length 1121;
Best Local Similarity 86.7%; Pred. No. 1.3e+03;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 agggngucggggagg 15
|||| |:||||||||
Db 323 agggagtcggggagg 337

Search completed: June 3, 2002, 22:11:06
Job time: 6072 sec

FT CDS 228..2762
FT /*tag= a
FT /product= GABA-BR1b
XX
PN WO9746675-A1.
XX
PD 11-DEC-1997.
XX
PF 19-MAR-1997; 97WO-EP01370.
XX
PR 22-NOV-1996; 96US-0756091.
PR 30-MAY-1996; 96US-0655716.
XX
PA (NOVS) NOVARTIS AG.
XX
PI Bettler B, Bittiger H, Froestl W, Kaupmann K, Mickel SJ;
XX
DR WPI; 1998-042183/04.
DR P-PSDB; AAW40118.
XX
PT Purified GABA-B receptor or receptor protein - and antagonists of
PT these which may be useful in treating nervous system disorders
XX
PS Claim 3; Page 67-74; 108pp; English.
XX
CC This cDNA sequence encodes a novel rat GABA-B receptor protein,
CC GABA-BR1b. GABA (gamma-aminobutyric acid) is the major inhibitory
CC neurotransmitter found in the brain and peripheral nervous system
CC and this receptor may be used for the identification of GABA-B
CC receptor agonists and antagonists. Such proteins may be used in
CC treatment of dementia, depression, anxiety, epilepsy, spasticity,
CC bronchial inflammation or asthma or to improve cognitive function.
CC GABA-B receptor ligands and probes derived from this sequence can be
CC used to assay for GABA-B receptors or DNA encoding them.
XX
SQ Sequence 2837 BP; 621 A; 842 C; 764 G; 610 T; 0 other;

Query Match 100.0%; Score 15; DB 19; Length 2837;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 agggcgtcggggagg 15
||||||||||||||||
Db 148 AGGGCGTCGGGGAGG 134

RESULT 9
AAX07369
ID AAX07369 standard; cDNA; 2427 BP.
XX
AC AAX07369;
XX
DT 07-JUN-1999 (first entry)
XX
DE Human P2Y11 receptor cDNA.
XX
KW P2Y11; G protein coupled receptor; human; infection; neutropaenia;
KW agranulocytosis; cancer; leukaemia; diagnosis; therapy; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 40..2427
FT /*tag= a
XX
PN WO9902675-A1.
XX
PD 21-JAN-1999.

XX
PF 09-JUL-1998; 98WO-BE00108.
XX
PR 09-JUL-1997; 97EP-0870101.
XX
PA (EURO-) EUROSCREEN SA.
XX
PI Boeynaems J, Communi D;
XX
DR WPI; 1999-120876/10.
DR P-PSDB; AAW97842.
XX
PT New G protein-coupled receptor - useful for diagnosis, treatment and
PT prevention of neutropaenia, agranulocytosis, infection and cancer
XX
PS Claim 11; Fig 1; 46pp; English.
XX
CC This cDNA clone encodes a novel human G protein coupled receptor,
CC termed P2Y11 (see AAW97842), that has selective affinity for ATP. A
CC human cDNA placenta cDNA library was screened with a human P2Y4
CC probe. Of 9 clones obtained, 3 corresponding to a partial sequence
CC encoding a new G protein coupled receptor displaying about 30%
CC identity with other P2Y receptors. This partial sequence was used
CC as a probe to screen a human genomic DNA library. 4 Overlapping
CC genomes clones were isolated. Mapping and sequencing showed the
CC new gene contained an intron at the 5' end of the coding region.
CC The 4 clones contained the entire open reading frame for the new
CC receptor, designated P2Y11. The invention also provides vectors,
CC transformed cells, anti-P2Y11 antibodies, nucleic acid probes,
CC pharmaceutical compositions comprising such products and transgenic
CC animals. Antisense nucleotides (claimed) that hybridise to mRNA
CC are used to decrease activity of P2Y11, while specific antibodies
CC are used to block binding of P2Y11 to its ligand. Probes are used
CC in hybridisation assays to detect expression of P2Y11 at the RNA
CC level, while antibodies are used similarly at the protein level in
CC standard immunoassays, particularly for diagnosis of leukaemia.
CC The transgenic animals are used to determine the effects of varying
CC levels of P2Y11 expression. These animals, and host cells, are
CC used in drug screening methods to identify (ant)agonists that are
CC potentially useful for treatment or prevention of disorders
CC associated with excessive or inadequate receptor activity,
CC specifically neutropaenia, agranulocytosis, infections and cancer.
CC Host cells are also used to produce recombinant P2Y11.
XX
SQ Sequence 2427 BP; 464 A; 790 C; 774 G; 399 T; 0 other;

Query Match 100.0%; Score 15; DB 20; Length 2427;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 agggcgtcggggagg 15
||||||||||||||| |
Db 902 agggcgtcggggagg 916

GenCore version 4.5

OM nucleic - nucleic search, using sw model

Run on: June 3, 2002, 22:11:58 ; Search time 366.71 Seconds
(without alignments)
70.229 Million cell updates/sec

Title: US-09-438-917-18
Perfect score: 15
Sequence: 1 agggcgtcggggagg 15

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1736436 seqs, 858457221 residues

Total number of hits satisfying chosen parameters: 3472872

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_032802:*
1: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2001A.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2001B.DAT:*
24: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	15	100.0	15	22	AAD06001	Human tumour suppr
	2	15	100.0	580	23	AAS86857	DNA encoding novel
c	3	15	100.0	1591	22	AAI59771	Human polynucleoti
c	4	15	100.0	1591	22	AAI59772	Human polynucleoti
	5	15	100.0	1664	22	AAD05991	Human tumour suppr
	6	15	100.0	1828	21	AAA12415	cDNA encoding a hu
	7	15	100.0	2240	22	AAI57986	Human polynucleoti
	8	15	100.0	2300	22	AAI57985	Human polynucleoti
	9	15	100.0	2427	20	AAX07369	Human P2Y11 recept
c	10	15	100.0	2732	23	AAS86858	DNA encoding novel
c	11	15	100.0	2837	19	AAV10266	Rat GABA-BR1b rece
	12	15	100.0	5379	24	ABL32331	Human immune syste
c	13	15	100.0	6714	23	ABL16321	Drosophila melanog
	14	15	100.0	7119	24	ABL32293	Human immune syste
	15	15	100.0	11838	23	ABL16320	Drosophila melanog
	16	15	100.0	13559	22	ABA15144	Human nervous syst
	17	14	93.3	16	22	AAD05988	Ribozyme binding D
	18	14	93.3	16	22	AAD06003	Ribozyme binding R
c	19	14	93.3	43	22	AAD05997	Human tumour suppr
c	20	14	93.3	1422	18	AAT59844	SOX4 coding sequen
c	21	14	93.3	1482	21	AAZ51486	Maize ZmKCS1 prote
c	22	14	93.3	1637	21	AAC48042	Zea mays DNA fragm
c	23	14	93.3	1954	21	AAZ50706	Maize ZmKCS1 prote
	24	14	93.3	3980	14	AAQ36780	Human cardiac cGI
	25	14	93.3	5283	22	AAS46539	Tumour suppressor
	26	14	93.3	6089	24	ABL32702	Human immune syste
	27	14	93.3	21034	19	AAV62154	HSV-2 strain SB5 C
	28	14	93.3	26338	19	AAV62134	HSV-2 strain SB5 C
	29	14	93.3	117213	19	AAV62176	HSV-2 strain SB5 C
	30	14	93.3	154746	24	AAD25519	Human herpesvirus
c	31	13.4	89.3	308	21	AAA32016	Plant microsatelli
c	32	13.4	89.3	336	22	AAF93281	Aortic endothelial
c	33	13.4	89.3	338	21	AAA31512	Plant microsatelli
	34	13.4	89.3	339	22	AAK57734	Human immune/haema
c	35	13.4	89.3	372	21	AAA31545	Plant microsatelli
c	36	13.4	89.3	407	21	AAC56675	Eucalyptus grandis
	37	13.4	89.3	441	21	AAA69703	Human ovarian carc
	38	13.4	89.3	451	22	AAK67787	Human immune/haema
c	39	13.4	89.3	453	23	ABL27921	Drosophila melanog
	40	13.4	89.3	514	22	AAK78496	Human immune/haema
c	41	13.4	89.3	535	21	AAA31372	Plant microsatelli
c	42	13.4	89.3	539	22	AAL01287	Human reproductive
c	43	13.4	89.3	567	22	AAI90687	Human polynucleoti
	44	13.4	89.3	677	22	AAS41937	Genomic sequence #
	45	13.4	89.3	677	22	AAS41938	Genomic sequence #

ALIGNMENTS

RESULT 1
AAD06001
ID AAD06001 standard; cDNA; 15 BP.
XX
AC AAD06001;
XX
DT 31-JUL-2001 (first entry)
XX
DE Human tumour suppressor 1 (HTS1) cDNA fragment.
XX
KW Human tumour suppressor 1; HTS1; HPPAN; neoplastic cell; cancer; tumour;
KW leukaemia; breast; bladder; colorectal; gynaecological; lung; cytostatic;
KW antiproliferative; gene therapy; ss.
XX
OS Homo sapiens.
XX
PN WO200134634-A2.
XX
PD 17-MAY-2001.
XX
PF 09-NOV-2000; 2000WO-US30951.
XX
PR 12-NOV-1999; 99US-0438917.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Welch PJ, Barber JR;
XX
DR WPI; 2001-329068/34.
XX
PT New tumor suppressor nucleic acid molecules for detecting a neoplastic
PT cell in a sample and for regulating cell proliferation, such as, for

PT treating cancer -
XX
PS Claim 2; Page 56; 84pp; English.
XX
CC The invention relates to human tumour suppressor 1 (HTS1) genes, also
CC referred as HPPAN and polypeptides encoded by them. The invention
CC also provides hairpin ribozymes and antibodies selective for the HTS1
CC molecules, and diagnostic methods for detecting a neoplastic cell in a
CC sample using detectable agents specific for HTS1 molecules. HTS1 and
CC its genes are useful for detecting a neoplastic cell in a sample and
CC are therefore used to diagnose and prognose cancer. HTS1 sequences are
CC introduced into neoplastic cells to regulate cell proliferation, and
CC are thus useful as therapeutics for treating cancer. They are also used
CC for identifying compounds that mimic or regulate the tumour suppressor
CC activity. Such compounds are used as therapeutics to treat cancer. HTS1
CC sequences are used to treat both solid tumours and leukaemias. They are
CC also used in gene therapy. The diagnostic methods are useful for
CC identification of neoplastic cells in solid tumours of breast, bladder,
CC colorectal, gynaecological, lung, renal cancers etc.
CC The present sequence is human tumour suppressor 1 (HTS1) cDNA fragment.
CC Ribozyme 568 is targeted to this region to enable the identification of
CC HTS1.
XX
SQ Sequence 15 BP; 2 A; 2 C; 10 G; 1 T; 0 other;

Query Match 100.0%; Score 15; DB 22; Length 15;
Best Local Similarity 100.0%; Pred. No. 6.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 agggcgtcggggagg 15
||||||||||||||||
Db 1 agggcgtcggggagg 15

RESULT 2
AAS86857
ID AAS86857 standard; cDNA; 580 BP.
XX
AC AAS86857;
XX
DT 13-FEB-2002 (first entry)
XX
DE DNA encoding novel human diagnostic protein #22661.
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder; ss.
XX
OS Homo sapiens.
XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US08631.
XX
PR 31-MAR-2000; 2000US-0540217.
PR 23-AUG-2000; 2000US-0649167.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-639362/73.
DR P-PSDB; ABG22670.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity -
XX
PS Claim 1; SEQ ID No 22661; 103pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy techniques
CC to restore normal activity of (II) or to treat disease states involving
CC (II). (II) is useful for generating antibodies against it, detecting or
CC quantitating a polypeptide in tissue, as molecular weight markers and as
CC a food supplement. (II) and its binding partners are useful in medical
CC imaging of sites expressing (II). (I) and (II) are useful for treating
CC disorders involving aberrant protein expression or biological activity.
CC The polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. AAS64197-AAS94564 represent novel human
CC diagnostic coding sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 580 BP; 149 A; 143 C; 200 G; 88 T; 0 other;

Query Match 100.0%; Score 15; DB 23; Length 580;
Best Local Similarity 100.0%; Pred. No. 4.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 agggcgtcggggagg 15
||||||||||||||||
Db 71 agggcgtcggggagg 85

RESULT 3
AAI59771/c
ID AAI59771 standard; cDNA; 1591 BP.
XX
AC AAI59771;
XX
DT 22-OCT-2001 (first entry)
XX
DE Human polynucleotide SEQ ID NO 3760.
XX
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia; ss.
XX
OS Homo sapiens.
XX
PN WO200153312-A1.
XX
PD 26-JUL-2001.
XX
PF 26-DEC-2000; 2000WO-US34263.
XX
PR 21-JAN-2000; 2000US-0488725.
PR 25-APR-2000; 2000US-0552317.
PR 09-JUL-2000; 2000US-0598042.
PR 19-JUL-2000; 2000US-0620312.
PR 03-AUG-2000; 2000US-0653450.
PR 14-SEP-2000; 2000US-0662191.
PR 19-OCT-2000; 2000US-0693036.
PR 29-NOV-2000; 2000US-0727344.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;

```
XX
DR   WPI; 2001-442253/47.
DR   P-PSDB; AAM40615.
XX
PT   Novel nucleic acids and polypeptides, useful for treating disorders
PT   such as central nervous system injuries -
XX
PS   Claim 1; SEQ ID NO 3760; 10078pp; English.
XX
CC   The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC   the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC   immunosuppressant and cytostatic activity. The polynucleotides are useful
CC   in gene therapy. A composition containing a polypeptide or polynucleotide
CC   of the invention may be used to treat diseases of the peripheral nervous
CC   system, such as peripheral nervous injuries, peripheral neuropathy and
CC   localised neuropathies and central nervous system diseases, such as
CC   Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC   lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC   utilisation of the activities such as: Immune system suppression,
CC   Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC   and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC   assays for receptor activity, arthritis and inflammation, leukaemias and
CC   C.N.S disorders.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification.
XX
SQ   Sequence 1591 BP; 247 A; 524 C; 463 G; 357 T; 0 other;


  Query Match             100.0%;  Score 15;  DB 22;  Length 1591;
  Best Local Similarity   100.0%;  Pred. No. 3.7e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 agggcgtcggggagg 15
          |||||||||||||||
Db    701 AGGGCGTCGGGGAGG 687


RESULT   4
AAI59772/c
ID   AAI59772 standard; cDNA; 1591 BP.
XX
AC   AAI59772;
XX
DT   22-OCT-2001  (first entry)

DE   Human polynucleotide SEQ ID NO 3761.
XX
KW   Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW   peripheral nervous system; neuropathy; central nervous system; CNS;
KW   Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW   amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW   chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW   leukaemia; ss.
XX
OS   Homo sapiens.
XX
PN   WO200153312-A1.
XX
PD   26-JUL-2001.
XX
PF   26-DEC-2000; 2000WO-US34263.
XX
PR   21-JAN-2000; 2000US-0488725.
PR   25-APR-2000; 2000US-0552317.
PR   09-JUL-2000; 2000US-0598042.
PR   19-JUL-2000; 2000US-0620312.
PR   03-AUG-2000; 2000US-0653450.
PR   14-SEP-2000; 2000US-0662191.
PR   19-OCT-2000; 2000US-0693036.
PR   29-NOV-2000; 2000US-0727344.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Asundi V,  Chen R,  Ma Y,  Qian XB,  Ren F,  Wang D;
PI   Wang J,  Wang Z,  Wehrman T,  Xu C,  Xue AJ,  Yang Y,  Zhang J;
PI   Zhao QA,  Zhou P,  Goodrich R,  Drmanac RT;
XX
DR   WPI; 2001-442253/47.
DR   P-PSDB; AAM40616.
XX
PT   Novel nucleic acids and polypeptides, useful for treating disorders
PT   such as central nervous system injuries -
XX
PS   Claim 1; SEQ ID NO 3761; 10078pp; English.
XX
CC   The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC   the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC   immunosuppressant and cytostatic activity. The polynucleotides are useful
CC   in gene therapy. A composition containing a polypeptide or polynucleotide
CC   of the invention may be used to treat diseases of the peripheral nervous
CC   system, such as peripheral nervous injuries, peripheral neuropathy and
CC   localised neuropathies and central nervous system diseases, such as
CC   Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC   lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC   utilisation of the activities such as: Immune system suppression,
CC   Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC   and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC   assays for receptor activity, arthritis and inflammation, leukaemias and
CC   C.N.S disorders.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification.
XX
SQ   Sequence 1591 BP; 247 A; 524 C; 463 G; 357 T; 0 other;


  Query Match             100.0%;  Score 15;  DB 22;  Length 1591;
  Best Local Similarity   100.0%;  Pred. No. 3.7e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;.

Qy      1 agggcgtcggggagg 15
          |||||||||||||||
Db    701 AGGGCGTCGGGGAGG 687


RESULT   5
AAD05991
ID   AAD05991 standard; cDNA; 1664 BP.
XX
AC   AAD05991;
XX
DT   31-JUL-2001  (first entry)
XX
DE   Human tumour suppressor 1 (HTS1) cDNA.
XX
KW   Human tumour suppressor 1; HTS1; HPPAN; neoplastic cell; cancer; tumour;
KW   leukaemia; breast; bladder; colorectal; gynaecological; lung; cytostatic;
KW   antiproliferative; gene therapy; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             103..1524
FT                   /*tag= a
FT                   /product= "Human tumour suppressor 1 (HTS1) protein"
FT                   /transl_except= (pos:1519..1521, aa:A-Z)
FT                   /note= "This translation exception occurs only
FT                   decoding the sequence (AAE01341) shown in figure 7"
XX
PN   WO200134634-A2.
XX
PD   17-MAY-2001.
XX
PF   09-NOV-2000; 2000WO-US30951.
XX
PR   12-NOV-1999;   99US-0438917.
```

```
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Welch PJ,  Barber JR;
XX
DR   WPI; 2001-329068/34.
DR   P-PSDB; AAE01341, AAE01350.
XX
PT   New tumor suppressor nucleic acid molecules for detecting a neoplastic
PT   cell in a sample and for regulating cell proliferation, such as, for
PT   treating cancer  -
XX
PS   Claim 3; Fig 6; 84pp; English.
XX
CC   The invention relates to human tumour suppressor 1 (HTS1) genes, also
CC   referred as HPPAN and polypeptides encoded by them. The invention
CC   also provides hairpin ribozymes and antibodies selective for the HTS1
CC   molecules, and diagnostic methods for detecting a neoplastic cell in a
CC   sample using detectable agents specific for HTS1 molecules. HTS1 and
CC   its genes are useful for detecting a neoplastic cell in a sample and
CC   are therefore used to diagnose and prognose cancer. HTS1 sequences are
CC   introduced into neoplastic cells to regulate cell proliferation, and
C    are thus useful as therapeutics for treating cancer. They are also used
     for identifying compounds that mimic or regulate the tumour suppressor
CC   activity. Such compounds are used as therapeutics to treat cancer. HTS1
CC   sequences are used to treat both solid tumours and leukaemias. They are
CC   also used in gene therapy. The diagnostic methods are useful for
CC   identification of neoplastic cells in solid tumours of breast, bladder,
CC   colorectal, gynaecological, lung, renal cancers etc.
CC   The present sequence is human tumour suppressor 1 (HTS1) cDNA.
XX
SQ   Sequence 1664 BP; 371 A; 492 C; 548 G; 253 T; 0 other;
```

```
  Query Match             100.0%;  Score 15;  DB 22;  Length 1664;
  Best Local Similarity   100.0%;  Pred. No. 3.7e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 agggcgtcggggagg 15
           |||||||||||||||
Db     965 agggcgtcggggagg 979
```

```
RESULT   6
AAA12415
ID   AAA12415 standard; cDNA; 1828 BP.
XX
AC   AAA12415;
XX
DT   25-JUL-2000  (first entry)
XX
     cDNA encoding a human RNA-associated protein.
XX
KW   Human; RNA-associated protein; cell proliferation; cancer; inflammation;
KW   immune response; reproductive disorder; actinic keratosis;
KW   atherosclerosis; arteriosclerosis; bursitis; cirrhosis; hepatitis;
KW   mixed connective tissue disease; myelofibrosis; primary thrombocythemia;
KW   paroxysomal nocturnal hemoglobinuria; polycythermia vera; psoriasis;
KW   trauma; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             89..1507
FT                   /*tag= a
FT                   /product= "RNA-associated protein"
XX
PN   WO200015799-A2.
XX
PD   23-MAR-2000.
XX
PF   17-SEP-1999;   99WO-US21688.
XX
PR   17-SEP-1998;   98US-0156039.
PR   22-SEP-1998;   98US-0158720.
PR   04-NOV-1998;   98US-0186815.
PR   08-APR-1999;   99US-0128660.
XX
PA   (INCY-) INCYTE PHARM INC.
XX
PI   Tang YT,  Corley NC,  Guegler KJ,  Gorgone GA,  Patterson C;
PI   Hillman JL,  Baughn MR,  Lal P,  Azimzai Y,  Yue H,  Yang J;
XX
DR   WPI; 2000-271437/23.
DR   P-PSDB; AAY84443.
XX
PT   New polypeptides and polynucleotides, useful for preventing and
PT   treating a disorder associated with increased or decreased expression
PT   of RNA associated proteins -
XX
PS   Claim 9; Page 123-124; 131pp; English.
XX
CC   The present sequence encodes a human RNA-associated protein. The
CC   expression of RNA-associated proteins is closely associated with
CC   reproductive tissues, nervous tissues, cell proliferation including
CC   cancer, inflammation and immune responses, and so they may be used
CC   for diagnosis, treatment or prevention of cell proliferative,
CC   immune/inflammatory disorders, and reproductive disorders. Diseases
CC   and disorders which may be treated include actinic keratosis,
CC   atherosclerosis, arteriosclerosis, bursitis, cirrhosis, hepatitis,
CC   mixed connective tissue disease, myelofibrosis, paroxysomal nocturnal
CC   hemoglobinuria, polycythermia vera, psoriasis, primary thrombocythemia
CC   and cancers, and trauma.
XX
SQ   Sequence 1828 BP; 387 A; 547 C; 607 G; 287 T; 0 other;
```

```
  Query Match             100.0%;  Score 15;  DB 21;  Length 1828;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 agggcgtcggggagg 15
           |||||||||||||||
Db     948 agggcgtcggggagg 962
```

```
RESULT   7
AAI57986
ID   AAI57986 standard; cDNA; 2240 BP.
XX
AC   AAI57986;
XX
DT   22-OCT-2001  (first entry)
XX
DE   Human polynucleotide SEQ ID NO 189.
XX
KW   Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW   peripheral nervous system; neuropathy; central nervous system; CNS;
KW   Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW   amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW   chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW   leukaemia; ss.
XX
OS   Homo sapiens.
XX
PN   WO200153312-A1.
XX
PD   26-JUL-2001.
XX
PF   26-DEC-2000; 2000WO-US34263.
XX
PR   21-JAN-2000; 2000US-0488725.
PR   25-APR-2000; 2000US-0552317.
PR   09-JUL-2000; 2000US-0598042.
PR   19-JUL-2000; 2000US-0620312.
PR   03-AUG-2000; 2000US-0653450.
```

PR 14-SEP-2000; 2000US-0662191.
PR 19-OCT-2000; 2000US-0693036.
PR 29-NOV-2000; 2000US-0727344.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
XX
DR WPI; 2001-442253/47.
DR P-PSDB; AAM38830.
XX
PT Novel nucleic acids and polypeptides, useful for treating disorders
PT such as central nervous system injuries -
XX
PS Claim 1; SEQ ID NO 189; 10078pp; English.
XX
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders.
CC Note: The sequence data for this patent did not form part of the printed
CC specification.
XX
SQ Sequence 2240 BP; 480 A; 636 C; 751 G; 365 T; 8 other;

Query Match 100.0%; Score 15; DB 22; Length 2240;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 agggcgtcggggagg 15
||||||||||||||||
Db 959 agggcgtcggggagg 973

RESULT 8
AAI57985
ID AAI57985 standard; cDNA; 2300 BP.
XX
AC AAI57985;
XX
DT 22-OCT-2001 (first entry)
XX
DE Human polynucleotide SEQ ID NO 188.
XX
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia; ss.
XX
OS Homo sapiens.
XX
PN WO200153312-A1.
XX
PD 26-JUL-2001.
XX
PF 26-DEC-2000; 2000WO-US34263.
XX
PR 21-JAN-2000; 2000US-0488725.
PR 25-APR-2000; 2000US-0552317.
PR 09-JUL-2000; 2000US-0598042.
PR 19-JUL-2000; 2000US-0620312.
PR 03-AUG-2000; 2000US-0653450.
PR 14-SEP-2000; 2000US-0662191.
PR 19-OCT-2000; 2000US-0693036.
PR 29-NOV-2000; 2000US-0727344.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
XX
DR WPI; 2001-442253/47.
DR P-PSDB; AAM38829.
XX
PT Novel nucleic acids and polypeptides, useful for treating disorders
PT such as central nervous system injuries -
XX
PS Claim 1; SEQ ID NO 188; 10078pp; English.
XX
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders.
CC Note: The sequence data for this patent did not form part of the printed
CC specification.
XX
SQ Sequence 2300 BP; 495 A; 647 C; 774 G; 376 T; 8 other;

Query Match 100.0%; Score 15; DB 22; Length 2300;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 agggcgtcggggagg 15
||||||||||||||||
Db 959 agggcgtcggggagg 973

RESULT 9
AAX07369
ID AAX07369 standard; cDNA; 2427 BP.
XX
AC AAX07369;
XX
DT 07-JUN-1999 (first entry)
XX
DE Human P2Y11 receptor cDNA.
XX
KW P2Y11; G protein coupled receptor; human; infection; neutropaenia;
KW agranulocytosis; cancer; leukaemia; diagnosis; therapy; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 40..2427
FT /*tag= a
XX
PN WO9902675-A1.
XX
PD 21-JAN-1999.

XX
PF 09-JUL-1998; 98WO-BE00108.
XX
PR 09-JUL-1997; 97EP-0870101.
XX
PA (EURO-) EUROSCREEN SA.
XX
PI Boeynaems J, Communi D;
XX
DR WPI; 1999-120876/10.
DR P-PSDB; AAW97842.
XX
PT New G protein-coupled receptor - useful for diagnosis, treatment and
PT prevention of neutropaenia, agranulocytosis, infection and cancer
XX
PS Claim 11; Fig 1; 46pp; English.
XX
CC This cDNA clone encodes a novel human G protein coupled receptor,
CC termed P2Y11 (see AAW97842), that has selective affinity for ATP. A
CC human cDNA placenta cDNA library was screened with a human P2Y4
CC probe. Of 9 clones obtained, 3 corresponding to a partial sequence
CC encoding a new G protein coupled receptor displaying about 30%
CC identity with other P2Y receptors. This partial sequence was used
CC as a probe to screen a human genomic DNA library. 4 Overlapping
CC genomes clones were isolated. Mapping and sequencing showed the
CC new gene contained an intron at the 5' end of the coding region.
CC The 4 clones contained the entire open reading frame for the new
CC receptor, designated P2Y11. The invention also provides vectors,
CC transformed cells, anti-P2Y11 antibodies, nucleic acid probes,
CC pharmaceutical compositions comprising such products and transgenic
CC animals. Antisense nucleotides (claimed) that hybridise to mRNA
CC are used to decrease activity of P2Y11, while specific antibodies
CC are used to block binding of P2Y11 to its ligand. Probes are used
CC in hybridisation assays to detect expression of P2Y11 at the RNA
CC level, while antibodies are used similarly at the protein level in
CC standard immunoassays, particularly for diagnosis of leukaemia.
CC The transgenic animals are used to determine the effects of varying
CC levels of P2Y11 expression. These animals, and host cells, are
CC used in drug screening methods to identify (ant)agonists that are
CC potentially useful for treatment or prevention of disorders
CC associated with excessive or inadequate receptor activity,
CC specifically neutropaenia, agranulocytosis, infections and cancer.
CC Host cells are also used to produce recombinant P2Y11.
XX
SQ Sequence 2427 BP; 464 A; 790 C; 774 G; 399 T; 0 other;

Query Match 100.0%; Score 15; DB 20; Length 2427;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 agggcgtcggggagg 15
||||||||||||||||
Db 902 agggcgtcggggagg 916

RESULT 10
AAS86858/c
ID AAS86858 standard; cDNA; 2732 BP.
XX
AC AAS86858;
XX
DT 13-FEB-2002 (first entry)
XX
DE DNA encoding novel human diagnostic protein #22662.
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder; ss.
XX
OS Homo sapiens.
XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US08631.
XX
PR 31-MAR-2000; 2000US-0540217.
PR 23-AUG-2000; 2000US-0649167.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-639362/73.
DR P-PSDB; ABG22671.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity -
XX
PS Claim 1; SEQ ID No 22662; 103pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy techniques
CC to restore normal activity of (II) or to treat disease states involving
CC (II). (II) is useful for generating antibodies against it, detecting or
CC quantitating a polypeptide in tissue, as molecular weight markers and as
CC a food supplement. (II) and its binding partners are useful in medical
CC imaging of sites expressing (II). (I) and (II) are useful for treating
CC disorders involving aberrant protein expression or biological activity.
CC The polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. AAS64197-AAS94564 represent novel human
CC diagnostic coding sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 2732 BP; 511 A; 782 C; 774 G; 665 T; 0 other;

Query Match 100.0%; Score 15; DB 23; Length 2732;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 agggcgtcggggagg 15
||||||||||||||||
Db 693 AGGGCGTCGGGGAGG 679

RESULT 11
AAV10266/c
ID AAV10266 standard; cDNA to mRNA; 2837 BP.
XX
AC AAV10266;
XX
DT 03-JUN-1998 (first entry)
XX
DE Rat GABA-BR1b receptor cDNA.
XX
KW Gamma-animobutyric acid; GABA-BR1b receptor; rat; brain; agonist;
KW inhibitory neurotransmitter; peripheral nervous system; antagonist;
KW treatment; dementia; depression; anxiety; bronchial inflammation; asthma;
KW epilepsy; cognitive function; ds.
XX
OS Rattus norvegicus.
XX
FH Key Location/Qualifiers

```
FT   CDS             228..2762
FT                   /*tag= a
FT                   /product= GABA-BR1b
XX
PN   WO9746675-A1.
XX
PD   11-DEC-1997.
XX
PF   19-MAR-1997;    97WO-EP01370.
XX
PR   22-NOV-1996;    96US-0756091.
PR   30-MAY-1996;    96US-0655716.
XX
PA   (NOVS ) NOVARTIS AG.
XX
PI   Bettler B,  Bittiger H,  Froestl W,  Kaupmann K,  Mickel SJ;

     WPI; 1998-042183/04.
     P-PSDB; AAW40118.
XX
PT   Purified GABA-B receptor or receptor protein - and antagonists of
PT   these which may be useful in treating nervous system disorders
XX
PS   Claim 3; Page 67-74; 108pp; English.
XX
CC   This cDNA sequence encodes a novel rat GABA-B receptor protein,
CC   GABA-BR1b. GABA (gamma-aminobutyric acid) is the major inhibitory
CC   neurotransmitter found in the brain and peripheral nervous system
CC   and this receptor may be used for the identification of GABA-B
CC   receptor agonists and antagonists. Such proteins may be used in
CC   treatment of dementia, depression, anxiety, epilepsy, spasticity,
CC   bronchial inflammation or asthma or to improve cognitive function.
CC   GABA-B receptor ligands and probes derived from this sequence can be
CC   used to assay for GABA-B receptors or DNA encoding them.
XX
SQ   Sequence 2837 BP; 621 A; 842 C; 764 G; 610 T; 0 other;


  Query Match             100.0%;  Score 15;  DB 19;  Length 2837;
  Best Local Similarity   100.0%;  Pred. No. 3.5e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 agggcgtcggggagg 15
           |||||||||||||||
Db     148 AGGGCGTCGGGGAGG 134


RESULT  12
ABL32331
ID   ABL32331 standard; DNA; 5379 BP.
XX
AC   ABL32331;
XX
DT   26-MAR-2002  (first entry)
XX
DE   Human immune system associated gene SEQ ID NO: 304.
XX
KW   Human; immune system disease; cytosine methylation; antiasthmatic;
KW   antiarteriosclerotic; antianaemic; cytostatic; nootropic;
KW   neuroprotective; anti-HIV; anticonvulsant; ophthalmological;
KW   antirheumatic; antiarthritic; antidiabetic; antipsoriatic;
KW   antiinflammatory; cancer; eye disease; arteriosclerosis; anaemia;
KW   acute myeloid leukaemia; Alzheimer's disease; AIDS; epilepsy;
KW   neurofibromatosis; rheumatoid arthritis; psoriasis; bowel disease;
KW   gene; ds.
XX
OS   Homo sapiens.
XX
PN   WO200200928-A2.
XX
PD   03-JAN-2002.
XX
PF   02-JUL-2001; 2001WO-EP07537.
XX
PR   30-JUN-2000; 2000DE-1032529.
PR   01-SEP-2000; 2000DE-1043826.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2002-130909/17.
XX
PT   Nucleic acid comprising fragment of chemically modified gene, useful
PT   for diagnosis and treatment of diseases associated with abnormal
PT   cytosine methylation -
XX
PS   Claim 1; SEQ ID NO 304; 32pp + Sequence Listing; German.
XX
CC   The present invention provides a number of human immune system associated
CC   genes which are modified by the methylation of cytosines. The sequences
CC   can be used in the diagnosis and treatment of immune system disorders,
CC   including eye diseases such as retinopathy, neovascular glaucoma and
CC   macular degeneration, arteriosclerosis, anaemia, cancer, acute myeloid
CC   leukaemia, Alzheimer's disease, AIDS, epilepsy, neurofibromatosis,
CC   rheumatoid arthritis, psoriasis and inflammatory/ulcerative bowel
CC   diseases. The present sequence is a gene of the invention.
XX
SQ   Sequence 5379 BP; 845 A; 491 C; 1898 G; 2145 T; 0 other;


  Query Match             100.0%;  Score 15;  DB 24;  Length 5379;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 agggcgtcggggagg 15
           |||||||||||||||
Db     575 agggcgtcggggagg 589


RESULT  13
ABL16321/c
ID   ABL16321 standard; DNA; 6714 BP.
XX
AC   ABL16321;
XX
DT   26-MAR-2002  (first entry)
XX
DE   Drosophila melanogaster genomic polynucleotide SEQ ID NO 436.
XX
KW   Drosophila; developmental biology; cell signalling; insecticide;
KW   pharmaceutical; gene; ds.
XX
OS   Drosophila melanogaster.
XX
PN   WO200171042-A2.
XX
PD   27-SEP-2001.
XX
PF   23-MAR-2001; 2001WO-US09231.
XX
PR   23-MAR-2000; 2000US-191637P.
PR   11-JUL-2000; 2000US-0614150.
XX
PA   (PEKE ) PE CORP NY.
XX
PI   Venter JC,  Adams M,  Li PWD,  Myers EW;
XX
DR   WPI; 2001-656860/75.
XX
PT   New isolated nucleic acid detection reagent for detecting 1000 or more
PT   genes from Drosophila and for elucidating cell signalling and cell-cell
PT   interactions -
XX
PS   Claim 1; SEQ ID NO 436; 21pp + Sequence Listing; English.
XX
```

CC The invention relates to an isolated nucleic acid detection reagent
CC capable of detecting 1000 or more genes from Drosophila. The invention is
CC useful in developmental biology and in elucidating cell signalling and
CC cell-cell interactions in higher eukaryotes for the development of
CC insecticides, therapeutics and pharmaceutical drugs. The invention
CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC sequences (ABL01840-ABL16175) and the encoded proteins
CC (ABB57737-ABB72072).
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 6714 BP; 1805 A; 1983 C; 1705 G; 1221 T; 0 other;

Query Match 100.0%; Score 15; DB 23; Length 6714;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 agggcgtcggggagg 15
||||||||||||||||
Db 5071 AGGGCGTCGGGGAGG 5057

RESULT 14
ABL32293
ID ABL32293 standard; DNA; 7119 BP.
XX
AC ABL32293;
XX
DT 26-MAR-2002 (first entry)
XX
DE Human immune system associated gene SEQ ID NO: 266.
XX
KW Human; immune system disease; cytosine methylation; antiasthmatic;
KW antiarteriosclerotic; antianaemic; cytostatic; nootropic;
KW neuroprotective; anti-HIV; anticonvulsant; ophthalmological;
KW antirheumatic; antiarthritic; antidiabetic; antipsoriatic;
KW antiinflammatory; cancer; eye disease; arteriosclerosis; anaemia;
KW acute myeloid leukaemia; Alzheimer's disease; AIDS; epilepsy;
KW neurofibromatosis; rheumatoid arthritis; psoriasis; bowel disease;
KW gene; ds.
XX
OS Homo sapiens.
XX
PN WO200200928-A2.
XX
PD 03-JAN-2002.
XX
PF 02-JUL-2001; 2001WO-EP07537.
XX
30-JUN-2000; 2000DE-1032529.
01-SEP-2000; 2000DE-1043826.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2002-130909/17.
XX
PT Nucleic acid comprising fragment of chemically modified gene, useful
PT for diagnosis and treatment of diseases associated with abnormal
PT cytosine methylation -
XX
PS Claim 1; SEQ ID NO 266; 32pp + Sequence Listing; German.
XX
CC The present invention provides a number of human immune system associated
CC genes which are modified by the methylation of cytosines. The sequences
CC can be used in the diagnosis and treatment of immune system disorders,
CC including eye diseases such as retinopathy, neovascular glaucoma and
CC macular degeneration, arteriosclerosis, anaemia, cancer, acute myeloid
CC leukaemia, Alzheimer's disease, AIDS, epilepsy, neurofibromatosis,
CC rheumatoid arthritis, psoriasis and inflammatory/ulcerative bowel
CC diseases. The present sequence is a gene of the invention.
XX
SQ Sequence 7119 BP; 1621 A; 211 C; 1983 G; 3304 T; 0 other;

Query Match 100.0%; Score 15; DB 24; Length 7119;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 agggcgtcggggagg 15
||||||||||||||||
Db 4585 agggcgtcggggagg 4599

RESULT 15
ABL16320
ID ABL16320 standard; DNA; 11838 BP.
XX
AC ABL16320;
XX
DT 26-MAR-2002 (first entry)
XX
DE Drosophila melanogaster genomic polynucleotide SEQ ID NO 433.
XX
KW Drosophila; developmental biology; cell signalling; insecticide;
KW pharmaceutical; gene; ds.
XX
OS Drosophila melanogaster.
XX
PN WO200171042-A2.
XX
PD 27-SEP-2001.
XX
PF 23-MAR-2001; 2001WO-US09231.
XX
PR 23-MAR-2000; 2000US-191637P.
PR 11-JUL-2000; 2000US-0614150.
XX
PA (PEKE) PE CORP NY.
XX
PI Venter JC, Adams M, Li PWD, Myers EW;
XX
DR WPI; 2001-656860/75.
XX
PT New isolated nucleic acid detection reagent for detecting 1000 or more
PT genes from Drosophila and for elucidating cell signalling and cell-cell
PT interactions -
XX
PS Claim 1; SEQ ID NO 433; 21pp + Sequence Listing; English.
XX
CC The invention relates to an isolated nucleic acid detection reagent
CC capable of detecting 1000 or more genes from Drosophila. The invention is
CC useful in developmental biology and in elucidating cell signalling and
CC cell-cell interactions in higher eukaryotes for the development of
CC insecticides, therapeutics and pharmaceutical drugs. The invention
CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC sequences (ABL01840-ABL16175) and the encoded proteins
CC (ABB57737-ABB72072).
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 11838 BP; 2824 A; 2496 C; 2919 G; 3599 T; 0 other;

Query Match 100.0%; Score 15; DB 23; Length 11838;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 agggcgtcggggagg 15
||||||||||||||||
Db 4493 agggcgtcggggagg 4507

Search completed: June 3, 2002, 22:12:01
Job time: 6127 sec